Everolimus Mitigates the Risk of Hepatocellular Carcinoma Recurrence after Liver Transplantation

<!DOCTYPE html> <html lang="en" xmlns:og="http://ogp.me/ns#" xmlns:fb="https://www.facebook.com/2008/fbml"> <head> <meta charset="utf-8"> <meta http-equiv="X-UA-Compatible" content="IE=edge,chrome=1"> <meta content="mdpi" name="sso-service" /> <meta content="width=device-width, initial-scale=1.0" name="viewport" /> <title>Everolimus Mitigates the Risk of Hepatocellular Carcinoma Recurrence after Liver Transplantation</title><link rel="stylesheet" href="https://pub.mdpi-res.com/assets/css/font-awesome.min.css?eb190a3a77e5e1ee?1732286508"> <link rel="stylesheet" href="https://pub.mdpi-res.com/assets/css/jquery.multiselect.css?f56c135cbf4d1483?1732286508"> <link rel="stylesheet" href="https://pub.mdpi-res.com/assets/css/chosen.min.css?d7ca5ca9441ef9e1?1732286508"> <link rel="stylesheet" href="https://pub.mdpi-res.com/assets/css/main2.css?69b39374e6b554b7?1732286508"> <link rel="mask-icon" href="https://pub.mdpi-res.com/img/mask-icon-128.svg?c1c7eca266cd7013?1732286508" color="#4f5671"> <link rel="apple-touch-icon" sizes="180x180" href="https://pub.mdpi-res.com/icon/apple-touch-icon-180x180.png?1732286508"> <link rel="apple-touch-icon" sizes="152x152" href="https://pub.mdpi-res.com/icon/apple-touch-icon-152x152.png?1732286508"> <link rel="apple-touch-icon" sizes="144x144" href="https://pub.mdpi-res.com/icon/apple-touch-icon-144x144.png?1732286508"> <link rel="apple-touch-icon" sizes="120x120" href="https://pub.mdpi-res.com/icon/apple-touch-icon-120x120.png?1732286508"> <link rel="apple-touch-icon" sizes="114x114" href="https://pub.mdpi-res.com/icon/apple-touch-icon-114x114.png?1732286508"> <link rel="apple-touch-icon" sizes="76x76" href="https://pub.mdpi-res.com/icon/apple-touch-icon-76x76.png?1732286508"> <link rel="apple-touch-icon" sizes="72x72" href="https://pub.mdpi-res.com/icon/apple-touch-icon-72x72.png?1732286508"> <link rel="apple-touch-icon" sizes="57x57" href="https://pub.mdpi-res.com/icon/apple-touch-icon-57x57.png?1732286508"> <link rel="apple-touch-icon" href="https://pub.mdpi-res.com/icon/apple-touch-icon-57x57.png?1732286508"> <link rel="apple-touch-icon-precomposed" href="https://pub.mdpi-res.com/icon/apple-touch-icon-57x57.png?1732286508"> <link rel="manifest" href="/manifest.json"> <meta name="theme-color" content="#ffffff"> <meta name="application-name" content=" "/> <link rel="apple-touch-startup-image" href="https://pub.mdpi-res.com/img/journals/cancers-logo-sq.png?8600e93ff98dbf14"> <link rel="apple-touch-icon" href="https://pub.mdpi-res.com/img/journals/cancers-logo-sq.png?8600e93ff98dbf14"> <meta name="msapplication-TileImage" content="https://pub.mdpi-res.com/img/journals/cancers-logo-sq.png?8600e93ff98dbf14"> <link rel="stylesheet" href="https://pub.mdpi-res.com/assets/css/jquery-ui-1.10.4.custom.min.css?80647d88647bf347?1732286508"> <link rel="stylesheet" href="https://pub.mdpi-res.com/assets/css/magnific-popup.min.css?04d343e036f8eecd?1732286508"> <link rel="stylesheet" href="https://pub.mdpi-res.com/assets/css/xml2html/article-html.css?230b005b39af4260?1732286508"> <style> h2, #abstract .related_suggestion_title { } .batch_articles a { color: #000; } a, .batch_articles .authors a, a:focus, a:hover, a:active, .batch_articles a:focus, .batch_articles a:hover, li.side-menu-li a { } span.label a { color: #fff; } #main-content a.title-link:hover, #main-content a.title-link:focus, #main-content div.generic-item a.title-link:hover, #main-content div.generic-item a.title-link:focus { } #main-content #middle-column .generic-item.article-item a.title-link:hover, #main-content #middle-column .generic-item.article-item a.title-link:focus { } .art-authors a.toEncode { color: #333; font-weight: 700; } #main-content #middle-column ul li::before { } .accordion-navigation.active a.accordion__title, .accordion-navigation.active a.accordion__title::after { } .accordion-navigation li:hover::before, .accordion-navigation li:hover a, .accordion-navigation li:focus a { } .relative-size-container .relative-size-image .relative-size { } .middle-column__help__fixed a:hover i, } input[type="checkbox"]:checked:after { } input[type="checkbox"]:not(:disabled):hover:before { } #main-content .bolded-text { } #main-content .hypothesis-count-container { } #main-content .hypothesis-count-container:before { } .full-size-menu ul li.menu-item .dropdown-wrapper { } .full-size-menu ul li.menu-item > a.open::after { } #title-story .title-story-orbit .orbit-caption { #background: url('/img/design/000000_background.png') !important; background: url('/img/design/ffffff_background.png') !important; color: rgb(51, 51, 51) !important; } #main-content .content__container__orbit { background-color: #000 !important; } #main-content .content__container__journal { color: #fff; } .html-article-menu .row span { } .html-article-menu .row span.active { } .accordion-navigation__journal .side-menu-li.active::before, .accordion-navigation__journal .side-menu-li.active a { color: rgba(26,59,132,0.75) !important; font-weight: 700; } .accordion-navigation__journal .side-menu-li:hover::before , .accordion-navigation__journal .side-menu-li:hover a { color: rgba(26,59,132,0.75) !important; } .side-menu-ul li.active a, .side-menu-ul li.active, .side-menu-ul li.active::before { color: rgba(26,59,132,0.75) !important; } .side-menu-ul li.active a { } .result-selected, .active-result.highlighted, .active-result:hover, .result-selected, .active-result.highlighted, .active-result:focus { } .search-container.search-container__default-scheme { } nav.tab-bar .open-small-search.active:after { } .search-container.search-container__default-scheme .custom-accordion-for-small-screen-link::after { color: #fff; } @media only screen and (max-width: 50em) { #main-content .content__container.journal-info { color: #fff; } #main-content .content__container.journal-info a { color: #fff; } } .button.button--color { } .button.button--color:hover, .button.button--color:focus { } .button.button--color-journal { position: relative; background-color: rgba(26,59,132,0.75); border-color: #fff; color: #fff !important; } .button.button--color-journal:hover::before { content: ''; position: absolute; top: 0; left: 0; height: 100%; width: 100%; background-color: #ffffff; opacity: 0.2; } .button.button--color-journal:visited, .button.button--color-journal:hover, .button.button--color-journal:focus { background-color: rgba(26,59,132,0.75); border-color: #fff; color: #fff !important; } .button.button--color path { } .button.button--color:hover path { fill: #fff; } #main-content #search-refinements .ui-slider-horizontal .ui-slider-range { } .breadcrumb__element:last-of-type a { } #main-header { } #full-size-menu .top-bar, #full-size-menu li.menu-item span.user-email { } .top-bar-section li:not(.has-form) a:not(.button) { } #full-size-menu li.menu-item .dropdown-wrapper li a:hover { } #full-size-menu li.menu-item a:hover, #full-size-menu li.menu.item a:focus, nav.tab-bar a:hover { } #full-size-menu li.menu.item a:active, #full-size-menu li.menu.item a.active { } #full-size-menu li.menu-item a.open-mega-menu.active, #full-size-menu li.menu-item div.mega-menu, a.open-mega-menu.active { } #full-size-menu li.menu-item div.mega-menu li, #full-size-menu li.menu-item div.mega-menu a { border-color: #9a9a9a; } div.type-section h2 { font-size: 20px; line-height: 26px; font-weight: 300; } div.type-section h3 { margin-left: 15px; margin-bottom: 0px; font-weight: 300; } .journal-tabs .tab-title.active a { } </style> <link rel="stylesheet" href="https://pub.mdpi-res.com/assets/css/slick.css?f38b2db10e01b157?1732286508"> <meta name="title" content="Everolimus Mitigates the Risk of Hepatocellular Carcinoma Recurrence after Liver Transplantation"> <meta name="description" content="To obtain long-term data on the use of everolimus in patients who underwent liver transplantation for hepatocellular carcinoma, we conducted a retrospective, single-center analysis of adult recipients transplanted between 2013 and 2021. Patients on everolimus-incorporating immunosuppression were matched with those on tacrolimus using an inverse probability of treatment weighting methodology. Two propensity-matched groups of patients were thus compared: 233 (45.6%) receiving everolimus versus 278 (54.4%) on tacrolimus. At a median (interquartile range) follow-up of 4.4 (3.8) years after transplantation, everolimus patients showed a reduced risk of recurrence versus tacrolimus (7.7% versus 16.9%; RR = 0.45; p = 0.002). At multivariable analysis, microvascular infiltration (HR = 1.22; p < 0.04) and a higher tumor grading (HR = 1.27; p < 0.04) were associated with higher recurrence rate while being within Milan criteria at transplant (HR = 0.56; p < 0.001), a successful pre-transplant downstaging (HR = 0.63; p = 0.01) and use of everolimus (HR = 0.46; p < 0.001) had a positive impact on the risk of post-transplant recurrence. EVR patients with earlier drug introduction (≤30 days; p < 0.001), longer treatment duration (p < 0.001), and higher drug exposure (≥5.9 ng/mL; p < 0.001) showed lower recurrence rates versus TAC. Based on our experience, everolimus provides a reduction in the relative risk of hepatocellular carcinoma recurrence, especially for advanced-stage patients and those with earlier drug administration, higher drug exposure, and longer time on treatment. These data advocate for early everolimus introduction after liver transplantation to reduce the attrition rate consequent to chronic immunosuppression." > <link rel="image_src" href="https://pub.mdpi-res.com/img/journals/cancers-logo.png?8600e93ff98dbf14" > <meta name="dc.title" content="Everolimus Mitigates the Risk of Hepatocellular Carcinoma Recurrence after Liver Transplantation"> <meta name="dc.creator" content="Paolo De Simone"> <meta name="dc.creator" content="Arianna Precisi"> <meta name="dc.creator" content="Quirino Lai"> <meta name="dc.creator" content="Juri Ducci"> <meta name="dc.creator" content="Daniela Campani"> <meta name="dc.creator" content="Piero Marchetti"> <meta name="dc.creator" content="Stefano Gitto"> <meta name="dc.type" content="Article"> <meta name="dc.source" content="Cancers 2024, Vol. 16, Page 1243"> <meta name="dc.date" content="2024-03-22"> <meta name ="dc.identifier" content="10.3390/cancers16071243"> <meta name="dc.publisher" content="Multidisciplinary Digital Publishing Institute"> <meta name="dc.rights" content="http://creativecommons.org/licenses/by/3.0/"> <meta name="dc.format" content="application/pdf" > <meta name="dc.language" content="en" > <meta name="dc.description" content="To obtain long-term data on the use of everolimus in patients who underwent liver transplantation for hepatocellular carcinoma, we conducted a retrospective, single-center analysis of adult recipients transplanted between 2013 and 2021. Patients on everolimus-incorporating immunosuppression were matched with those on tacrolimus using an inverse probability of treatment weighting methodology. Two propensity-matched groups of patients were thus compared: 233 (45.6%) receiving everolimus versus 278 (54.4%) on tacrolimus. At a median (interquartile range) follow-up of 4.4 (3.8) years after transplantation, everolimus patients showed a reduced risk of recurrence versus tacrolimus (7.7% versus 16.9%; RR = 0.45; p = 0.002). At multivariable analysis, microvascular infiltration (HR = 1.22; p < 0.04) and a higher tumor grading (HR = 1.27; p < 0.04) were associated with higher recurrence rate while being within Milan criteria at transplant (HR = 0.56; p < 0.001), a successful pre-transplant downstaging (HR = 0.63; p = 0.01) and use of everolimus (HR = 0.46; p < 0.001) had a positive impact on the risk of post-transplant recurrence. EVR patients with earlier drug introduction (≤30 days; p < 0.001), longer treatment duration (p < 0.001), and higher drug exposure (≥5.9 ng/mL; p < 0.001) showed lower recurrence rates versus TAC. Based on our experience, everolimus provides a reduction in the relative risk of hepatocellular carcinoma recurrence, especially for advanced-stage patients and those with earlier drug administration, higher drug exposure, and longer time on treatment. These data advocate for early everolimus introduction after liver transplantation to reduce the attrition rate consequent to chronic immunosuppression." > <meta name="dc.subject" content="liver transplantation" > <meta name="dc.subject" content="immunosuppression" > <meta name="dc.subject" content="everolimus" > <meta name="dc.subject" content="hepatocellular carcinoma" > <meta name="dc.subject" content="recurrence" > <meta name ="prism.issn" content="2072-6694"> <meta name ="prism.publicationName" content="Cancers"> <meta name ="prism.publicationDate" content="2024-03-22"> <meta name ="prism.volume" content="16"> <meta name ="prism.number" content="7"> <meta name ="prism.section" content="Article" > <meta name ="prism.startingPage" content="1243" > <meta name="citation_issn" content="2072-6694"> <meta name="citation_journal_title" content="Cancers"> <meta name="citation_publisher" content="Multidisciplinary Digital Publishing Institute"> <meta name="citation_title" content="Everolimus Mitigates the Risk of Hepatocellular Carcinoma Recurrence after Liver Transplantation"> <meta name="citation_publication_date" content="2024/1"> <meta name="citation_online_date" content="2024/03/22"> <meta name="citation_volume" content="16"> <meta name="citation_issue" content="7"> <meta name="citation_firstpage" content="1243"> <meta name="citation_author" content="De Simone, Paolo"> <meta name="citation_author" content="Precisi, Arianna"> <meta name="citation_author" content="Lai, Quirino"> <meta name="citation_author" content="Ducci, Juri"> <meta name="citation_author" content="Campani, Daniela"> <meta name="citation_author" content="Marchetti, Piero"> <meta name="citation_author" content="Gitto, Stefano"> <meta name="citation_doi" content="10.3390/cancers16071243"> <meta name="citation_id" content="mdpi-cancers16071243"> <meta name="citation_abstract_html_url" content="https://www.mdpi.com/2072-6694/16/7/1243"> <meta name="citation_pdf_url" content="https://www.mdpi.com/2072-6694/16/7/1243/pdf?version=1711092729"> <link rel="alternate" type="application/pdf" title="PDF Full-Text" href="https://www.mdpi.com/2072-6694/16/7/1243/pdf?version=1711092729"> <meta name="fulltext_pdf" content="https://www.mdpi.com/2072-6694/16/7/1243/pdf?version=1711092729"> <meta name="citation_fulltext_html_url" content="https://www.mdpi.com/2072-6694/16/7/1243/htm"> <link rel="alternate" type="text/html" title="HTML Full-Text" href="https://www.mdpi.com/2072-6694/16/7/1243/htm"> <meta name="fulltext_html" content="https://www.mdpi.com/2072-6694/16/7/1243/htm"> <link rel="alternate" type="text/xml" title="XML Full-Text" href="https://www.mdpi.com/2072-6694/16/7/1243/xml"> <meta name="fulltext_xml" content="https://www.mdpi.com/2072-6694/16/7/1243/xml"> <meta name="citation_xml_url" content="https://www.mdpi.com/2072-6694/16/7/1243/xml"> <meta name="twitter:card" content="summary" /> <meta name="twitter:site" content="@MDPIOpenAccess" /> <meta name="twitter:image" content="https://pub.mdpi-res.com/img/journals/cancers-logo-social.png?8600e93ff98dbf14" /> <meta property="fb:app_id" content="131189377574"/> <meta property="og:site_name" content="MDPI"/> <meta property="og:type" content="article"/> <meta property="og:url" content="https://www.mdpi.com/2072-6694/16/7/1243" /> <meta property="og:title" content="Everolimus Mitigates the Risk of Hepatocellular Carcinoma Recurrence after Liver Transplantation" /> <meta property="og:description" content="To obtain long-term data on the use of everolimus in patients who underwent liver transplantation for hepatocellular carcinoma, we conducted a retrospective, single-center analysis of adult recipients transplanted between 2013 and 2021. Patients on everolimus-incorporating immunosuppression were matched with those on tacrolimus using an inverse probability of treatment weighting methodology. Two propensity-matched groups of patients were thus compared: 233 (45.6%) receiving everolimus versus 278 (54.4%) on tacrolimus. At a median (interquartile range) follow-up of 4.4 (3.8) years after transplantation, everolimus patients showed a reduced risk of recurrence versus tacrolimus (7.7% versus 16.9%; RR = 0.45; p = 0.002). At multivariable analysis, microvascular infiltration (HR = 1.22; p < 0.04) and a higher tumor grading (HR = 1.27; p < 0.04) were associated with higher recurrence rate while being within Milan criteria at transplant (HR = 0.56; p < 0.001), a successful pre-transplant downstaging (HR = 0.63; p = 0.01) and use of everolimus (HR = 0.46; p < 0.001) had a positive impact on the risk of post-transplant recurrence. EVR patients with earlier drug introduction (≤30 days; p < 0.001), longer treatment duration (p < 0.001), and higher drug exposure (≥5.9 ng/mL; p < 0.001) showed lower recurrence rates versus TAC. Based on our experience, everolimus provides a reduction in the relative risk of hepatocellular carcinoma recurrence, especially for advanced-stage patients and those with earlier drug administration, higher drug exposure, and longer time on treatment. These data advocate for early everolimus introduction after liver transplantation to reduce the attrition rate consequent to chronic immunosuppression." /> <meta property="og:image" content="https://pub.mdpi-res.com/cancers/cancers-16-01243/article_deploy/html/images/cancers-16-01243-g001-550.jpg?1711092852" /> <link rel="alternate" type="application/rss+xml" title="MDPI Publishing - Latest articles" href="https://www.mdpi.com/rss"> <meta name="google-site-verification" content="PxTlsg7z2S00aHroktQd57fxygEjMiNHydKn3txhvwY"> <meta name="facebook-domain-verification" content="mcoq8dtq6sb2hf7z29j8w515jjoof7" /> <script id="Cookiebot" data-cfasync="false" src="https://consent.cookiebot.com/uc.js" data-cbid="51491ddd-fe7a-4425-ab39-69c78c55829f" type="text/javascript" async></script>  <script type="text/plain" data-cookieconsent="statistics"> (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start': new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0], j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src= 'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f); })(window,document,'script','dataLayer','GTM-WPK7SW5'); </script> <script type="text/plain" data-cookieconsent="statistics"> _linkedin_partner_id = "2846186"; window._linkedin_data_partner_ids = window._linkedin_data_partner_ids || []; window._linkedin_data_partner_ids.push(_linkedin_partner_id); </script><script type="text/javascript"> (function(){var s = document.getElementsByTagName("script")[0]; var b = document.createElement("script"); b.type = "text/javascript";b.async = true; b.src = "https://snap.licdn.com/li.lms-analytics/insight.min.js"; s.parentNode.insertBefore(b, s);})(); </script> <script type="text/plain" data-cookieconsent="statistics" data-cfasync="false" src="//script.crazyegg.com/pages/scripts/0116/4951.js" async="async" ></script> </head> <body> <div class="direction direction_right" id="small_right" style="border-right-width: 0px; padding:0;"> <i class="fa fa-caret-right fa-2x"></i> </div> <div class="big_direction direction_right" id="big_right" style="border-right-width: 0px;"> <div style="text-align: right;"> Next Article in Journal<br> <div><a href="/2072-6694/16/7/1245">Immunotherapy and Cannabis: A Harmful Drug Interaction or Reefer Madness?</a></div> Next Article in Special Issue<br> <div><a href="/2072-6694/16/10/1803">Liver Transplantation from Elderly Donors (≥85 Years Old)</a></div> </div> </div> <div class="direction" id="small_left" style="border-left-width: 0px"> <i class="fa fa-caret-left fa-2x"></i> </div> <div class="big_direction" id="big_left" style="border-left-width: 0px;"> <div> Previous Article in Journal<br> <div><a href="/2072-6694/16/6/1242">Synthetic Circular RNA for microRNA-1269a Suppresses Tumor Progression in Oral Squamous Cell Carcinoma</a></div> Previous Article in Special Issue<br> <div><a href="/2072-6694/16/5/920">Liver Transplantation for Hepatocellular Carcinoma beyond the Milan Criteria: A Specific Role for Living Donor Liver Transplantation after Neoadjuvant Therapy</a></div> </div> </div> <div style="clear: both;"></div> <div id="menuModal" class="reveal-modal reveal-modal-new reveal-modal-menu" aria-hidden="true" data-reveal role="dialog"> <div class="menu-container"> <div class="UI_NavMenu"> <div class="content__container " > <div class="custom-accordion-for-small-screen-link " > <h2>Journals</h2> </div> <div class="target-item custom-accordion-for-small-screen-content show-for-medium-up"> <div class="menu-container__links"> <div style="width: 100%; float: left;"> <a href="/about/journals">Active Journals</a> <a href="/about/journalfinder">Find a Journal</a> <a href="/about/journals/proposal">Journal Proposal</a> <a href="/about/proceedings">Proceedings Series</a> </div> </div> </div> </div> <a href="/topics"> <h2>Topics</h2> </a> <div class="content__container " > <div class="custom-accordion-for-small-screen-link " > <h2>Information</h2> </div> <div class="target-item custom-accordion-for-small-screen-content show-for-medium-up"> <div class="menu-container__links"> <div style="width: 100%; max-width: 200px; float: left;"> <a href="/authors">For Authors</a> <a href="/reviewers">For Reviewers</a> <a href="/editors">For Editors</a> <a href="/librarians">For Librarians</a> <a href="/publishing_services">For Publishers</a> <a href="/societies">For Societies</a> <a href="/conference_organizers">For Conference Organizers</a> </div> <div style="width: 100%; max-width: 250px; float: left;"> <a href="/openaccess">Open Access Policy</a> <a href="/ioap">Institutional Open Access Program</a> <a href="/special_issues_guidelines">Special Issues Guidelines</a> <a href="/editorial_process">Editorial Process</a> <a href="/ethics">Research and Publication Ethics</a> <a href="/apc">Article Processing Charges</a> <a href="/awards">Awards</a> <a href="/testimonials">Testimonials</a> </div> </div> </div> </div> <a href="/authors/english"> <h2>Editing Services</h2> </a> <div class="content__container " > <div class="custom-accordion-for-small-screen-link " > <h2>Initiatives</h2> </div> <div class="target-item custom-accordion-for-small-screen-content show-for-medium-up"> <div class="menu-container__links"> <div style="width: 100%; float: left;"> <a href="https://sciforum.net" target="_blank" rel="noopener noreferrer">Sciforum</a> <a href="https://www.mdpi.com/books" target="_blank" rel="noopener noreferrer">MDPI Books</a> <a href="https://www.preprints.org" target="_blank" rel="noopener noreferrer">Preprints.org</a> <a href="https://www.scilit.net" target="_blank" rel="noopener noreferrer">Scilit</a> <a href="https://sciprofiles.com" target="_blank" rel="noopener noreferrer">SciProfiles</a> <a href="https://encyclopedia.pub" target="_blank" rel="noopener noreferrer">Encyclopedia</a> <a href="https://jams.pub" target="_blank" rel="noopener noreferrer">JAMS</a> <a href="/about/proceedings">Proceedings Series</a> </div> </div> </div> </div> <div class="content__container " > <div class="custom-accordion-for-small-screen-link " > <h2>About</h2> </div> <div class="target-item custom-accordion-for-small-screen-content show-for-medium-up"> <div class="menu-container__links"> <div style="width: 100%; float: left;"> <a href="/about">Overview</a> <a href="/about/contact">Contact</a> <a href="https://careers.mdpi.com" target="_blank" rel="noopener noreferrer">Careers</a> <a href="/about/announcements">News</a> <a href="/about/press">Press</a> <a href="http://blog.mdpi.com/" target="_blank" rel="noopener noreferrer">Blog</a> </div> </div> </div> </div> </div> <div class="menu-container__buttons"> <a class="button UA_SignInUpButton" href="/user/login">Sign In / Sign Up</a> </div> </div> </div> <div id="captchaModal" class="reveal-modal reveal-modal-new reveal-modal-new--small" data-reveal aria-label="Captcha" aria-hidden="true" role="dialog"></div> <div id="actionDisabledModal" class="reveal-modal" data-reveal aria-labelledby="actionDisableModalTitle" aria-hidden="true" role="dialog" style="width: 300px;"> <h2 id="actionDisableModalTitle">Notice</h2> <form action="/email/captcha" method="post" id="emailCaptchaForm"> <div class="row"> <div id="js-action-disabled-modal-text" class="small-12 columns"> </div> <div id="js-action-disabled-modal-submit" class="small-12 columns" style="margin-top: 10px; display: none;"> You can make submissions to other journals <a href="https://susy.mdpi.com/user/manuscripts/upload">here</a>. </div> </div> </form> <a class="close-reveal-modal" aria-label="Close"> <i class="material-icons">clear</i> </a> </div> <div id="rssNotificationModal" class="reveal-modal reveal-modal-new" data-reveal aria-labelledby="rssNotificationModalTitle" aria-hidden="true" role="dialog"> <div class="row"> <div class="small-12 columns"> <h2 id="rssNotificationModalTitle">Notice</h2> <p> You are accessing a machine-readable page. In order to be human-readable, please install an RSS reader. </p> </div> </div> <div class="row"> <div class="small-12 columns"> <a class="button button--color js-rss-notification-confirm">Continue</a> <a class="button button--grey" onclick="$(this).closest('.reveal-modal').find('.close-reveal-modal').click(); return false;">Cancel</a> </div> </div> <a class="close-reveal-modal" aria-label="Close"> <i class="material-icons">clear</i> </a> </div> <div id="drop-article-label-openaccess" class="f-dropdown medium" data-dropdown-content aria-hidden="true" tabindex="-1"> <p> All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to <a href="https://www.mdpi.com/openaccess">https://www.mdpi.com/openaccess</a>. </p> </div> <div id="drop-article-label-feature" class="f-dropdown medium" data-dropdown-content aria-hidden="true" tabindex="-1"> <p> Feature papers represent the most advanced research with significant potential for high impact in the field. A Feature Paper should be a substantial original Article that involves several techniques or approaches, provides an outlook for future research directions and describes possible research applications. </p> <p> Feature papers are submitted upon individual invitation or recommendation by the scientific editors and must receive positive feedback from the reviewers. </p> </div> <div id="drop-article-label-choice" class="f-dropdown medium" data-dropdown-content aria-hidden="true" tabindex="-1"> <p> Editor’s Choice articles are based on recommendations by the scientific editors of MDPI journals from around the world. Editors select a small number of articles recently published in the journal that they believe will be particularly interesting to readers, or important in the respective research area. The aim is to provide a snapshot of some of the most exciting work published in the various research areas of the journal. <div style="margin-top: -10px;"> <div id="drop-article-label-choice-journal-link" style="display: none; margin-top: -10px; padding-top: 10px;"> </div> </div> </p> </div> <div id="drop-article-label-resubmission" class="f-dropdown medium" data-dropdown-content aria-hidden="true" tabindex="-1"> <p> Original Submission Date Received: <span id="drop-article-label-resubmission-date"></span>. </p> </div> <div id="container"> <noscript> <div id="no-javascript"> You seem to have javascript disabled. Please note that many of the page functionalities won't work as expected without javascript enabled. </div> </noscript> <div class="fixed"> <nav class="tab-bar show-for-medium-down"> <div class="row full-width collapse"> <div class="medium-3 small-4 columns"> <a href="/"> <img class="full-size-menu__mdpi-logo" src="https://pub.mdpi-res.com/img/design/mdpi-pub-logo-black-small1.svg?da3a8dcae975a41c?1732286508" style="width: 64px;" title="MDPI Open Access Journals"> </a> </div> <div class="medium-3 small-4 columns right-aligned"> <div class="show-for-medium-down"> <a href="#" style="display: none;"> <i class="material-icons" onclick="$('#menuModal').foundation('reveal', 'close'); return false;">clear</i> </a> <a class="js-toggle-desktop-layout-link" title="Toggle desktop layout" style="display: none;" href="/toggle_desktop_layout_cookie"> <i class="material-icons">zoom_out_map</i> </a> <a href="#" class="js-open-small-search open-small-search"> <i class="material-icons show-for-small only">search</i> </a> <a title="MDPI main page" class="js-open-menu" data-reveal-id="menuModal" href="#"> <i class="material-icons">menu</i> </a> </div> </div> </div> </nav> </div> <section class="main-section"> <header> <div class="full-size-menu show-for-large-up"> <div class="row full-width"> <div class="large-1 columns"> <a href="/"> <img class="full-size-menu__mdpi-logo" src="https://pub.mdpi-res.com/img/design/mdpi-pub-logo-black-small1.svg?da3a8dcae975a41c?1732286508" title="MDPI Open Access Journals"> </a> </div> <div class="large-8 columns text-right UI_NavMenu"> <ul> <li class="menu-item"> <a href="/about/journals" data-dropdown="journals-dropdown" aria-controls="journals-dropdown" aria-expanded="false" data-options="is_hover: true; hover_timeout: 200">Journals</a> <ul id="journals-dropdown" class="f-dropdown dropdown-wrapper dropdown-wrapper__small" data-dropdown-content aria-hidden="true" tabindex="-1"> <li> <div class="row"> <div class="small-12 columns"> <ul> <li> <a href="/about/journals"> Active Journals </a> </li> <li> <a href="/about/journalfinder"> Find a Journal </a> </li> <li> <a href="/about/journals/proposal"> Journal Proposal </a> </li> <li> <a href="/about/proceedings"> Proceedings Series </a> </li> </ul> </div> </div> </li> </ul> </li> <li class="menu-item"> <a href="/topics">Topics</a> </li> <li class="menu-item"> <a href="/authors" data-dropdown="information-dropdown" aria-controls="information-dropdown" aria-expanded="false" data-options="is_hover:true; hover_timeout:200">Information</a> <ul id="information-dropdown" class="f-dropdown dropdown-wrapper" data-dropdown-content aria-hidden="true" tabindex="-1"> <li> <div class="row"> <div class="small-5 columns right-border"> <ul> <li> <a href="/authors">For Authors</a> </li> <li> <a href="/reviewers">For Reviewers</a> </li> <li> <a href="/editors">For Editors</a> </li> <li> <a href="/librarians">For Librarians</a> </li> <li> <a href="/publishing_services">For Publishers</a> </li> <li> <a href="/societies">For Societies</a> </li> <li> <a href="/conference_organizers">For Conference Organizers</a> </li> </ul> </div> <div class="small-7 columns"> <ul> <li> <a href="/openaccess">Open Access Policy</a> </li> <li> <a href="/ioap">Institutional Open Access Program</a> </li> <li> <a href="/special_issues_guidelines">Special Issues Guidelines</a> </li> <li> <a href="/editorial_process">Editorial Process</a> </li> <li> <a href="/ethics">Research and Publication Ethics</a> </li> <li> <a href="/apc">Article Processing Charges</a> </li> <li> <a href="/awards">Awards</a> </li> <li> <a href="/testimonials">Testimonials</a> </li> </ul> </div> </div> </li> </ul> </li> <li class="menu-item"> <a href="/authors/english">Editing Services</a> </li> <li class="menu-item"> <a href="/about/initiatives" data-dropdown="initiatives-dropdown" aria-controls="initiatives-dropdown" aria-expanded="false" data-options="is_hover: true; hover_timeout: 200">Initiatives</a> <ul id="initiatives-dropdown" class="f-dropdown dropdown-wrapper dropdown-wrapper__small" data-dropdown-content aria-hidden="true" tabindex="-1"> <li> <div class="row"> <div class="small-12 columns"> <ul> <li> <a href="https://sciforum.net" target="_blank" rel="noopener noreferrer"> Sciforum </a> </li> <li> <a href="https://www.mdpi.com/books" target="_blank" rel="noopener noreferrer"> MDPI Books </a> </li> <li> <a href="https://www.preprints.org" target="_blank" rel="noopener noreferrer"> Preprints.org </a> </li> <li> <a href="https://www.scilit.net" target="_blank" rel="noopener noreferrer"> Scilit </a> </li> <li> <a href="https://sciprofiles.com" target="_blank" rel="noopener noreferrer"> SciProfiles </a> </li> <li> <a href="https://encyclopedia.pub" target="_blank" rel="noopener noreferrer"> Encyclopedia </a> </li> <li> <a href="https://jams.pub" target="_blank" rel="noopener noreferrer"> JAMS </a> </li> <li> <a href="/about/proceedings"> Proceedings Series </a> </li> </ul> </div> </div> </li> </ul> </li> <li class="menu-item"> <a href="/about" data-dropdown="about-dropdown" aria-controls="about-dropdown" aria-expanded="false" data-options="is_hover: true; hover_timeout: 200">About</a> <ul id="about-dropdown" class="f-dropdown dropdown-wrapper dropdown-wrapper__small" data-dropdown-content aria-hidden="true" tabindex="-1"> <li> <div class="row"> <div class="small-12 columns"> <ul> <li> <a href="/about"> Overview </a> </li> <li> <a href="/about/contact"> Contact </a> </li> <li> <a href="https://careers.mdpi.com" target="_blank" rel="noopener noreferrer"> Careers </a> </li> <li> <a href="/about/announcements"> News </a> </li> <li> <a href="/about/press"> Press </a> </li> <li> <a href="http://blog.mdpi.com/" target="_blank" rel="noopener noreferrer"> Blog </a> </li> </ul> </div> </div> </li> </ul> </li> </ul> </div> <div class="large-3 columns text-right full-size-menu__buttons"> <div> <a class="button button--default-inversed UA_SignInUpButton" href="/user/login">Sign In / Sign Up</a> <a class="button button--default js-journal-active-only-link js-journal-active-only-submit-link UC_NavSubmitButton" href=" https://susy.mdpi.com/user/manuscripts/upload?journal=cancers " data-disabledmessage="new submissions are not possible.">Submit</a> </div> </div> </div> </div> <div class="header-divider"> </div> <div class="search-container hide-for-small-down row search-container__homepage-scheme"> <form id="basic_search" style="background-color: inherit !important;" class="large-12 medium-12 columns " action="/search" method="get"> <div class="row search-container__main-elements"> <div class="large-2 medium-2 small-12 columns text-right1 small-only-text-left"> <div class="show-for-medium-up"> <div class="search-input-label"> </div> </div> <span class="search-container__title">Search<span class="hide-for-medium"> for Articles</span><span class="hide-for-small">:</span></span> </div> <div class="custom-accordion-for-small-screen-content"> <div class="large-2 medium-2 small-6 columns "> <div class=""> <div class="search-input-label">Title / Keyword</div> </div> <input type="text" placeholder="Title / Keyword" id="q" tabindex="1" name="q" value="" /> </div> <div class="large-2 medium-2 small-6 columns "> <div class=""> <div class="search-input-label">Author / Affiliation / Email</div> </div> <input type="text" id="authors" placeholder="Author / Affiliation / Email" tabindex="2" name="authors" value="" /> </div> <div class="large-2 medium-2 small-6 columns "> <div class=""> <div class="search-input-label">Journal</div> </div> <select id="journal" tabindex="3" name="journal" class="chosen-select"> <option value="">All Journals</option> <option value="acoustics" > Acoustics </option> <option value="amh" > Acta Microbiologica Hellenica (AMH) </option> <option value="actuators" > Actuators </option> <option value="admsci" > Administrative Sciences </option> <option value="adolescents" > Adolescents </option> <option value="arm" > Advances in Respiratory Medicine (ARM) </option> <option value="aerobiology" > Aerobiology </option> <option value="aerospace" > Aerospace </option> <option value="agriculture" > Agriculture </option> <option value="agriengineering" > AgriEngineering </option> <option value="agrochemicals" > Agrochemicals </option> <option value="agronomy" > Agronomy </option> <option value="ai" > AI </option> <option value="air" > Air </option> <option value="algorithms" > Algorithms </option> <option value="allergies" > Allergies </option> <option value="alloys" > Alloys </option> <option value="analytica" > Analytica </option> <option value="analytics" > Analytics </option> <option value="anatomia" > Anatomia </option> <option value="anesthres" > Anesthesia Research </option> <option value="animals" > Animals </option> <option value="antibiotics" > Antibiotics </option> <option value="antibodies" > Antibodies </option> <option value="antioxidants" > Antioxidants </option> <option value="applbiosci" > Applied Biosciences </option> <option value="applmech" > Applied Mechanics </option> <option value="applmicrobiol" > Applied Microbiology </option> <option value="applnano" > Applied Nano </option> <option value="applsci" > Applied Sciences </option> <option value="asi" > Applied System Innovation (ASI) </option> <option value="appliedchem" > AppliedChem </option> <option value="appliedmath" > AppliedMath </option> <option value="aquacj" > Aquaculture Journal </option> <option value="architecture" > Architecture </option> <option value="arthropoda" > Arthropoda </option> <option value="arts" > Arts </option> <option value="astronomy" > Astronomy </option> <option value="atmosphere" > Atmosphere </option> <option value="atoms" > Atoms </option> <option value="audiolres" > Audiology Research </option> <option value="automation" > Automation </option> <option value="axioms" > Axioms </option> <option value="bacteria" > Bacteria </option> <option value="batteries" > Batteries </option> <option value="behavsci" > Behavioral Sciences </option> <option value="beverages" > Beverages </option> <option value="BDCC" > Big Data and Cognitive Computing (BDCC) </option> <option value="biochem" > BioChem </option> <option value="bioengineering" > Bioengineering </option> <option value="biologics" > Biologics </option> <option value="biology" > Biology </option> <option value="blsf" > Biology and Life Sciences Forum </option> <option value="biomass" > Biomass </option> <option value="biomechanics" > Biomechanics </option> <option value="biomed" > BioMed </option> <option value="biomedicines" > Biomedicines </option> <option value="biomedinformatics" > BioMedInformatics </option> <option value="biomimetics" > Biomimetics </option> <option value="biomolecules" > Biomolecules </option> <option value="biophysica" > Biophysica </option> <option value="biosensors" > Biosensors </option> <option value="biotech" > BioTech </option> <option value="birds" > Birds </option> <option value="blockchains" > Blockchains </option> <option value="brainsci" > Brain Sciences </option> <option value="buildings" > Buildings </option> <option value="businesses" > Businesses </option> <option value="carbon" > C </option> <option value="cancers" selected='selected'> Cancers </option> <option value="cardiogenetics" > Cardiogenetics </option> <option value="catalysts" > Catalysts </option> <option value="cells" > Cells </option> <option value="ceramics" > Ceramics </option> <option value="challenges" > Challenges </option> <option value="ChemEngineering" > ChemEngineering </option> <option value="chemistry" > Chemistry </option> <option value="chemproc" > Chemistry Proceedings </option> <option value="chemosensors" > Chemosensors </option> <option value="children" > Children </option> <option value="chips" > Chips </option> <option value="civileng" > CivilEng </option> <option value="cleantechnol" > Clean Technologies (Clean Technol.) </option> <option value="climate" > Climate </option> <option value="ctn" > Clinical and Translational Neuroscience (CTN) </option> <option value="clinbioenerg" > Clinical Bioenergetics </option> <option value="clinpract" > Clinics and Practice </option> <option value="clockssleep" > Clocks & Sleep </option> <option value="coasts" > Coasts </option> <option value="coatings" > Coatings </option> <option value="colloids" > Colloids and Interfaces </option> <option value="colorants" > Colorants </option> <option value="commodities" > Commodities </option> <option value="complications" > Complications </option> <option value="compounds" > Compounds </option> <option value="computation" > Computation </option> <option value="csmf" > Computer Sciences & Mathematics Forum </option> <option value="computers" > Computers </option> <option value="condensedmatter" > Condensed Matter </option> <option value="conservation" > Conservation </option> <option value="constrmater" > Construction Materials </option> <option value="cmd" > Corrosion and Materials Degradation (CMD) </option> <option value="cosmetics" > Cosmetics </option> <option value="covid" > COVID </option> <option value="crops" > Crops </option> <option value="cryo" > Cryo </option> <option value="cryptography" > Cryptography </option> <option value="crystals" > Crystals </option> <option value="cimb" > Current Issues in Molecular Biology (CIMB) </option> <option value="curroncol" > Current Oncology </option> <option value="dairy" > Dairy </option> <option value="data" > Data </option> <option value="dentistry" > Dentistry Journal </option> <option value="dermato" > Dermato </option> <option value="dermatopathology" > Dermatopathology </option> <option value="designs" > Designs </option> <option value="diabetology" > Diabetology </option> <option value="diagnostics" > Diagnostics </option> <option value="dietetics" > Dietetics </option> <option value="digital" > Digital </option> <option value="disabilities" > Disabilities </option> <option value="diseases" > Diseases </option> <option value="diversity" > Diversity </option> <option value="dna" > DNA </option> <option value="drones" > Drones </option> <option value="ddc" > Drugs and Drug Candidates (DDC) </option> <option value="dynamics" > Dynamics </option> <option value="earth" > Earth </option> <option value="ecologies" > Ecologies </option> <option value="econometrics" > Econometrics </option> <option value="economies" > Economies </option> <option value="education" > Education Sciences </option> <option value="electricity" > Electricity </option> <option value="electrochem" > Electrochem </option> <option value="electronicmat" > Electronic Materials </option> <option value="electronics" > Electronics </option> <option value="ecm" > Emergency Care and Medicine </option> <option value="encyclopedia" > Encyclopedia </option> <option value="endocrines" > Endocrines </option> <option value="energies" > Energies </option> <option value="esa" > Energy Storage and Applications (ESA) </option> <option value="eng" > Eng </option> <option value="engproc" > Engineering Proceedings </option> <option value="entropy" > Entropy </option> <option value="environsciproc" > Environmental Sciences Proceedings </option> <option value="environments" > Environments </option> <option value="epidemiologia" > Epidemiologia </option> <option value="epigenomes" > Epigenomes </option> <option value="ebj" > European Burn Journal (EBJ) </option> <option value="ejihpe" > European Journal of Investigation in Health, Psychology and Education (EJIHPE) </option> <option value="fermentation" > Fermentation </option> <option value="fibers" > Fibers </option> <option value="fintech" > FinTech </option> <option value="fire" > Fire </option> <option value="fishes" > Fishes </option> <option value="fluids" > Fluids </option> <option value="foods" > Foods </option> <option value="forecasting" > Forecasting </option> <option value="forensicsci" > Forensic Sciences </option> <option value="forests" > Forests </option> <option value="fossstud" > Fossil Studies </option> <option value="foundations" > Foundations </option> <option value="fractalfract" > Fractal and Fractional (Fractal Fract) </option> <option value="fuels" > Fuels </option> <option value="future" > Future </option> <option value="futureinternet" > Future Internet </option> <option value="futurepharmacol" > Future Pharmacology </option> <option value="futuretransp" > Future Transportation </option> <option value="galaxies" > Galaxies </option> <option value="games" > Games </option> <option value="gases" > Gases </option> <option value="gastroent" > Gastroenterology Insights </option> <option value="gastrointestdisord" > Gastrointestinal Disorders </option> <option value="gastronomy" > Gastronomy </option> <option value="gels" > Gels </option> <option value="genealogy" > Genealogy </option> <option value="genes" > Genes </option> <option value="geographies" > Geographies </option> <option value="geohazards" > GeoHazards </option> <option value="geomatics" > Geomatics </option> <option value="geometry" > Geometry </option> <option value="geosciences" > Geosciences </option> <option value="geotechnics" > Geotechnics </option> <option value="geriatrics" > Geriatrics </option> <option value="glacies" > Glacies </option> <option value="gucdd" > Gout, Urate, and Crystal Deposition Disease (GUCDD) </option> <option value="grasses" > Grasses </option> <option value="hardware" > Hardware </option> <option value="healthcare" > Healthcare </option> <option value="hearts" > Hearts </option> <option value="hemato" > Hemato </option> <option value="hematolrep" > Hematology Reports </option> <option value="heritage" > Heritage </option> <option value="histories" > Histories </option> <option value="horticulturae" > Horticulturae </option> <option value="hospitals" > Hospitals </option> <option value="humanities" > Humanities </option> <option value="humans" > Humans </option> <option value="hydrobiology" > Hydrobiology </option> <option value="hydrogen" > Hydrogen </option> <option value="hydrology" > Hydrology </option> <option value="hygiene" > Hygiene </option> <option value="immuno" > Immuno </option> <option value="idr" > Infectious Disease Reports </option> <option value="informatics" > Informatics </option> <option value="information" > Information </option> <option value="infrastructures" > Infrastructures </option> <option value="inorganics" > Inorganics </option> <option value="insects" > Insects </option> <option value="instruments" > Instruments </option> <option value="iic" > Intelligent Infrastructure and Construction </option> <option value="ijerph" > International Journal of Environmental Research and Public Health (IJERPH) </option> <option value="ijfs" > International Journal of Financial Studies (IJFS) </option> <option value="ijms" > International Journal of Molecular Sciences (IJMS) </option> <option value="IJNS" > International Journal of Neonatal Screening (IJNS) </option> <option value="ijpb" > International Journal of Plant Biology (IJPB) </option> <option value="ijt" > International Journal of Topology </option> <option value="ijtm" > International Journal of Translational Medicine (IJTM) </option> <option value="ijtpp" > International Journal of Turbomachinery, Propulsion and Power (IJTPP) </option> <option value="ime" > International Medical Education (IME) </option> <option value="inventions" > Inventions </option> <option value="IoT" > IoT </option> <option value="ijgi" > ISPRS International Journal of Geo-Information (IJGI) </option> <option value="J" > J </option> <option value="jal" > Journal of Ageing and Longevity (JAL) </option> <option value="jcdd" > Journal of Cardiovascular Development and Disease (JCDD) </option> <option value="jcto" > Journal of Clinical & Translational Ophthalmology (JCTO) </option> <option value="jcm" > Journal of Clinical Medicine (JCM) </option> <option value="jcs" > Journal of Composites Science (J. Compos. Sci.) </option> <option value="jcp" > Journal of Cybersecurity and Privacy (JCP) </option> <option value="jdad" > Journal of Dementia and Alzheimer's Disease (JDAD) </option> <option value="jdb" > Journal of Developmental Biology (JDB) </option> <option value="jeta" > Journal of Experimental and Theoretical Analyses (JETA) </option> <option value="jfb" > Journal of Functional Biomaterials (JFB) </option> <option value="jfmk" > Journal of Functional Morphology and Kinesiology (JFMK) </option> <option value="jof" > Journal of Fungi (JoF) </option> <option value="jimaging" > Journal of Imaging (J. Imaging) </option> <option value="jintelligence" > Journal of Intelligence (J. Intell.) </option> <option value="jlpea" > Journal of Low Power Electronics and Applications (JLPEA) </option> <option value="jmmp" > Journal of Manufacturing and Materials Processing (JMMP) </option> <option value="jmse" > Journal of Marine Science and Engineering (JMSE) </option> <option value="jmahp" > Journal of Market Access & Health Policy (JMAHP) </option> <option value="jmp" > Journal of Molecular Pathology (JMP) </option> <option value="jnt" > Journal of Nanotheranostics (JNT) </option> <option value="jne" > Journal of Nuclear Engineering (JNE) </option> <option value="ohbm" > Journal of Otorhinolaryngology, Hearing and Balance Medicine (JOHBM) </option> <option value="jop" > Journal of Parks </option> <option value="jpm" > Journal of Personalized Medicine (JPM) </option> <option value="jpbi" > Journal of Pharmaceutical and BioTech Industry (JPBI) </option> <option value="jor" > Journal of Respiration (JoR) </option> <option value="jrfm" > Journal of Risk and Financial Management (JRFM) </option> <option value="jsan" > Journal of Sensor and Actuator Networks (JSAN) </option> <option value="joma" > Journal of the Oman Medical Association (JOMA) </option> <option value="jtaer" > Journal of Theoretical and Applied Electronic Commerce Research (JTAER) </option> <option value="jvd" > Journal of Vascular Diseases (JVD) </option> <option value="jox" > Journal of Xenobiotics (JoX) </option> <option value="jzbg" > Journal of Zoological and Botanical Gardens (JZBG) </option> <option value="journalmedia" > Journalism and Media </option> <option value="kidneydial" > Kidney and Dialysis </option> <option value="kinasesphosphatases" > Kinases and Phosphatases </option> <option value="knowledge" > Knowledge </option> <option value="labmed" > LabMed </option> <option value="laboratories" > Laboratories </option> <option value="land" > Land </option> <option value="languages" > Languages </option> <option value="laws" > Laws </option> <option value="life" > Life </option> <option value="limnolrev" > Limnological Review </option> <option value="lipidology" > Lipidology </option> <option value="liquids" > Liquids </option> <option value="literature" > Literature </option> <option value="livers" > Livers </option> <option value="logics" > Logics </option> <option value="logistics" > Logistics </option> <option value="lubricants" > Lubricants </option> <option value="lymphatics" > Lymphatics </option> <option value="make" > Machine Learning and Knowledge Extraction (MAKE) </option> <option value="machines" > Machines </option> <option value="macromol" > Macromol </option> <option value="magnetism" > Magnetism </option> <option value="magnetochemistry" > Magnetochemistry </option> <option value="marinedrugs" > Marine Drugs </option> <option value="materials" > Materials </option> <option value="materproc" > Materials Proceedings </option> <option value="mca" > Mathematical and Computational Applications (MCA) </option> <option value="mathematics" > Mathematics </option> <option value="medsci" > Medical Sciences </option> <option value="msf" > Medical Sciences Forum </option> <option value="medicina" > Medicina </option> <option value="medicines" > Medicines </option> <option value="membranes" > Membranes </option> <option value="merits" > Merits </option> <option value="metabolites" > Metabolites </option> <option value="metals" > Metals </option> <option value="meteorology" > Meteorology </option> <option value="methane" > Methane </option> <option value="mps" > Methods and Protocols (MPs) </option> <option value="metrics" > Metrics </option> <option value="metrology" > Metrology </option> <option value="micro" > Micro </option> <option value="microbiolres" > Microbiology Research </option> <option value="micromachines" > Micromachines </option> <option value="microorganisms" > Microorganisms </option> <option value="microplastics" > Microplastics </option> <option value="minerals" > Minerals </option> <option value="mining" > Mining </option> <option value="modelling" > Modelling </option> <option value="mmphys" > Modern Mathematical Physics </option> <option value="molbank" > Molbank </option> <option value="molecules" > Molecules </option> <option value="mti" > Multimodal Technologies and Interaction (MTI) </option> <option value="muscles" > Muscles </option> <option value="nanoenergyadv" > Nanoenergy Advances </option> <option value="nanomanufacturing" > Nanomanufacturing </option> <option value="nanomaterials" > Nanomaterials </option> <option value="ndt" > NDT </option> <option value="network" > Network </option> <option value="neuroglia" > Neuroglia </option> <option value="neurolint" > Neurology International </option> <option value="neurosci" > NeuroSci </option> <option value="nitrogen" > Nitrogen </option> <option value="ncrna" > Non-Coding RNA (ncRNA) </option> <option value="nursrep" > Nursing Reports </option> <option value="nutraceuticals" > Nutraceuticals </option> <option value="nutrients" > Nutrients </option> <option value="obesities" > Obesities </option> <option value="oceans" > Oceans </option> <option value="onco" > Onco </option> <option value="optics" > Optics </option> <option value="oral" > Oral </option> <option value="organics" > Organics </option> <option value="organoids" > Organoids </option> <option value="osteology" > Osteology </option> <option value="oxygen" > Oxygen </option> <option value="parasitologia" > Parasitologia </option> <option value="particles" > Particles </option> <option value="pathogens" > Pathogens </option> <option value="pathophysiology" > Pathophysiology </option> <option value="pediatrrep" > Pediatric Reports </option> <option value="pets" > Pets </option> <option value="pharmaceuticals" > Pharmaceuticals </option> <option value="pharmaceutics" > Pharmaceutics </option> <option value="pharmacoepidemiology" > Pharmacoepidemiology </option> <option value="pharmacy" > Pharmacy </option> <option value="philosophies" > Philosophies </option> <option value="photochem" > Photochem </option> <option value="photonics" > Photonics </option> <option value="phycology" > Phycology </option> <option value="physchem" > Physchem </option> <option value="psf" > Physical Sciences Forum </option> <option value="physics" > Physics </option> <option value="physiologia" > Physiologia </option> <option value="plants" > Plants </option> <option value="plasma" > Plasma </option> <option value="platforms" > Platforms </option> <option value="pollutants" > Pollutants </option> <option value="polymers" > Polymers </option> <option value="polysaccharides" > Polysaccharides </option> <option value="populations" > Populations </option> <option value="poultry" > Poultry </option> <option value="powders" > Powders </option> <option value="proceedings" > Proceedings </option> <option value="processes" > Processes </option> <option value="prosthesis" > Prosthesis </option> <option value="proteomes" > Proteomes </option> <option value="psychiatryint" > Psychiatry International </option> <option value="psychoactives" > Psychoactives </option> <option value="psycholint" > Psychology International </option> <option value="publications" > Publications </option> <option value="qubs" > Quantum Beam Science (QuBS) </option> <option value="quantumrep" > Quantum Reports </option> <option value="quaternary" > Quaternary </option> <option value="radiation" > Radiation </option> <option value="reactions" > Reactions </option> <option value="realestate" > Real Estate </option> <option value="receptors" > Receptors </option> <option value="recycling" > Recycling </option> <option value="rsee" > Regional Science and Environmental Economics (RSEE) </option> <option value="religions" > Religions </option> <option value="remotesensing" > Remote Sensing </option> <option value="reports" > Reports </option> <option value="reprodmed" > Reproductive Medicine (Reprod. Med.) </option> <option value="resources" > Resources </option> <option value="rheumato" > Rheumato </option> <option value="risks" > Risks </option> <option value="robotics" > Robotics </option> <option value="ruminants" > Ruminants </option> <option value="safety" > Safety </option> <option value="sci" > Sci </option> <option value="scipharm" > Scientia Pharmaceutica (Sci. Pharm.) </option> <option value="sclerosis" > Sclerosis </option> <option value="seeds" > Seeds </option> <option value="sensors" > Sensors </option> <option value="separations" > Separations </option> <option value="sexes" > Sexes </option> <option value="signals" > Signals </option> <option value="sinusitis" > Sinusitis </option> <option value="smartcities" > Smart Cities </option> <option value="socsci" > Social Sciences </option> <option value="siuj" > Société Internationale d’Urologie Journal (SIUJ) </option> <option value="societies" > Societies </option> <option value="software" > Software </option> <option value="soilsystems" > Soil Systems </option> <option value="solar" > Solar </option> <option value="solids" > Solids </option> <option value="spectroscj" > Spectroscopy Journal </option> <option value="sports" > Sports </option> <option value="standards" > Standards </option> <option value="stats" > Stats </option> <option value="stresses" > Stresses </option> <option value="surfaces" > Surfaces </option> <option value="surgeries" > Surgeries </option> <option value="std" > Surgical Techniques Development </option> <option value="sustainability" > Sustainability </option> <option value="suschem" > Sustainable Chemistry </option> <option value="symmetry" > Symmetry </option> <option value="synbio" > SynBio </option> <option value="systems" > Systems </option> <option value="targets" > Targets </option> <option value="taxonomy" > Taxonomy </option> <option value="technologies" > Technologies </option> <option value="telecom" > Telecom </option> <option value="textiles" > Textiles </option> <option value="thalassrep" > Thalassemia Reports </option> <option value="therapeutics" > Therapeutics </option> <option value="thermo" > Thermo </option> <option value="timespace" > Time and Space </option> <option value="tomography" > Tomography </option> <option value="tourismhosp" > Tourism and Hospitality </option> <option value="toxics" > Toxics </option> <option value="toxins" > Toxins </option> <option value="transplantology" > Transplantology </option> <option value="traumacare" > Trauma Care </option> <option value="higheredu" > Trends in Higher Education </option> <option value="tropicalmed" > Tropical Medicine and Infectious Disease (TropicalMed) </option> <option value="universe" > Universe </option> <option value="urbansci" > Urban Science </option> <option value="uro" > Uro </option> <option value="vaccines" > Vaccines </option> <option value="vehicles" > Vehicles </option> <option value="venereology" > Venereology </option> <option value="vetsci" > Veterinary Sciences </option> <option value="vibration" > Vibration </option> <option value="virtualworlds" > Virtual Worlds </option> <option value="viruses" > Viruses </option> <option value="vision" > Vision </option> <option value="waste" > Waste </option> <option value="water" > Water </option> <option value="wild" > Wild </option> <option value="wind" > Wind </option> <option value="women" > Women </option> <option value="world" > World </option> <option value="wevj" > World Electric Vehicle Journal (WEVJ) </option> <option value="youth" > Youth </option> <option value="zoonoticdis" > Zoonotic Diseases </option> </select> </div> <div class="large-2 medium-2 small-6 columns "> <div class=""> <div class="search-input-label">Article Type</div> </div> <select id="article_type" tabindex="4" name="article_type" class="chosen-select"> <option value="">All Article Types</option> <option value="research-article">Article</option> <option value="review-article">Review</option> <option value="rapid-communication">Communication</option> <option value="editorial">Editorial</option> <option value="abstract">Abstract</option> <option value="book-review">Book Review</option> <option value="brief-communication">Brief Communication</option> <option value="brief-report">Brief Report</option> <option value="case-report">Case Report</option> <option value="clinicopathological-challenge">Clinicopathological Challenge</option> <option value="article-commentary">Comment</option> <option value="commentary">Commentary</option> <option value="concept-paper">Concept Paper</option> <option value="conference-report">Conference Report</option> <option value="correction">Correction</option> <option value="creative">Creative</option> <option value="data-descriptor">Data Descriptor</option> <option value="discussion">Discussion</option> <option value="Entry">Entry</option> <option value="essay">Essay</option> <option value="expression-of-concern">Expression of Concern</option> <option value="extended-abstract">Extended Abstract</option> <option value="field-guide">Field Guide</option> <option value="guidelines">Guidelines</option> <option value="hypothesis">Hypothesis</option> <option value="interesting-image">Interesting Images</option> <option value="letter">Letter</option> <option value="books-received">New Book Received</option> <option value="obituary">Obituary</option> <option value="opinion">Opinion</option> <option value="perspective">Perspective</option> <option value="proceedings">Proceeding Paper</option> <option value="project-report">Project Report</option> <option value="protocol">Protocol</option> <option value="registered-report">Registered Report</option> <option value="reply">Reply</option> <option value="retraction">Retraction</option> <option value="note">Short Note</option> <option value="study-protocol">Study Protocol</option> <option value="systematic_review">Systematic Review</option> <option value="technical-note">Technical Note</option> <option value="tutorial">Tutorial</option> <option value="viewpoint">Viewpoint</option> </select> </div> <div class="large-1 medium-1 small-6 end columns small-push-6 medium-reset-order large-reset-order js-search-collapsed-button-container"> <div class="search-input-label"> </div> <input type="submit" id="search" value="Search" class="button button--dark button--full-width searchButton1 US_SearchButton" tabindex="12"> </div> <div class="large-1 medium-1 small-6 end columns large-text-left small-only-text-center small-pull-6 medium-reset-order large-reset-order js-search-collapsed-link-container"> <div class="search-input-label"> </div> <a class="main-search-clear search-container__link" href="#" onclick="openAdvanced(''); return false;">Advanced<span class="show-for-small-only"> Search</span></a> </div> </div> </div> <div class="search-container__advanced" style="margin-top: 0; padding-top: 0px; background-color: inherit; color: inherit;"> <div class="row"> <div class="large-2 medium-2 columns show-for-medium-up"> </div> <div class="large-2 medium-2 small-6 columns "> <div class=""> <div class="search-input-label">Section</div> </div> <select id="section" tabindex="5" name="section" class="chosen-select"> <option value=""></option> </select> </div> <div class="large-2 medium-2 small-6 columns "> <div class=""> <div class="search-input-label">Special Issue</div> </div> <select id="special_issue" tabindex="6" name="special_issue" class="chosen-select"> <option value=""></option> </select> </div> <div class="large-1 medium-1 small-6 end columns "> <div class="search-input-label">Volume</div> <input type="text" id="volume" tabindex="7" name="volume" placeholder="..." value="16" /> </div> <div class="large-1 medium-1 small-6 end columns "> <div class="search-input-label">Issue</div> <input type="text" id="issue" tabindex="8" name="issue" placeholder="..." value="7" /> </div> <div class="large-1 medium-1 small-6 end columns "> <div class="search-input-label">Number</div> <input type="text" id="number" tabindex="9" name="number" placeholder="..." value="" /> </div> <div class="large-1 medium-1 small-6 end columns "> <div class="search-input-label">Page</div> <input type="text" id="page" tabindex="10" name="page" placeholder="..." value="" /> </div> <div class="large-1 medium-1 small-6 columns small-push-6 medium-reset order large-reset-order medium-reset-order js-search-expanded-button-container"></div> <div class="large-1 medium-1 small-6 columns large-text-left small-only-text-center small-pull-6 medium-reset-order large-reset-order js-search-expanded-link-container"></div> </div> </div> </form> <form id="advanced-search" class="large-12 medium-12 columns"> <div class="search-container__advanced"> <div id="advanced-search-template" class="row advanced-search-row"> <div class="large-2 medium-2 small-12 columns show-for-medium-up"> </div> <div class="large-2 medium-2 small-3 columns connector-div"> <div class="search-input-label"><span class="show-for-medium-up">Logical Operator</span><span class="show-for-small">Operator</span></div> <select class="connector"> <option value="and">AND</option> <option value="or">OR</option> </select> </div> <div class="large-3 medium-3 small-6 columns search-text-div"> <div class="search-input-label">Search Text</div> <input type="text" class="search-text" placeholder="Search text"> </div> <div class="large-2 medium-2 small-6 large-offset-0 medium-offset-0 small-offset-3 columns search-field-div"> <div class="search-input-label">Search Type</div> <select class="search-field"> <option value="all">All fields</option> <option value="title">Title</option> <option value="abstract">Abstract</option> <option value="keywords">Keywords</option> <option value="authors">Authors</option> <option value="affiliations">Affiliations</option> <option value="doi">Doi</option> <option value="full_text">Full Text</option> <option value="references">References</option> </select> </div> <div class="large-1 medium-1 small-3 columns"> <div class="search-input-label"> </div> <div class="search-action-div"> <div class="search-plus"> <i class="material-icons">add_circle_outline</i> </div> </div> <div class="search-action-div"> <div class="search-minus"> <i class="material-icons">remove_circle_outline</i> </div> </div> </div> <div class="large-1 medium-1 small-6 large-offset-0 medium-offset-0 small-offset-3 end columns"> <div class="search-input-label"> </div> <input class="advanced-search-button button button--dark search-submit" type="submit" value="Search"> </div> <div class="large-1 medium-1 small-6 end columns show-for-medium-up"></div> </div> </div> </form> </div> <div class="header-divider"> </div> <div class="breadcrumb row full-row"> <div class="breadcrumb__element"> <a href="/about/journals">Journals</a> </div> <div class="breadcrumb__element"> <a href="/journal/cancers">Cancers</a> </div> <div class="breadcrumb__element"> <a href="/2072-6694/16">Volume 16</a> </div> <div class="breadcrumb__element"> <a href="/2072-6694/16/7">Issue 7</a> </div> <div class="breadcrumb__element"> <a href="#">10.3390/cancers16071243</a> </div> </div> </header> <div id="main-content" class=""> <div class="row full-width row-fixed-left-column"> <div id="left-column" class="content__column large-3 medium-3 small-12 columns"> <div class="content__container"> <a href="/journal/cancers"> <img src="https://pub.mdpi-res.com/img/journals/cancers-logo.png?8600e93ff98dbf14" alt="cancers-logo" title="Cancers" style="max-height: 60px; margin: 0 0 0 0;"> </a> <div class="generic-item no-border"> <a class="button button--color button--full-width js-journal-active-only-link js-journal-active-only-submit-link UC_ArticleSubmitButton" href="https://susy.mdpi.com/user/manuscripts/upload?form%5Bjournal_id%5D%3D23" data-disabledmessage="creating new submissions is not possible."> Submit to this Journal </a> <a class="button button--color button--full-width js-journal-active-only-link UC_ArticleReviewButton" href="https://susy.mdpi.com/volunteer/journals/review" data-disabledmessage="volunteering as journal reviewer is not possible."> Review for this Journal </a> <a class="button button--color-inversed button--color-journal button--full-width js-journal-active-only-link UC_ArticleEditIssueButton" href="/journalproposal/sendproposalspecialissue/cancers" data-path="/2072-6694/16/7/1243" data-disabledmessage="proposing new special issue is not possible."> Propose a Special Issue </a> </div> <div class="generic-item link-article-menu show-for-small"> <a href="#" class="link-article-menu show-for-small"> <span class="closed">►</span> <span class="open" style="display: none;">▼</span> Article Menu </a> </div> <div class="hide-small-down-initially UI_ArticleMenu"> <div class="generic-item"> <h2>Article Menu</h2> </div> <ul class="accordion accordion__menu" data-accordion data-options="multi_expand:true;toggleable: true"> <li class="accordion-navigation"> <a href="#academic_editors" class="accordion__title">Academic Editor</a> <div id="academic_editors" class="content active"> <div class="academic-editor-container " title="Institute of Translational Research, Ochsner Health System, New Orleans, LA 70121, USA"> <div class="sciprofiles-link" style="display: inline-block"><a class="sciprofiles-link__link" href="https://sciprofiles.com/profile/439435?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name" target="_blank" rel="noopener noreferrer"><img class="sciprofiles-link__image" src="/bundles/mdpisciprofileslink/img/unknown-user.png" style="width: auto; height: 16px; border-radius: 50%;"><span class="sciprofiles-link__name">Paul T. Thevenot</span></a></div> </div> </div> </li> <li class="accordion-direct-link"> <a href="/2072-6694/16/7/1243/scifeed_display" data-reveal-id="scifeed-modal" data-reveal-ajax="true">Subscribe SciFeed</a> </li> <li class="accordion-direct-link js-article-similarity-container" style="display: none"> <a href="#" class="js-similarity-related-articles">Recommended Articles</a> </li> <li class="accordion-navigation"> <a href="#related" class="accordion__title">Related Info Links</a> <div id="related" class="content UI_ArticleMenu_RelatedLinks"> <ul> <li class="li-link"> <a href="http://www.ncbi.nlm.nih.gov/sites/entrez/38610921" target="_blank" rel="noopener noreferrer">PubMed/Medline</a> </li> <li class="li-link"> <a href="https://scholar.google.com/scholar?q=Everolimus%20Mitigates%20the%20Risk%20of%20Hepatocellular%20Carcinoma%20Recurrence%20after%20Liver%20Transplantation" target="_blank" rel="noopener noreferrer">Google Scholar</a> </li> </ul> </div> </li> <li class="accordion-navigation"> <a href="#authors" class="accordion__title">More by Authors Links</a> <div id="authors" class="content UI_ArticleMenu_AuthorsLinks"> <ul class="side-menu-ul"> <li> <a class="expand" onclick='$(this).closest("li").next("div").toggle(); return false;'>on DOAJ</a> </li> <div id="AuthorDOAJExpand" style="display:none;"> <ul class="submenu"> <li class="li-link"> <a href='http://doaj.org/search/articles?source=%7B%22query%22%3A%7B%22query_string%22%3A%7B%22query%22%3A%22%5C%22Paolo%20De%20Simone%5C%22%22%2C%22default_operator%22%3A%22AND%22%2C%22default_field%22%3A%22bibjson.author.name%22%7D%7D%7D' target="_blank" rel="noopener noreferrer">De Simone, P.</a> <li> </li> <li class="li-link"> <a href='http://doaj.org/search/articles?source=%7B%22query%22%3A%7B%22query_string%22%3A%7B%22query%22%3A%22%5C%22Arianna%20Precisi%5C%22%22%2C%22default_operator%22%3A%22AND%22%2C%22default_field%22%3A%22bibjson.author.name%22%7D%7D%7D' target="_blank" rel="noopener noreferrer">Precisi, A.</a> <li> </li> <li class="li-link"> <a href='http://doaj.org/search/articles?source=%7B%22query%22%3A%7B%22query_string%22%3A%7B%22query%22%3A%22%5C%22Quirino%20Lai%5C%22%22%2C%22default_operator%22%3A%22AND%22%2C%22default_field%22%3A%22bibjson.author.name%22%7D%7D%7D' target="_blank" rel="noopener noreferrer">Lai, Q.</a> <li> </li> <li class="li-link"> <a href='http://doaj.org/search/articles?source=%7B%22query%22%3A%7B%22query_string%22%3A%7B%22query%22%3A%22%5C%22Juri%20Ducci%5C%22%22%2C%22default_operator%22%3A%22AND%22%2C%22default_field%22%3A%22bibjson.author.name%22%7D%7D%7D' target="_blank" rel="noopener noreferrer">Ducci, J.</a> <li> </li> <li class="li-link"> <a href='http://doaj.org/search/articles?source=%7B%22query%22%3A%7B%22query_string%22%3A%7B%22query%22%3A%22%5C%22Daniela%20Campani%5C%22%22%2C%22default_operator%22%3A%22AND%22%2C%22default_field%22%3A%22bibjson.author.name%22%7D%7D%7D' target="_blank" rel="noopener noreferrer">Campani, D.</a> <li> </li> <li class="li-link"> <a href='http://doaj.org/search/articles?source=%7B%22query%22%3A%7B%22query_string%22%3A%7B%22query%22%3A%22%5C%22Piero%20Marchetti%5C%22%22%2C%22default_operator%22%3A%22AND%22%2C%22default_field%22%3A%22bibjson.author.name%22%7D%7D%7D' target="_blank" rel="noopener noreferrer">Marchetti, P.</a> <li> </li> <li class="li-link"> <a href='http://doaj.org/search/articles?source=%7B%22query%22%3A%7B%22query_string%22%3A%7B%22query%22%3A%22%5C%22Stefano%20Gitto%5C%22%22%2C%22default_operator%22%3A%22AND%22%2C%22default_field%22%3A%22bibjson.author.name%22%7D%7D%7D' target="_blank" rel="noopener noreferrer">Gitto, S.</a> <li> </li> </ul> </div> <li> <a class="expand" onclick='$(this).closest("li").next("div").toggle(); return false;'>on Google Scholar</a> </li> <div id="AuthorGoogleExpand" style="display:none;"> <ul class="submenu"> <li class="li-link"> <a href="https://scholar.google.com/scholar?q=Paolo%20De%20Simone" target="_blank" rel="noopener noreferrer">De Simone, P.</a> <li> </li> <li class="li-link"> <a href="https://scholar.google.com/scholar?q=Arianna%20Precisi" target="_blank" rel="noopener noreferrer">Precisi, A.</a> <li> </li> <li class="li-link"> <a href="https://scholar.google.com/scholar?q=Quirino%20Lai" target="_blank" rel="noopener noreferrer">Lai, Q.</a> <li> </li> <li class="li-link"> <a href="https://scholar.google.com/scholar?q=Juri%20Ducci" target="_blank" rel="noopener noreferrer">Ducci, J.</a> <li> </li> <li class="li-link"> <a href="https://scholar.google.com/scholar?q=Daniela%20Campani" target="_blank" rel="noopener noreferrer">Campani, D.</a> <li> </li> <li class="li-link"> <a href="https://scholar.google.com/scholar?q=Piero%20Marchetti" target="_blank" rel="noopener noreferrer">Marchetti, P.</a> <li> </li> <li class="li-link"> <a href="https://scholar.google.com/scholar?q=Stefano%20Gitto" target="_blank" rel="noopener noreferrer">Gitto, S.</a> <li> </li> </ul> </div> <li> <a class="expand" onclick='$(this).closest("li").next("div").toggle(); return false;'>on PubMed</a> </li> <div id="AuthorPubMedExpand" style="display:none;"> <ul class="submenu"> <li class="li-link"> <a href="http://www.pubmed.gov/?cmd=Search&term=Paolo%20De%20Simone" target="_blank" rel="noopener noreferrer">De Simone, P.</a> <li> </li> <li class="li-link"> <a href="http://www.pubmed.gov/?cmd=Search&term=Arianna%20Precisi" target="_blank" rel="noopener noreferrer">Precisi, A.</a> <li> </li> <li class="li-link"> <a href="http://www.pubmed.gov/?cmd=Search&term=Quirino%20Lai" target="_blank" rel="noopener noreferrer">Lai, Q.</a> <li> </li> <li class="li-link"> <a href="http://www.pubmed.gov/?cmd=Search&term=Juri%20Ducci" target="_blank" rel="noopener noreferrer">Ducci, J.</a> <li> </li> <li class="li-link"> <a href="http://www.pubmed.gov/?cmd=Search&term=Daniela%20Campani" target="_blank" rel="noopener noreferrer">Campani, D.</a> <li> </li> <li class="li-link"> <a href="http://www.pubmed.gov/?cmd=Search&term=Piero%20Marchetti" target="_blank" rel="noopener noreferrer">Marchetti, P.</a> <li> </li> <li class="li-link"> <a href="http://www.pubmed.gov/?cmd=Search&term=Stefano%20Gitto" target="_blank" rel="noopener noreferrer">Gitto, S.</a> <li> </li> </ul> </div> </ul> </div> </li> </ul> <span style="display:none" id="scifeed_hidden_flag"></span> <span style="display:none" id="scifeed_subscribe_url">/ajax/scifeed/subscribe</span> </div> </div> <div class="content__container responsive-moving-container large medium active hidden" data-id="article-counters"> <div id="counts-wrapper" class="row generic-item no-border" data-equalizer> <div id="js-counts-wrapper__views" class="small-12 hide columns count-div-container"> <a href="#metrics" > <div class="count-div" data-equalizer-watch> <span class="name">Article Views</span> <span class="count view-number"></span> </div> </a> </div> <div id="js-counts-wrapper__citations" class="small-12 columns hide count-div-container"> <a href="#metrics" > <div class="count-div" data-equalizer-watch> <span class="name">Citations</span> <span class="count citations-number Var_ArticleMaxCitations">-</span> </div> </a> </div> </div> </div> <div class="content__container"> <div class="hide-small-down-initially"> <ul class="accordion accordion__menu" data-accordion data-options="multi_expand:true;toggleable: true"> <li class="accordion-navigation"> <a href="#table_of_contents" class="accordion__title">Table of Contents</a> <div id="table_of_contents" class="content active"> <div class="menu-caption" id="html-quick-links-title"></div> </div> </li> </ul> </div> </div>  <div id="pbgrd-sky"></div> <script src="https://cdn.pbgrd.com/core-mdpi.js"></script> <style>.content__container { min-width: 300px; }</style>  </div> <div id="middle-column" class="content__column large-9 medium-9 small-12 columns end middle-bordered"> <div class="middle-column__help"> <div class="middle-column__help__fixed show-for-medium-up"> <span id="js-altmetrics-donut" href="#" target="_blank" rel="noopener noreferrer" style="display: none;"> <span data-badge-type='donut' class='altmetric-embed' data-doi='10.3390/cancers16071243'></span> <span>Altmetric</span> </span> <a href="#" class="UA_ShareButton" data-reveal-id="main-share-modal" title="Share"> <i class="material-icons">share</i> <span>Share</span> </a> <a href="#" data-reveal-id="main-help-modal" title="Help"> <i class="material-icons">announcement</i> <span>Help</span> </a> <a href="javascript:void(0);" data-reveal-id="cite-modal" data-counterslink = "https://www.mdpi.com/2072-6694/16/7/1243/cite" > <i class="material-icons">format_quote</i> <span>Cite</span> </a> <a href="https://sciprofiles.com/discussion-groups/public/10.3390/cancers16071243?utm_source=mpdi.com&utm_medium=publication&utm_campaign=discuss_in_sciprofiles" target="_blank" rel="noopener noreferrer" title="Discuss in Sciprofiles"> <i class="material-icons">question_answer</i> <span>Discuss in SciProfiles</span> </a> <a href="#" class="" data-hypothesis-trigger-endorses-tab title="Endorse"> <i data-hypothesis-endorse-trigger class="material-icons" >thumb_up</i> <div data-hypothesis-endorsement-count data-hypothesis-trigger-endorses-tab class="hypothesis-count-container"> ... </div> <span>Endorse</span> </a> <a href="#" data-hypothesis-trigger class="js-hypothesis-open UI_ArticleAnnotationsButton" title="Comment"> <i class="material-icons">textsms</i> <div data-hypothesis-annotation-count class="hypothesis-count-container"> ... </div> <span>Comment</span> </a> </div> <div id="main-help-modal" class="reveal-modal reveal-modal-new" data-reveal aria-labelledby="modalTitle" aria-hidden="true" role="dialog"> <div class="row"> <div class="small-12 columns"> <h2 style="margin: 0;">Need Help?</h2> </div> <div class="small-6 columns"> <h3>Support</h3> <p> Find support for a specific problem in the support section of our website. </p> <a target="_blank" href="/about/contactform" class="button button--color button--full-width"> Get Support </a> </div> <div class="small-6 columns"> <h3>Feedback</h3> <p> Please let us know what you think of our products and services. </p> <a target="_blank" href="/feedback/send" class="button button--color button--full-width"> Give Feedback </a> </div> <div class="small-6 columns end"> <h3>Information</h3> <p> Visit our dedicated information section to learn more about MDPI. </p> <a target="_blank" href="/authors" class="button button--color button--full-width"> Get Information </a> </div> </div> <a class="close-reveal-modal" aria-label="Close"> <i class="material-icons">clear</i> </a> </div> </div> <div class="middle-column__main "> <div class="page-highlight"> <style type="text/css"> img.review-status { width: 30px; } </style> <div id="jmolModal" class="reveal-modal" data-reveal aria-labelledby="Captcha" aria-hidden="true" role="dialog"> <h2>JSmol Viewer</h2> <div class="row"> <div class="small-12 columns text-center"> <iframe style="width: 520px; height: 520px;" frameborder="0" id="jsmol-content"></iframe> <div class="content"></div> </div> </div> <a class="close-reveal-modal" aria-label="Close"> <i class="material-icons">clear</i> </a> </div> <div itemscope itemtype="http://schema.org/ScholarlyArticle" id="abstract" class="abstract_div"> <div class="js-check-update-container"></div> <div class="html-content__container content__container content__container__combined-for-large__first" style="overflow: auto; position: inherit;"> <div class='html-profile-nav'> <div class='top-bar'> <div class='nav-sidebar-btn show-for-large-up' data-status='opened' > <i class='material-icons'>first_page</i> </div> <a id="js-button-download" class="button button--color-inversed" style="display: none;" href="/2072-6694/16/7/1243/pdf?version=1711092729" data-name="Everolimus Mitigates the Risk of Hepatocellular Carcinoma Recurrence after Liver Transplantation" data-journal="cancers"> <i class="material-icons custom-download"></i> Download PDF </a> <div class='nav-btn'> <i class='material-icons'>settings</i> </div> <a href="/2072-6694/16/7/1243/reprints" id="js-button-reprints" class="button button--color-inversed"> Order Article Reprints </a> </div> <div class='html-article-menu'> <div class='html-first-step row'> <div class='html-font-family large-6 medium-6 small-12 columns'> <div class='row'> <div class='html-font-label large-4 medium-4 small-12 columns'> Font Type: </div> <div class='large-8 medium-8 small-12 columns'> <span class="html-article-menu-option"><i style='font-family:Arial, Arial, Helvetica, sans-serif;' data-fontfamily='Arial, Arial, Helvetica, sans-serif'>Arial</i></span> <span class="html-article-menu-option"><i style='font-family:Georgia1, Georgia, serif;' data-fontfamily='Georgia1, Georgia, serif'>Georgia</i></span> <span class="html-article-menu-option"><i style='font-family:Verdana, Verdana, Geneva, sans-serif;' data-fontfamily='Verdana, Verdana, Geneva, sans-serif' >Verdana</i></span> </div> </div> </div> <div class='html-font-resize large-6 medium-6 small-12 columns'> <div class='row'> <div class='html-font-label large-4 medium-4 small-12 columns'>Font Size:</div> <div class='large-8 medium-8 small-12 columns'> <span class="html-article-menu-option a1" data-percent="100">Aa</span> <span class="html-article-menu-option a2" data-percent="120">Aa</span> <span class="html-article-menu-option a3" data-percent="160">Aa</span> </div> </div> </div> </div> <div class='row'> <div class='html-line-space large-6 medium-6 small-12 columns'> <div class='row'> <div class='html-font-label large-4 medium-4 small-12 columns' >Line Spacing:</div> <div class='large-8 medium-8 small-12 columns'> <span class="html-article-menu-option a1" data-line-height="1.5em"> <i class="fa"></i> </span> <span class="html-article-menu-option a2" data-line-height="1.8em"> <i class="fa"></i> </span> <span class="html-article-menu-option a3" data-line-height="2.1em"> <i class="fa"></i> </span> </div> </div> </div> <div class='html-column-width large-6 medium-6 small-12 columns'> <div class='row'> <div class='html-font-label large-4 medium-4 small-12 columns' >Column Width:</div> <div class='large-8 medium-8 small-12 columns'> <span class="html-article-menu-option a1" data-column-width="20%"> <i class="fa"></i> </span> <span class="html-article-menu-option a2" data-column-width="10%"> <i class="fa"></i> </span> <span class="html-article-menu-option a3" data-column-width="0%"> <i class="fa"></i> </span> </div> </div> </div> </div> <div class='row'> <div class='html-font-bg large-6 medium-6 small-12 columns end'> <div class='row'> <div class='html-font-label large-4 medium-4 small-12 columns'>Background:</div> <div class='large-8 medium-8 small-12 columns'> <div class="html-article-menu-option html-nav-bg html-nav-bright" data-bg="bright"> <i class="fa fa-file-text"></i> </div> <div class="html-article-menu-option html-nav-bg html-nav-dark" data-bg="dark"> <i class="fa fa-file-text-o"></i> </div> <div class="html-article-menu-option html-nav-bg html-nav-creme" data-bg="creme"> <i class="fa fa-file-text"></i> </div> </div> </div> </div> </div> </div> </div> <article ><div class='html-article-content'> <span itemprop="publisher" content="Multidisciplinary Digital Publishing Institute"></span><span itemprop="url" content="https://www.mdpi.com/2072-6694/16/7/1243"></span> <div class="article-icons"><span class="label openaccess" data-dropdown="drop-article-label-openaccess" aria-expanded="false">Open Access</span><span class="label articletype">Article</span></div> <h1 class="title hypothesis_container" itemprop="name"> Everolimus Mitigates the Risk of Hepatocellular Carcinoma Recurrence after Liver Transplantation </h1> <div class="art-authors hypothesis_container"> by <span class="inlineblock "><div class='profile-card-drop' data-dropdown='profile-card-drop12476644' data-options='is_hover:true, hover_timeout:5000'> Paolo De Simone</div><div id="profile-card-drop12476644" data-dropdown-content class="f-dropdown content profile-card-content" aria-hidden="true" tabindex="-1"><div class="profile-card__title"><div class="sciprofiles-link" style="display: inline-block"><div class="sciprofiles-link__link"><img class="sciprofiles-link__image" src="/bundles/mdpisciprofileslink/img/unknown-user.png" style="width: auto; height: 16px; border-radius: 50%;"><span class="sciprofiles-link__name">Paolo De Simone</span></div></div></div><div class="profile-card__buttons" style="margin-bottom: 10px;"><a href="https://sciprofiles.com/profile/3425892?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name" class="button button--color-inversed" target="_blank"> SciProfiles </a><a href="https://scilit.net/scholars?q=Paolo%20De%20Simone" class="button button--color-inversed" target="_blank"> Scilit </a><a href="https://www.preprints.org/search?search1=Paolo%20De%20Simone&field1=authors" class="button button--color-inversed" target="_blank"> Preprints.org </a><a href="https://scholar.google.com/scholar?q=Paolo%20De%20Simone" class="button button--color-inversed" target="_blank" rels="noopener noreferrer"> Google Scholar </a></div></div><sup> 1,2,*</sup><span style="display: inline; margin-left: 5px;"></span><a class="toEncode emailCaptcha visibility-hidden" data-author-id="12476644" href="/cdn-cgi/l/email-protection#dbf4b8b5bff6b8bcb2f4b7f4beb6bab2b7f6aba9b4afbeb8afb2b4b5f8ebebeaeaecebeabdeab8eabdeebeeaefeaeeebe8eae2eabfeabdeabeeaeee8ebebeeeabeeae2ebebeae2eebeeae2ebef"><sup><i class="fa fa-envelope-o"></i></sup></a><a href="https://orcid.org/0000-0001-6713-6170" target="_blank" rel="noopener noreferrer"><img src="https://pub.mdpi-res.com/img/design/orcid.png?0465bc3812adeb52?1732286508" title="ORCID" style="position: relative; width: 13px; margin-left: 3px; max-width: 13px !important; height: auto; top: -5px;"></a>, </span><span class="inlineblock "><div class='profile-card-drop' data-dropdown='profile-card-drop12476645' data-options='is_hover:true, hover_timeout:5000'> Arianna Precisi</div><div id="profile-card-drop12476645" data-dropdown-content class="f-dropdown content profile-card-content" aria-hidden="true" tabindex="-1"><div class="profile-card__title"><div class="sciprofiles-link" style="display: inline-block"><div class="sciprofiles-link__link"><img class="sciprofiles-link__image" src="/bundles/mdpisciprofileslink/img/unknown-user.png" style="width: auto; height: 16px; border-radius: 50%;"><span class="sciprofiles-link__name">Arianna Precisi</span></div></div></div><div class="profile-card__buttons" style="margin-bottom: 10px;"><a href="https://sciprofiles.com/profile/author/ekVRV2NoVzg0amp3TGRGUkc4SVd4Zjl0dkM0U3JFclVZcDJKWFJkQkY1OD0=?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name" class="button button--color-inversed" target="_blank"> SciProfiles </a><a href="https://scilit.net/scholars?q=Arianna%20Precisi" class="button button--color-inversed" target="_blank"> Scilit </a><a href="https://www.preprints.org/search?search1=Arianna%20Precisi&field1=authors" class="button button--color-inversed" target="_blank"> Preprints.org </a><a href="https://scholar.google.com/scholar?q=Arianna%20Precisi" class="button button--color-inversed" target="_blank" rels="noopener noreferrer"> Google Scholar </a></div></div><sup> 3</sup><span style="display: inline; margin-left: 5px;"></span><a class="toEncode emailCaptcha visibility-hidden" data-author-id="12476645" href="/cdn-cgi/l/email-protection#c5eaa6aba1e8a6a2aceaa9eaa0a8a4aca9e8b5b7aab1a0a6b1acaaabe6f5f5f1a3f3f4f4f4f4f6f5f1f5f7f5fdf4f7f5fdf7f4f5f5f5a0f1a6f4f4f5fdf4f7f5f5f1a3f4f0f5a0f4f7f5f7f5f5f5a3f5f5f1a3f5fdf4f0"><sup><i class="fa fa-envelope-o"></i></sup></a>, </span><span class="inlineblock "><div class='profile-card-drop' data-dropdown='profile-card-drop12476646' data-options='is_hover:true, hover_timeout:5000'> Quirino Lai</div><div id="profile-card-drop12476646" data-dropdown-content class="f-dropdown content profile-card-content" aria-hidden="true" tabindex="-1"><div class="profile-card__title"><div class="sciprofiles-link" style="display: inline-block"><div class="sciprofiles-link__link"><img class="sciprofiles-link__image" src="/bundles/mdpisciprofileslink/img/unknown-user.png" style="width: auto; height: 16px; border-radius: 50%;"><span class="sciprofiles-link__name">Quirino Lai</span></div></div></div><div class="profile-card__buttons" style="margin-bottom: 10px;"><a href="https://sciprofiles.com/profile/974088?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name" class="button button--color-inversed" target="_blank"> SciProfiles </a><a href="https://scilit.net/scholars?q=Quirino%20Lai" class="button button--color-inversed" target="_blank"> Scilit </a><a href="https://www.preprints.org/search?search1=Quirino%20Lai&field1=authors" class="button button--color-inversed" target="_blank"> Preprints.org </a><a href="https://scholar.google.com/scholar?q=Quirino%20Lai" class="button button--color-inversed" target="_blank" rels="noopener noreferrer"> Google Scholar </a></div></div><sup> 4</sup><span style="display: inline; margin-left: 5px;"></span><a class="toEncode emailCaptcha visibility-hidden" data-author-id="12476646" href="/cdn-cgi/l/email-protection#cce3afa2a8e1afaba5e3a0e3a9a1ada5a0e1bcbea3b8a9afb8a5a3a2effcfcfcf8fbfdfdf4fcfffdf4fdaafda9f9aafda8fdfcfdf4fffdfcf8fdaafdf4fcfffda9fdaffdfcf8fcf9aafdf4fcf9"><sup><i class="fa fa-envelope-o"></i></sup></a>, </span><span class="inlineblock "><div class='profile-card-drop' data-dropdown='profile-card-drop12476647' data-options='is_hover:true, hover_timeout:5000'> Juri Ducci</div><div id="profile-card-drop12476647" data-dropdown-content class="f-dropdown content profile-card-content" aria-hidden="true" tabindex="-1"><div class="profile-card__title"><div class="sciprofiles-link" style="display: inline-block"><div class="sciprofiles-link__link"><img class="sciprofiles-link__image" src="/bundles/mdpisciprofileslink/img/unknown-user.png" style="width: auto; height: 16px; border-radius: 50%;"><span class="sciprofiles-link__name">Juri Ducci</span></div></div></div><div class="profile-card__buttons" style="margin-bottom: 10px;"><a href="https://sciprofiles.com/profile/3407044?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name" class="button button--color-inversed" target="_blank"> SciProfiles </a><a href="https://scilit.net/scholars?q=Juri%20Ducci" class="button button--color-inversed" target="_blank"> Scilit </a><a href="https://www.preprints.org/search?search1=Juri%20Ducci&field1=authors" class="button button--color-inversed" target="_blank"> Preprints.org </a><a href="https://scholar.google.com/scholar?q=Juri%20Ducci" class="button button--color-inversed" target="_blank" rels="noopener noreferrer"> Google Scholar </a></div></div><sup> 5</sup><span style="display: inline; margin-left: 5px;"></span><a class="toEncode emailCaptcha visibility-hidden" data-author-id="12476647" href="/cdn-cgi/l/email-protection#4a6529242e67292d236526652f272b2326673a38253e2f293e232524697a7a7e7e7c2b7a2f7b2c7a737a737a79782b7a287a7f7e7d7b2b7a797b737a287e7e7b2f7a7f7b737a737a287a7e7a287e7e7a797b2f"><sup><i class="fa fa-envelope-o"></i></sup></a>, </span><span class="inlineblock "><div class='profile-card-drop' data-dropdown='profile-card-drop12476648' data-options='is_hover:true, hover_timeout:5000'> Daniela Campani</div><div id="profile-card-drop12476648" data-dropdown-content class="f-dropdown content profile-card-content" aria-hidden="true" tabindex="-1"><div class="profile-card__title"><div class="sciprofiles-link" style="display: inline-block"><div class="sciprofiles-link__link"><img class="sciprofiles-link__image" src="/bundles/mdpisciprofileslink/img/unknown-user.png" style="width: auto; height: 16px; border-radius: 50%;"><span class="sciprofiles-link__name">Daniela Campani</span></div></div></div><div class="profile-card__buttons" style="margin-bottom: 10px;"><a href="https://sciprofiles.com/profile/author/UEZKNVdhRWlGbExwR0pQRi9jZlNCd1R2ZUtLelF5Uy9OQ3czcWJObXBacz0=?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name" class="button button--color-inversed" target="_blank"> SciProfiles </a><a href="https://scilit.net/scholars?q=Daniela%20Campani" class="button button--color-inversed" target="_blank"> Scilit </a><a href="https://www.preprints.org/search?search1=Daniela%20Campani&field1=authors" class="button button--color-inversed" target="_blank"> Preprints.org </a><a href="https://scholar.google.com/scholar?q=Daniela%20Campani" class="button button--color-inversed" target="_blank" rels="noopener noreferrer"> Google Scholar </a></div></div><sup> 2,6</sup><span style="display: inline; margin-left: 5px;"></span><a class="toEncode emailCaptcha visibility-hidden" data-author-id="12476648" href="/cdn-cgi/l/email-protection#83ace0ede7aee0e4eaaceface6eee2eaefaef3f1ecf7e6e0f7eaeceda0b3b3b3b6b5b7b3e2b3e7b3b2b3bbb3b6b7e2b3b4b3b6b3bab2b7b3b6b3e2b3e7b1b7b2b2b3e2b3e7b2b7b3e7b7e2b3e7b2b3"><sup><i class="fa fa-envelope-o"></i></sup></a>, </span><span class="inlineblock "><div class='profile-card-drop' data-dropdown='profile-card-drop12476649' data-options='is_hover:true, hover_timeout:5000'> Piero Marchetti</div><div id="profile-card-drop12476649" data-dropdown-content class="f-dropdown content profile-card-content" aria-hidden="true" tabindex="-1"><div class="profile-card__title"><div class="sciprofiles-link" style="display: inline-block"><div class="sciprofiles-link__link"><img class="sciprofiles-link__image" src="/bundles/mdpisciprofileslink/img/unknown-user.png" style="width: auto; height: 16px; border-radius: 50%;"><span class="sciprofiles-link__name">Piero Marchetti</span></div></div></div><div class="profile-card__buttons" style="margin-bottom: 10px;"><a href="https://sciprofiles.com/profile/1944586?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name" class="button button--color-inversed" target="_blank"> SciProfiles </a><a href="https://scilit.net/scholars?q=Piero%20Marchetti" class="button button--color-inversed" target="_blank"> Scilit </a><a href="https://www.preprints.org/search?search1=Piero%20Marchetti&field1=authors" class="button button--color-inversed" target="_blank"> Preprints.org </a><a href="https://scholar.google.com/scholar?q=Piero%20Marchetti" class="button button--color-inversed" target="_blank" rels="noopener noreferrer"> Google Scholar </a></div></div><sup> 7</sup><span style="display: inline; margin-left: 5px;"></span><a class="toEncode emailCaptcha visibility-hidden" data-author-id="12476649" href="/cdn-cgi/l/email-protection#2b0448454f06484c420447044e464a4247065b59445f4e485f424445081b1b1a121c1b1a1e1b191a4d1e4e1a4f1a1a1b191a181a131a1e1b1f1b1f1a12181b1b1e1a4e1a121b1b1a121e4e1a121b1f"><sup><i class="fa fa-envelope-o"></i></sup></a> and </span><span class="inlineblock "><div class='profile-card-drop' data-dropdown='profile-card-drop12476650' data-options='is_hover:true, hover_timeout:5000'> Stefano Gitto</div><div id="profile-card-drop12476650" data-dropdown-content class="f-dropdown content profile-card-content" aria-hidden="true" tabindex="-1"><div class="profile-card__title"><div class="sciprofiles-link" style="display: inline-block"><div class="sciprofiles-link__link"><img class="sciprofiles-link__image" src="/bundles/mdpisciprofileslink/img/unknown-user.png" style="width: auto; height: 16px; border-radius: 50%;"><span class="sciprofiles-link__name">Stefano Gitto</span></div></div></div><div class="profile-card__buttons" style="margin-bottom: 10px;"><a href="https://sciprofiles.com/profile/163150?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name" class="button button--color-inversed" target="_blank"> SciProfiles </a><a href="https://scilit.net/scholars?q=Stefano%20Gitto" class="button button--color-inversed" target="_blank"> Scilit </a><a href="https://www.preprints.org/search?search1=Stefano%20Gitto&field1=authors" class="button button--color-inversed" target="_blank"> Preprints.org </a><a href="https://scholar.google.com/scholar?q=Stefano%20Gitto" class="button button--color-inversed" target="_blank" rels="noopener noreferrer"> Google Scholar </a></div></div><sup> 8,9</sup><span style="display: inline; margin-left: 5px;"></span><a class="toEncode emailCaptcha visibility-hidden" data-author-id="12476650" href="/cdn-cgi/l/email-protection#351a565b511856525c1a591a5058545c591845475a415056415c5a5b1605050502020604030400040704510456005104010454050205020456060605030451045404000454005104540502"><sup><i class="fa fa-envelope-o"></i></sup></a></span> </div> <div class="nrm"></div> <span style="display:block; height:6px;"></span> <div></div> <div style="margin: 5px 0 15px 0;" class="hypothesis_container"> <div class="art-affiliations"> <div class="affiliation "> <div class="affiliation-item"><sup>1</sup></div> <div class="affiliation-name ">Liver Transplant Program, University of Pisa Medical School Hospital, 56124 Pisa, Italy</div> </div> <div class="affiliation "> <div class="affiliation-item"><sup>2</sup></div> <div class="affiliation-name ">Department of Surgical, Medical, Biochemical Pathology and Intensive Care, University of Pisa, 56126 Pisa, Italy</div> </div> <div class="affiliation "> <div class="affiliation-item"><sup>3</sup></div> <div class="affiliation-name ">Transplant Laboratory, University of Pisa Medical School Hospital, 56126 Pisa, Italy</div> </div> <div class="affiliation "> <div class="affiliation-item"><sup>4</sup></div> <div class="affiliation-name ">AOU Umberto I Policlinico of Rome, Sapienza University of Rome, 00161 Rome, Italy</div> </div> <div class="affiliation "> <div class="affiliation-item"><sup>5</sup></div> <div class="affiliation-name ">Azienda Ospedaliero Universitaria Pisana, 56124 Pisa, Italy</div> </div> <div class="affiliation "> <div class="affiliation-item"><sup>6</sup></div> <div class="affiliation-name ">Department of Pathology, University of Pisa Medical School Hospital, 56124 Pisa, Italy</div> </div> <div class="affiliation "> <div class="affiliation-item"><sup>7</sup></div> <div class="affiliation-name ">Diabetology Unit, University of Pisa Medical School Hospital, 56124 Pisa, Italy</div> </div> <div class="affiliation "> <div class="affiliation-item"><sup>8</sup></div> <div class="affiliation-name ">Internal Medicine and Liver Unit, University Hospital Careggi, 50134 Florence, Italy</div> </div> <div class="affiliation "> <div class="affiliation-item"><sup>9</sup></div> <div class="affiliation-name ">Department of Experimental and Clinical Medicine, University of Florence, 50134 Florence, Italy</div> </div> <div class="affiliation"> <div class="affiliation-item"><sup>*</sup></div> <div class="affiliation-name ">Author to whom correspondence should be addressed. </div> </div> </div> </div> <div class="bib-identity" style="margin-bottom: 10px;"> <em>Cancers</em> <b>2024</b>, <em>16</em>(7), 1243; <a href="https://doi.org/10.3390/cancers16071243">https://doi.org/10.3390/cancers16071243</a> </div> <div class="pubhistory" style="font-weight: bold; padding-bottom: 10px;"> <span style="display: inline-block">Submission received: 12 January 2024</span> / <span style="display: inline-block">Revised: 10 March 2024</span> / <span style="display: inline-block">Accepted: 19 March 2024</span> / <span style="display: inline-block">Published: 22 March 2024</span> </div> <div class="belongsTo" style="margin-bottom: 10px;"> (This article belongs to the Special Issue <a href=" /journal/cancers/special_issues/45E6IV0Z9X ">Advances and Future Developments in Liver Transplantation for Cancers</a>)<br/> </div> <div class="highlight-box1"> <div class="download"> <a class="button button--color-inversed button--drop-down" data-dropdown="drop-download-1361716" aria-controls="drop-supplementary-1361716" aria-expanded="false"> Download <i class="material-icons">keyboard_arrow_down</i> </a> <div id="drop-download-1361716" class="f-dropdown label__btn__dropdown label__btn__dropdown--button" data-dropdown-content aria-hidden="true" tabindex="-1"> <a class="UD_ArticlePDF" href="/2072-6694/16/7/1243/pdf?version=1711092729" data-name="Everolimus Mitigates the Risk of Hepatocellular Carcinoma Recurrence after Liver Transplantation" data-journal="cancers">Download PDF</a> <br/> <a id="js-pdf-with-cover-access-captcha" href="#" data-target="/2072-6694/16/7/1243/pdf-with-cover" class="accessCaptcha">Download PDF with Cover</a> <br/> <a id="js-xml-access-captcha" href="#" data-target="/2072-6694/16/7/1243/xml" class="accessCaptcha">Download XML</a> <br/> <a href="/2072-6694/16/7/1243/epub" id="epub_link">Download Epub</a> <br/> </div> <div class="js-browse-figures" style="display: inline-block;"> <a href="#" class="button button--color-inversed margin-bottom-10 openpopupgallery UI_BrowseArticleFigures" data-target='article-popup' data-counterslink = "https://www.mdpi.com/2072-6694/16/7/1243/browse" >Browse Figures</a> </div> <div id="article-popup" class="popupgallery" style="display: inline; line-height: 200%"> <a href="https://pub.mdpi-res.com/cancers/cancers-16-01243/article_deploy/html/images/cancers-16-01243-g001.png?1711092850" title=" <strong>Figure 1</strong><br/> <p>Flowchart of the study cohort.</p> "> </a> <a href="https://pub.mdpi-res.com/cancers/cancers-16-01243/article_deploy/html/images/cancers-16-01243-g002.png?1711092853" title=" <strong>Figure 2</strong><br/> <p>Illustrates the OS according to the Milan criteria at transplant and the type of immunosuppressant (EVR versus TAC). The 1-, 3-, and 5-year actuarial OS (95% CI) for EVR patients within the Milan criteria as per pre-transplant radiologic staging were 98% (93–99%), 89% (82–90%), and 84% (79–88%) versus 98% (94–99%), 89% (83–90%), and 85% (80–87%) for EVR and TAC, respectively. For patients exceeding the Milan criteria, the OS (95% CI) was 94% (91–96%), 84% (81–86%), and 76% (72–79%) versus 92% (89–94%), 79% (73–80%), and 69% (66–70%) for EVR and TAC, respectively. Due to the crossing of the Kaplan–Meier curves of patients within the Milan criteria indicating non-proportional hazards, we used Peto-Peto-Prentice’s version of the log-rank test to measure differences across patient groups (log-rank <span class="html-italic">p</span> = 0.03; χ<sup>2</sup> = 8.34; df = 3).</p> "> </a> <a href="https://pub.mdpi-res.com/cancers/cancers-16-01243/article_deploy/html/images/cancers-16-01243-g003.png?1711092856" title=" <strong>Figure 3</strong><br/> <p>Kaplan–Meier (KM) probability of post-transplant recurrence-free survival (RFS) according to everolimus (EVR) versus tacrolimus (TAC) and Milan stage at transplantation. 1 = Milan-in EVR; 2 = Milan-in TAC; 3 = Milan-out EVR; 4 = Milan-out TAC. Log-rank <span class="html-italic">p</span> = 0.006 (χ<sup>2</sup> = 12.13; df = 3).</p> "> </a> </div> <a class="button button--color-inversed" href="/2072-6694/16/7/1243/review_report">Review Reports</a> <a class="button button--color-inversed" href="/2072-6694/16/7/1243/notes">Versions Notes</a> </div> </div> <div class="responsive-moving-container small hidden" data-id="article-counters" style="margin-top: 15px;"></div> <div class="html-dynamic"> <section> <div class="art-abstract art-abstract-new in-tab hypothesis_container"> <p> <div><section class="html-abstract" id="html-abstract"> <h2 id="html-abstract-title">Abstract</h2><b>:</b> <section id="SimpleSummary" type=""><h2 data-nested="1"> Simple Summary</h2><div class="html-p">Everolimus is an immunosuppressive drug used to prevent rejection after liver transplantation. It is an attractive alternative to tacrolimus for patients with hepatocellular carcinoma who are undergoing liver transplantation due to its antiproliferative effects. In our study, we investigated whether liver transplant patients who received everolimus after transplantation had a reduced risk of hepatocellular carcinoma recurrence compared to those on tacrolimus. In a group of 511 patients, recipients treated with everolimus exhibited a reduced risk of tumor recurrence after transplantation. This was particularly true for patients with more advanced tumors and who received the drug earlier and for longer periods. We recommend including everolimus in the post-transplant immunosuppressive regimen to optimize outcomes of liver transplantation for hepatocellular carcinoma.</div></section><section id="Abstract" type=""><h2 data-nested="1"> Abstract</h2><div class="html-p">To obtain long-term data on the use of everolimus in patients who underwent liver transplantation for hepatocellular carcinoma, we conducted a retrospective, single-center analysis of adult recipients transplanted between 2013 and 2021. Patients on everolimus-incorporating immunosuppression were matched with those on tacrolimus using an inverse probability of treatment weighting methodology. Two propensity-matched groups of patients were thus compared: 233 (45.6%) receiving everolimus versus 278 (54.4%) on tacrolimus. At a median (interquartile range) follow-up of 4.4 (3.8) years after transplantation, everolimus patients showed a reduced risk of recurrence versus tacrolimus (7.7% versus 16.9%; RR = 0.45; <span class="html-italic">p</span> = 0.002). At multivariable analysis, microvascular infiltration (HR = 1.22; <span class="html-italic">p</span> < 0.04) and a higher tumor grading (HR = 1.27; <span class="html-italic">p</span> < 0.04) were associated with higher recurrence rate while being within Milan criteria at transplant (HR = 0.56; <span class="html-italic">p</span> < 0.001), a successful pre-transplant downstaging (HR = 0.63; <span class="html-italic">p</span> = 0.01) and use of everolimus (HR = 0.46; <span class="html-italic">p</span> < 0.001) had a positive impact on the risk of post-transplant recurrence. EVR patients with earlier drug introduction (≤30 days; <span class="html-italic">p</span> < 0.001), longer treatment duration (<span class="html-italic">p</span> < 0.001), and higher drug exposure (≥5.9 ng/mL; <span class="html-italic">p</span> < 0.001) showed lower recurrence rates versus TAC. Based on our experience, everolimus provides a reduction in the relative risk of hepatocellular carcinoma recurrence, especially for advanced-stage patients and those with earlier drug administration, higher drug exposure, and longer time on treatment. These data advocate for early everolimus introduction after liver transplantation to reduce the attrition rate consequent to chronic immunosuppression.</div></section> </section> <div id="html-keywords"> <div class="html-gwd-group"><div id="html-keywords-title">Keywords: </div><a href="/search?q=liver+transplantation">liver transplantation</a>; <a href="/search?q=immunosuppression">immunosuppression</a>; <a href="/search?q=everolimus">everolimus</a>; <a href="/search?q=hepatocellular+carcinoma">hepatocellular carcinoma</a>; <a href="/search?q=recurrence">recurrence</a></div> <div> </div> </div> </div> </p> </div> </section> </div> <div class="hypothesis_container"> <ul class="menu html-nav" data-prev-node="#html-quick-links-title"> </ul> <div class="html-body"> <section id='sec1-cancers-16-01243' type='intro'><h2 data-nested='1'> 1. Introduction</h2><div class='html-p'>Complications of chronic immunosuppression impact long-term survival after liver transplantation (LT) [<a href="#B1-cancers-16-01243" class="html-bibr">1</a>]. Nearly all long-term survivors show diverse co-morbidities, the most frequent being hypertension, chronic kidney dysfunction (CKD), de novo malignancies, diabetes mellitus (DM), and metabolic disease [<a href="#B2-cancers-16-01243" class="html-bibr">2</a>]. Complications often arise from CNI use (e.g., cyclosporine (CyA) and tacrolimus (TAC)) alongside factors such as surgery, co-medication, age, and liver disease [<a href="#B1-cancers-16-01243" class="html-bibr">1</a>,<a href="#B2-cancers-16-01243" class="html-bibr">2</a>]. Introduced in clinical practice a decade ago [<a href="#B3-cancers-16-01243" class="html-bibr">3</a>,<a href="#B4-cancers-16-01243" class="html-bibr">4</a>,<a href="#B5-cancers-16-01243" class="html-bibr">5</a>], everolimus (EVR) is a member of the mammalian target of rapamycin (mTOR) inhibitors (mTORi) group together with sirolimus (SRL) and has been extensively studied in pre-clinical studies [<a href="#B6-cancers-16-01243" class="html-bibr">6</a>], registration trials [<a href="#B3-cancers-16-01243" class="html-bibr">3</a>,<a href="#B4-cancers-16-01243" class="html-bibr">4</a>,<a href="#B5-cancers-16-01243" class="html-bibr">5</a>], and real-life clinical practice [<a href="#B7-cancers-16-01243" class="html-bibr">7</a>]. Although approved for use with tacrolimus (TAC) [<a href="#B3-cancers-16-01243" class="html-bibr">3</a>], numerous reports have investigated its administration as a single immunosuppressant. This is especially true for treating CNI-associated nephrotoxicity and for the prevention/treatment of post-transplant de novo or recurrent malignancies [<a href="#B8-cancers-16-01243" class="html-bibr">8</a>]. Several pooled and meta-analyses have shown that incorporating EVR into immunosuppression therapy can improve renal function [<a href="#B9-cancers-16-01243" class="html-bibr">9</a>,<a href="#B10-cancers-16-01243" class="html-bibr">10</a>,<a href="#B11-cancers-16-01243" class="html-bibr">11</a>]. In addition, it can reduce the risk of post-transplant malignancies and recurrence of hepatocellular carcinoma (HCC) [<a href="#B12-cancers-16-01243" class="html-bibr">12</a>]. However, there is a large variability in reported outcomes across studies due to differences in patient selection, indications for EVR use, mode of administration and exposure, and study designs.</div><div class='html-p'>The antiproliferative profile of EVR makes it an ideal immunosuppressive agent for patients with HCC, especially for recipients with an advanced tumor stage or a higher risk of post-transplant recurrence [<a href="#B8-cancers-16-01243" class="html-bibr">8</a>]. However, the impact of any immunosuppressive strategy on the risk of post-transplant tumor recurrence is dependent on a complex interplay of tumor-related (i.e., stage at transplantation, response to pre-transplant downstaging, biological markers), condition-related (i.e., indication to transplantation, native liver disease, severity of liver dysfunction), and treatment-related correlates (i.e., time, mode, and duration of drug administration) [<a href="#B1-cancers-16-01243" class="html-bibr">1</a>]. To elucidate these interactions in large populations and in the long term, we conducted a retrospective analysis at our center on the post-transplant recurrence of HCC in adult LT recipients. </div></section><section id='sec2-cancers-16-01243' type=''><h2 data-nested='1'> 2. Materials and Methods</h2><section id='sec2dot1-cancers-16-01243' type=''><h4 class='html-italic' data-nested='2'> 2.1. Study Design </h4><div class='html-p'>We conducted a retrospective, single-center study at a National Health System (NHS)-based LT center.</div></section><section id='sec2dot2-cancers-16-01243' type=''><h4 class='html-italic' data-nested='2'> 2.2. Population</h4><div class='html-p'>Two groups of adult HCC patients who underwent whole-size transplantation from deceased brain-dead donors (DCD) at our institution were compared using a two-tiered approach. Out of the entire cohort of patients transplanted at our center, we initially selected LT recipients with HCC on explant histology, excluding those with macrovascular tumor portal infiltration and mixed cellular lineage (i.e., hepato-cholangio-hepatocellular carcinoma (CHC-HCC)). We then compared patients who received immunosuppression with EVR (alone or in combination with tacrolimus (TAC)) to those who received TAC with or without mycophenolate derivatives (MPA) between 2013 and 2021 (<a href="#cancers-16-01243-f001" class="html-fig">Figure 1</a>).</div></section><section id='sec2dot3-cancers-16-01243' type=''><h4 class='html-italic' data-nested='2'> 2.3. Primary Exposure</h4><div class='html-p'>Our primary exposure was the use of EVR alone or in combination with TAC versus TAC (±MPA) in the post-transplant immunosuppressive schedule. </div></section><section id='sec2dot4-cancers-16-01243' type=''><h4 class='html-italic' data-nested='2'> 2.4. Data Source</h4><div class='html-p'>We used data from the regional transplant authority (CRT) and our institution’s recipient database, which we maintain prospectively. The CRT data system maintains records of all donors, candidates on the waitlist, and transplant recipients and ensures that the data are accurate, valid, and transparent. The local ethics committee of the University of Pisa approved all procedures (Prot. 0036349/2020).</div></section><section id='sec2dot5-cancers-16-01243' type=''><h4 class='html-italic' data-nested='2'> 2.5. Measure Outcomes</h4><div class='html-p'>Our primary outcome was the cumulative incidence of HCC recurrence after transplantation in patients who received EVR versus those who received TAC. The secondary outcome was overall survival (OS). All these measures were treated as time-to-event occurrences. Data were censored at the time of the event, the last follow-up visit, or 31 December 2022, whichever came first.</div></section><section id='sec2dot6-cancers-16-01243' type=''><h4 class='html-italic' data-nested='2'> 2.6. Immunosuppression</h4><div class='html-p'>During the study period, de novo immunosuppression consisted of triple or quadruple schedules with anti-CD25 (basiliximab, Simulect<sup>®</sup>, Novartis, Origgio (VA), Italy), calcineurin inhibitors (CNI), CyA or TAC, steroids (S), and antimetabolites (azathioprine (AZA) or mycophenolic acid (MPA) derivatives) according to era, pre-transplant, intra-operative, and post-transplant patient characteristics. </div><div class='html-p'>When used for prophylaxis of HCC recurrence or prevention of TAC-related adverse events, EVR (Certican<sup>®</sup>, Novartis, Origgio (VA), Italy) was introduced ≥1 month after transplantation at a dose of 1.0 mg bid with antimetabolite elimination and stepwise TAC dose reduction, unless otherwise clinically indicated. Before EVR introduction, patients were tested for liver function (LFT), hematocrit, lipid profile, and creatinine/protein ratio. When used in combination schedules, EVR was adjusted to a trough level between 3 and 8 ng/mL and TAC between 3 and 5 ng/mL. When used alone, the EVR trough level was between 6 and 10 ng/mL, as clinically appropriate. When introduced for TAC-related complications, the time, mode, and dose of EVR were dependent on clinical indications. </div><div class='html-p'>Rejection episodes were histologically confirmed and graded according to the BANFF classification system [<a href="#B13-cancers-16-01243" class="html-bibr">13</a>]. Treatment of rejection was with steroid boluses for non-HCV patients, whereas CNI and MPA dose increase/reintroduction were preferred for HCV-RNA positive recipients. In case of refractory rejection episodes, we tested the patients for donor-specific and anti-HLA antibodies and used plasmapheresis, intravenous immunoglobulin, or rabbit anti-thymocyte immunoglobulin (rATG) as clinically appropriate. Anti-CMV prophylaxis was used in recipients without acquired immunity (i.e., D+/R− and D−/R− combinations).</div></section><section id='sec2dot7-cancers-16-01243' type=''><h4 class='html-italic' data-nested='2'> 2.7. Drug Exposure Assay</h4><div class='html-p'>EVR exposure was tested in whole blood with the QMS™ Everolimus Immunoassay, a homogeneous particle-enhanced turbidimetric immunoassay based on Quantitative Microparticle System (QMS<sup>®</sup>) technology. The mean EVR exposure was calculated based on samples obtained at our institution at follow-up visits. </div></section><section id='sec2dot8-cancers-16-01243' type=''><h4 class='html-italic' data-nested='2'> 2.8. Special Considerations</h4><div class='html-p'>The study period saw changes in the transplant procedure, perioperative management, and immunosuppressive schedules in accordance with technological advancements and scientific evidence. Donor-specific antibody (DSA) testing was usually performed on pre-transplant samples, but its positivity did not preclude transplantation. Celsior<sup>®</sup> (IGL, Lissieu, France) was used for graft perfusion until 2017 and was replaced by Servator C<sup>®</sup> (SALF, Cenate Sotto (BG), Italy). Bypassing or the classical technique were standard until 2017. Direct antiviral agents (DAAs) were used pre- or post-transplantation for HCV RNA-positive patients, as appropriate. In HBsAg-positive recipients, HBV recurrence prophylaxis was with lifelong anti-HBs immunoglobulin (HBIg) and antivirals, according to the era. Anti-HBsAg donors were used for anti-HBsAg recipients only after histological graft evaluation and exclusion of HDV co-infection. When anti-HBc positive grafts were used for naïve recipients, lifelong prophylaxis with antivirals was used. </div></section><section id='sec2dot9-cancers-16-01243' type=''><h4 class='html-italic' data-nested='2'> 2.9. Pre-Transplant Management of HCC</h4><div class='html-p'>The diagnosis of HCC was made according to the European Association for the Study of Liver Disease (EASL) guidelines [<a href="#B14-cancers-16-01243" class="html-bibr">14</a>]. Patients within the Barcelona Clinic Liver Cancer (BCLC) stage B (intermediate) were considered for transplantation [<a href="#B15-cancers-16-01243" class="html-bibr">15</a>]. Pre-transplant downstaging/bridging was indicated for patients with >3 cm tumor mass, those with AFP levels > 400 ng/mL, or with segmental portal infiltration. The down-staging technique was agreed upon during the tumor board case evaluation based on tumor size, location, and number of nodules. It consisted of transarterial chemoembolization (TACE), radiofrequency/microwave ablation, transarterial radioembolization (TARE), or surgery as appropriate. A successful downstaging procedure was associated with regression from beyond to within the Milan criteria as per pre-transplant imaging or explant histology. </div></section><section id='sec2dot10-cancers-16-01243' type=''><h4 class='html-italic' data-nested='2'> 2.10. Post-Transplant Management of Recurrent HCC</h4><div class='html-p'>HCC recurrence was diagnosed with a contrast-enhanced CT scan or MR based on the EASL guidelines [<a href="#B14-cancers-16-01243" class="html-bibr">14</a>]. Histology was performed when appropriate. These patients were converted to EVR monotherapy whenever feasible and referred for surgical, radiological treatment, or chemotherapy with VEGFR inhibitors based on multidisciplinary board consensus. </div></section><section id='sec2dot11-cancers-16-01243' type=''><h4 class='html-italic' data-nested='2'> 2.11. Cut-Offs and Definitions</h4><div class='html-p'>Cold ischemia time (CIT) was the time from donor cross-clamping until the organ was removed from the ice for implantation. The warm ischemia time (WIT) was the duration of ischemia during graft implantation. The definition of EAD was based on the research of Olthoff et al. [<a href="#B16-cancers-16-01243" class="html-bibr">16</a>]. Retrospectively, MELD scores were recalculated using the laboratory data available at the time of transplantation. Retrospectively, MELD scores were recalculated using the laboratory data available at the time of transplantation. The recurrence of HCV was confirmed through liver biopsy when HCV-RNA was positive. The recurrence of HBV infection was defined as the reappearance of HBsAg (±HBV DNA) in previously seroconverted patients, regardless of liver function. Renal function was evaluated using the Modification of Diet in Renal Disease-4 formula to estimate the glomerular filtration rate (eGFR). Chronic kidney dysfunction (CKD) was defined as follows: (a) estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m<sup>2</sup> for a post-LT period greater than three months as per the Kidney Disease: Improving Global Outcomes (KDIGO) criteria in patients with previous eGFR ≥60 mL/min/1.73 m<sup>2</sup> [<a href="#B17-cancers-16-01243" class="html-bibr">17</a>]; (b) evidence of intrinsic renal disease (proteinuria or kidney disease at ultrasound) [<a href="#B17-cancers-16-01243" class="html-bibr">17</a>]; or (c) presence of end-stage renal disease requiring renal replacement therapy [<a href="#B17-cancers-16-01243" class="html-bibr">17</a>]. Acute kidney injury (AKI) was defined as a doubling of baseline serum creatine (sCr) and/or a ≥50% reduction in eGFR within 14 days [<a href="#B17-cancers-16-01243" class="html-bibr">17</a>]. Deteriorating renal function was defined as ≥one-grade downward shift in the kidney function category according to the KDIGO classification system [<a href="#B18-cancers-16-01243" class="html-bibr">18</a>]. Post-transplant diabetes mellitus (PTDM) was determined using the comprehensive American Diabetes Association (ADA) 2018 criteria [<a href="#B19-cancers-16-01243" class="html-bibr">19</a>].</div><div class='html-p'>Arterial hypertension was defined as having a blood pressure of 140/90 mmHg or higher during two consecutive visits or requiring medication. Dyslipidemia was defined as having high levels of cholesterol (>220 mg/dL) and/or triglycerides (>200 mg/dL) at two consecutive visits. Biliary complications included biliary fistula, biliary stones, anastomotic biliary strictures, and posttransplant ischemic-type biliary lesion (ITBL), all of which were symptomatic and treated. ITBL was defined as any non-anastomotic stenosis that required an endoscopic or surgical procedure because of associated symptoms or signs without vascular complications.</div></section><section id='sec2dot12-cancers-16-01243' type=''><h4 class='html-italic' data-nested='2'> 2.12. Statistical Analyses</h4><div class='html-p'>Initially, 2 groups of patients were extracted from the original population of HCC recipients transplanted at our center between 1996 and 2021 based on the presence of HCC in the explant histology and excluding those with mixed HCC–CHC and macrovascular portal infiltration in the explant liver. The EVR group included 463 patients who received the drug in their de novo immunosuppressive regimen for prophylaxis of post-transplant tumor recurrence or CNI-related complications other than HCC recurrence (i.e., renal function deterioration) and 556 patients who received CNI until complications or the latest follow-up (<a href="#cancers-16-01243-f001" class="html-fig">Figure 1</a>). </div><div class='html-p'>Later, we addressed the non-randomized design of the analysis by balancing the two groups using an inverse probability of treatment weighting (IPTW) approach. Two pseudo-groups were thus generated: EVR (i.e., patients on EVR ± TAC) and TAC. A propensity score for each patient in the original population was developed. The score was created using a multivariate logistic regression model that considered post-transplant HCC recurrence (no/yes) as the dependent variable. Eighteen confounding factors that have clinical significance were chosen to serve as covariates for both DFS and OS: patient sex [<a href="#B20-cancers-16-01243" class="html-bibr">20</a>]; age [<a href="#B21-cancers-16-01243" class="html-bibr">21</a>]; HCV [<a href="#B22-cancers-16-01243" class="html-bibr">22</a>]; diabetes mellitus at transplant [<a href="#B23-cancers-16-01243" class="html-bibr">23</a>]; CKD at transplant [<a href="#B24-cancers-16-01243" class="html-bibr">24</a>]; MELD score [<a href="#B25-cancers-16-01243" class="html-bibr">25</a>]; donor sex [<a href="#B26-cancers-16-01243" class="html-bibr">26</a>]; donor age [<a href="#B27-cancers-16-01243" class="html-bibr">27</a>]; cerebrovascular accident (CVA) as donor cause of death [<a href="#B28-cancers-16-01243" class="html-bibr">28</a>]; use of machine perfusion (MP) [<a href="#B29-cancers-16-01243" class="html-bibr">29</a>]; CIT [<a href="#B30-cancers-16-01243" class="html-bibr">30</a>]; pre-transplant tumor stage according to Milan criteria [<a href="#B31-cancers-16-01243" class="html-bibr">31</a>]; pre-transplant alpha-fetoprotein (AFP) [<a href="#B32-cancers-16-01243" class="html-bibr">32</a>]; efficacy of pre-transplant downstaging and defined as downstaging from beyond to within Milan criteria [<a href="#B33-cancers-16-01243" class="html-bibr">33</a>]; tumor stage at histology according to Milan criteria [<a href="#B31-cancers-16-01243" class="html-bibr">31</a>,<a href="#B32-cancers-16-01243" class="html-bibr">32</a>,<a href="#B33-cancers-16-01243" class="html-bibr">33</a>]; G3–G4 tumor grading [<a href="#B34-cancers-16-01243" class="html-bibr">34</a>]; presence of microvascular infiltration [<a href="#B34-cancers-16-01243" class="html-bibr">34</a>]; and mean TAC trough level within the first post-transplant month (≤10 ng/mL) [<a href="#B35-cancers-16-01243" class="html-bibr">35</a>].</div><div class='html-p'>To reduce artificial sample size modification in pseudo-data, stabilized weights (SW) were used with the following formula:<div class='html-disp-formula-info' id=''> <div class='f'> <span class='html-italic'>SW</span> = <span class='html-italic'>p/PS for the study group and SW</span> = (<span class='html-italic'>1 p</span>)/(<span class='html-italic'>1 PS</span>) <span class='html-italic'>for the control group</span> </div> <div class='l'> <label >(1)</label> </div> </div> where p is the probability of etiology without considering covariates, and PS is the propensity score. A stabilized approach was preferred not to inflate the sample populations versus the original ones.</div><div class='html-p'>To avoid biases from population size, comparisons between covariate subgroups were reported as effect size (Cohen’s D value). Values with differences lower than |0.1| were considered negligible. Differences between |0.1| and |0.3| were small, those between |0.3| and |0.5| were moderate, and those above |0.5| were considerable.</div><div class='html-p'>After stabilizing IPTW, multivariate Cox regression analyses were performed to identify risk factors for HCC recurrence after transplantation. Hazard ratios (HR) and 95.0% confidence intervals (CI) were reported for significant variables. Survival analyses were performed using the Kaplan—Meier method, and the appropriate version of the log-rank test was adopted to compare the survival rates. Statistical significance was a <span class='html-italic'>p</span>-value of 0.05.</div><div class='html-p'>Finally, after propensity matching, 3 further co-variates were used to explore the impact of EVR administration on the risk of HCC recurrence: (1) timing of EVR introduction, (2) duration of EVR treatment, and (3) EVR whole blood concentration throughout the study period. Patients were dichotomized according to median values, and sensitivity analyses were performed between recurring and non-recurring patients. </div><div class='html-p'>Frequency and percentages, medians, interquartile ranges (IQR), or means and standard deviations (SD) were used to express variables as appropriate. Data errors and missingness were identified across the database and solved. Missing data in the dataset were addressed using a single imputation method. In detail, the median of nearby point imputation was adopted. In this case, the median was chosen as a measure of central tendency because the distribution of the managed variables was not symmetrical and was skewed toward one end. Recurrence-free survival (RFS) was defined as the time (months) from transplantation to diagnosis of HCC recurrence. OS was the time from transplantation to death or last observation. </div><div class='html-p'>All statistical analyses and plots were performed using SPSS (version 27.0, SPSS Inc., Chicago, IL, USA). This study adheres to the ethical principles of the 1975 Declaration of Helsinki, as reflected in its a priori approval by the institution’s human research committee. It was also conducted according to the Guidelines for Strengthening the Reporting of Observational Studies in Epidemiology (STROBE).</div></section></section><section id='sec3-cancers-16-01243' type='results'><h2 data-nested='1'> 3. Results </h2><section id='sec3dot1-cancers-16-01243' type=''><h4 class='html-italic' data-nested='2'> 3.1. Demographics and Clinical Characteristics of the Original Cohort</h4><div class='html-p'>A total of 1019 adult patients transplanted for HCC at our center between 1996 and 2021 were initially considered (<a href="#cancers-16-01243-t001" class="html-table">Table 1</a>). Among them, 463 (45.4%) received EVR for HCC recurrence prophylaxis or complications other than HCC recurrence, whereas 556 (54.6%) received CNI (either TAC or CyA) as the primary de novo immunosuppressant until HCC recurrence. At a median (IQR) follow-up of 8.7 (8.1) years, 384 (37.6%) patients died, 41 (4.0%) were retransplanted, and 635 (62.3%) were alive. The 1, 5, and 10-year Kaplan–Meier probability (95% CI) of survival was 91% (89–93%) and 90.2% (88–93%), 77% (74–80%), and 75.8% (72–79%), 67% (63–71%), and 65% (61%–70.2%) for patient and graft, respectively.</div><div class='html-p'><a href="#cancers-16-01243-t001" class="html-table">Table 1</a> shows the clinical features of the recipients and donors from 1996 to 2021 and before matching. CNI patients were more frequently transplanted before 2013 (66.0% versus 31.7%; <span class='html-italic'>p</span> < 0.0001), whereas EVR patients were more frequently transplanted beyond the Milan criteria (32.8% versus 18.1%; <span class='html-italic'>p</span> < 0.0001), underwent more frequent pre-transplant downstaging procedures (59.6% versus 62.4%; <span class='html-italic'>p</span> = 0.01), and showed higher median (IQR) AFP levels before surgery (46.3 (28) versus 4.7 (19) ng/mL; <span class='html-italic'>p</span> = 0.002). Similarly, the proportion of G3–G4 grading (31.9% versus 25.1%; <span class='html-italic'>p</span> = 0.01) and microvascular infiltration (39.5% versus 32.7%; <span class='html-italic'>p</span> = 0.02) were higher in the EVR group.</div></section><section id='sec3dot2-cancers-16-01243' type=''><h4 class='html-italic' data-nested='2'> 3.2. Stabilized IPTW Effect </h4><div class='html-p'>To minimize the effect of selection biases caused by the non-randomized design of this retrospective study, the EVR and TAC pseudogroups were balanced using a stabilized IPTW method. <a href="#cancers-16-01243-t002" class="html-table">Table 2</a> illustrates the results of the balancing procedure for the 18 potential confounders. Namely, seven variables showed insignificant differences before balancing, seven small, and four moderate. After IPTW, 14 variables showed insignificant differences, and three were small. The IPTW yielded two pseudogroups, i.e., 233 EVR patients versus 278 on TAC. </div></section><section id='sec3dot3-cancers-16-01243' type=''><h4 class='html-italic' data-nested='2'> 3.3. Results in the Balanced Groups</h4><div class='html-p'>After performing IPTW balancing, <a href="#cancers-16-01243-t003" class="html-table">Table 3</a> presents the clinical characteristics of both groups. At a median follow-up of 4.4 (3.8) years after transplantation, the number of deaths, re-transplants, and HCC recurrences were 167 (32.7%), 20 (4.0%), and 65 (12.7%), respectively (<a href="#cancers-16-01243-t004" class="html-table">Table 4</a>). TAC patients showed higher death (37.8% versus 26.6%; RR = 1.41; <span class='html-italic'>p</span> = 0.007) and HCC recurrence rates (16.9% versus 7.7%; RR = 2.2; <span class='html-italic'>p</span> = 0.002). The main reasons for death in the TAC and EVR groups included HCC recurrence (15.1% versus 6.8%; RR = 2.51; <span class='html-italic'>p</span> = 0.003), HCV recurrence (5.4% versus 6.9%; RR = 0.8; <span class='html-italic'>p</span> = 0.48), infections/sepsis (5.7% versus 5.1%; RR = 1.11; <span class='html-italic'>p</span> = 0.84), and de novo malignancies (3.9% versus 2.1%; RR = 1.85; <span class='html-italic'>p</span> = 0.31) (<a href="#cancers-16-01243-t004" class="html-table">Table 4</a>). </div></section><section id='sec3dot4-cancers-16-01243' type=''><h4 class='html-italic' data-nested='2'> 3.4. Re-Transplantation</h4><div class='html-p'>A total of 20 (3.9%) patients were re-transplanted (<a href="#cancers-16-01243-t004" class="html-table">Table 4</a>). The main indication was primary non-function (PNF) of the liver graft, which accounted for 40% of such cases, followed by ischemic cholangiopathy (30%) and hepatic artery thrombosis (HAT) (15.0%). No significant difference was found in the causes of re-transplantation between the two groups.</div></section><section id='sec3dot5-cancers-16-01243' type=''><h4 class='html-italic' data-nested='2'> 3.5. HCC Recurrence</h4><div class='html-p'>HCC recurred at a median (IQR) of 26.1 (48.7) months after transplantation and accounted for 15.1% of deaths in TAC patients versus 6.8% in EVR patients (RR = 2.51; <span class='html-italic'>p</span> = 0.003). One-third of recurrences were in the liver only, whereas TAC patients showed more frequent multi-organ involvement (<span class='html-italic'>p</span> = 0.002) (<a href="#cancers-16-01243-t004" class="html-table">Table 4</a>). In the EVR group, a numerically lower incidence of HCC recurrences was observed for patients on EVR monotherapy (n = 12, 6.8%) versus those on EVR + rTAC (n = 6, 10.8%; <span class='html-italic'>p</span> = 0.33) was observed (<a href="#cancers-16-01243-f001" class="html-fig">Figure 1</a>). </div></section><section id='sec3dot6-cancers-16-01243' type=''><h4 class='html-italic' data-nested='2'> 3.6. Immunosuppression</h4><div class='html-p'><a href="#cancers-16-01243-t005" class="html-table">Table 5</a> and <a href="#cancers-16-01243-t006" class="html-table">Table 6</a> illustrate the immunosuppressive regimen in the EVR group with respect to indication, timing of introduction, duration of treatment, and median exposure. EVR was introduced at a median (IQR) post-transplantation interval of 30 (16) days for a median (IQR) of 46.6 (36.1) months. Median (IQR) EVR whole blood exposure was 5.8 (1.7) ng/mL. As many as 177 (75.9%) patients in the EVR group received EVR monotherapy, whereas 56 (24.1%) combined EVR and reduced-exposure TAC (<a href="#cancers-16-01243-f001" class="html-fig">Figure 1</a>). At the latest follow-up, EVR was discontinued in 12 (5.1%) patients, for tBPAR in 4 (1.7%), progressing proteinuria in 5 (2.1%), and infection in 3 (1.3%) (<a href="#cancers-16-01243-t005" class="html-table">Table 5</a>).</div><div class='html-p'>In the EVR group, patients with HCC recurrence showed later EVR introduction (median (IQR) = 52 (26.4) versus 30 (12) days; <span class='html-italic'>p</span> < 0.001), shorter duration of treatment (median (IQR) = 47.6 (57.0) versus 69.9 (24.8) months; <span class='html-italic'>p</span> < 0.001), and lower drug exposure (median (IQR) = 3.65 (0.55) versus 5.9 (1.4) ng/mL; <span class='html-italic'>p</span> < 0.001) (<a href="#cancers-16-01243-t006" class="html-table">Table 6</a>). </div></section><section id='sec3dot7-cancers-16-01243' type=''><h4 class='html-italic' data-nested='2'> 3.7. Risk Factors for Recurrence-Free and Overall Survival</h4><div class='html-p'><a href="#cancers-16-01243-t007" class="html-table">Table 7</a> illustrates the results of the multivariate analysis of risk factors for OS and RFS in the entire post-IPTW population. Successful pre-transplant downstaging (HR = 0.79; <span class='html-italic'>p</span> = 0.006), being within Milan criteria at transplant (HR = 0.67; <span class='html-italic'>p</span> < 0.001) and at histology (HR = 0.78; <span class='html-italic'>p</span> = 0.02) and use of EVR (HR = 0.69; <span class='html-italic'>p</span> = 0.009) had a positive impact on survival.</div><div class='html-p'>As for HCC recurrence, the presence of vascular micro-infiltration (HR = 1.22; <span class='html-italic'>p</span> = 0.04) and higher tumor grading (HR = 1.27; <span class='html-italic'>p</span> = 0.044) had a negative impact on RFS, while a successful pre-transplant downstaging (HR = 0.65; <span class='html-italic'>p</span> = 0.01), being within Milan criteria at transplant (HR = 0.56; <span class='html-italic'>p</span> = 0.01) and at histology (HR = 0.68; <span class='html-italic'>p</span> = 0.012) and use of EVR (HR = 0.46; <span class='html-italic'>p</span> < 0.001) had a positive impact on the probability of tumor-free survival. </div><div class='html-p'><a href="#cancers-16-01243-f002" class="html-fig">Figure 2</a>: Kaplan–Meier (KM) survival function probability of post-transplant overall patient survival according to everolimus (EVR) versus tacrolimus (TAC) and Milan stage at transplantation. 1 = Milan-in EVR; 2 = Milan-in TAC; 3 = Milan-out EVR; 4 = Milan-out TAC. Overall log-rank <span class='html-italic'>p</span> for the four groups was 0.03 (χ<sup>2</sup> = 8.34; df = 3). </div><div class='html-p'><a href="#cancers-16-01243-f003" class="html-fig">Figure 3</a> illustrates the RFS according to Milan criteria at transplantation and the type of immunosuppressant (EVR versus TAC). The actuarial (95% CI) RFS for patients within the Milan criteria was 96% (94–100%), 87% (84–89%), and 82% (77–89%) at 1, 3, and 5 years in the EVR group versus 96% (CI 88–99%), 87% (74–91%), and 80% (72–84%) in the TAC group, respectively. On the other hand, it was 90% (82–94%), 78% (64–81%), and 68% (57–71%) at 1, 3, and 5 years for EVR patients exceeding the Milan criteria versus 86% (72–90%), 75% (66–84%), and 65% (52–69%) for TAC patients beyond the Milan criteria. (log-rank <span class='html-italic'>p</span> = 0.006; χ<sup>2</sup> = 12.13; df = 3 according to the Peto-Peto and Prentice). </div></section></section><section id='sec4-cancers-16-01243' type='discussion'><h2 data-nested='1'> 4. Discussion</h2><div class='html-p'>This is one of the largest single-center series on the use of EVR in recipients of a liver graft for HCC, with long-term follow-up data available in the international literature. Despite the expansion of the practice of LT for advanced HCC, information on the impact of EVR or SRL is derived mainly from systematic reviews and meta-analyses incorporating both drugs [<a href="#B11-cancers-16-01243" class="html-bibr">11</a>,<a href="#B36-cancers-16-01243" class="html-bibr">36</a>,<a href="#B37-cancers-16-01243" class="html-bibr">37</a>,<a href="#B38-cancers-16-01243" class="html-bibr">38</a>,<a href="#B39-cancers-16-01243" class="html-bibr">39</a>,<a href="#B40-cancers-16-01243" class="html-bibr">40</a>], with only a few multi-institutional research studies [<a href="#B9-cancers-16-01243" class="html-bibr">9</a>,<a href="#B41-cancers-16-01243" class="html-bibr">41</a>,<a href="#B42-cancers-16-01243" class="html-bibr">42</a>,<a href="#B43-cancers-16-01243" class="html-bibr">43</a>] and real-life clinical series [<a href="#B44-cancers-16-01243" class="html-bibr">44</a>,<a href="#B45-cancers-16-01243" class="html-bibr">45</a>,<a href="#B46-cancers-16-01243" class="html-bibr">46</a>]. Although some authors dispute the advantage of mTORi for the reduction of post-transplant HCC recurrence [<a href="#B43-cancers-16-01243" class="html-bibr">43</a>], the overall evidence originating from these studies supports the use of mTORi for patients with HCC, earlier drug introduction and higher exposure levels to achieve more significant antiproliferative activity [<a href="#B46-cancers-16-01243" class="html-bibr">46</a>]. </div><div class='html-p'>Dysregulation of the mTOR pathway is frequently observed in HCC [<a href="#B47-cancers-16-01243" class="html-bibr">47</a>]. However, transferring this evidence from the in vitro experimental setting to clinical practice is challenging because the overall impact of EVR on post-transplant HCC appears to be dependent on a complex interplay of molecular signaling, tumor cell viability, total tumor volume, plasma, and tumor drug concentration [<a href="#B48-cancers-16-01243" class="html-bibr">48</a>]. In addition, pre-transplant tumor characteristics, response to adjuvant treatment, type of native liver disease, quality of liver graft, surgery, and immunosuppressive regimens all account for the variable outcomes reported in the literature. One strategy to overcome these limitations is to analyze real-life clinical practice and large datasets using propensity-matching methodologies to reduce selection biases. Therefore, we opted for a retrospective comparison of two propensity-matched samples of HCC patients using the IPTW methodology. </div><div class='html-p'>The analysis revealed that the use of EVR could reduce the risk of HCC recurrence and increase RFS and OS in LT recipients. This was especially true for tumors beyond the Milan criteria and for patients with earlier drug introduction (≤30 days), longer time on treatment (about 5 years), and higher median EVR exposure level (≥5.9 ng/mL). In such cases, a twofold reduction in the relative risk of HCC recurrence was observed alongside improved OS. In patients within the Milan criteria, the oncological impact of EVR-based immunosuppression was weaker, but the overarching benefits of EVR on renal function deterioration and de novo malignancies favor its use in this category of patients. </div><div class='html-p'>Our data contradict previous experiences regarding the phase-3 trial on SRL reported by Geissler et al. in 2016 [<a href="#B41-cancers-16-01243" class="html-bibr">41</a>]. In their study, the authors compared 264 patients on SRL-free immunosuppression with 261 on SRL-incorporating regimens. Patients with low-risk hepatocellular carcinoma (within Milan criteria) experienced a significant benefit in RFS and OS within the first 3 to 5 years [<a href="#B41-cancers-16-01243" class="html-bibr">41</a>]. In our study, patients within the Milan criteria did not show different RFS and OS according to the type of immunosuppression, whereas the impact of EVR was observed for those beyond the Milan criteria (i.e., high-risk). To understand the apparent contradiction, the study conducted by Geissler et al. was a multicenter trial across 44 centers, with 42 centers situated in Europe, 1 in Australia, and another 1 in Canada. The study was conducted from 2006 (when the first patient visited) to 2014 (when the last patient finished their visit). This means their study was conducted well before our experience, from 2013 to 2021. Geissler’s patients were grouped based on the histology of their explant liver, and the low-risk and high-risk groups were determined using histologic data. In our study, the comparison between the treatment groups was based on the Milan stage as per the latest radiological examination before transplantation. Approximately 60% of the patients underwent downstaging/bridging procedures before transplantation, a quarter were successfully downstaged, and patients with macrovascular portal infiltration were excluded from the analysis. Their low AFP levels indicate that our patients beyond the Milan criteria were carefully selected and had less unfavorable biological criteria than those in Geissler’s study. Finally, our center has extensive experience managing EVR-related complications in LT recipients, as indicated by the lower EVR discontinuation and graft rejection rates in the current experience compared with previously reported data [<a href="#B3-cancers-16-01243" class="html-bibr">3</a>,<a href="#B4-cancers-16-01243" class="html-bibr">4</a>,<a href="#B5-cancers-16-01243" class="html-bibr">5</a>]. All these factors might explain the difference between our experience and Geissler and colleagues.</div><div class='html-p'>Transferring these considerations to current clinical practice, however, is not simple. </div><div class='html-p'>Earlier EVR administration requires proper patient management due to a reported higher incidence of leukopenia, thrombocytopenia, dyslipidemia, and infections with the use of mTORi versus CNIs, as well as a higher discontinuation rate for patients on higher drug exposure [<a href="#B3-cancers-16-01243" class="html-bibr">3</a>,<a href="#B10-cancers-16-01243" class="html-bibr">10</a>]. Therefore, the initially recommended exposure levels for EVR monotherapy (i.e., 6–10 ng/mL) [<a href="#B3-cancers-16-01243" class="html-bibr">3</a>,<a href="#B4-cancers-16-01243" class="html-bibr">4</a>,<a href="#B5-cancers-16-01243" class="html-bibr">5</a>] are seldom implemented in clinical practice to avoid concentration-related adverse events. Furthermore, the current focus on immunosuppression minimization has expanded from CNI to include antimetabolites and mTORi alongside increased concerns about transplant recipients’ quality of life [<a href="#B49-cancers-16-01243" class="html-bibr">49</a>]. </div><div class='html-p'>Despite its large number of patients and robust statistical methodology, our study has several limitations. First, retrospective designs do not always provide sufficient detailed information for clinically transferable data. For instance, we could not appropriately investigate the role of DSA positivity on post-transplant outcomes [<a href="#B50-cancers-16-01243" class="html-bibr">50</a>], the role of inflammatory markers (beyond the NLR), or the role of serologic donor–recipient mismatching regarding HBV prophylaxis. Pre-transplant information on tumor clinical course and biology was also limited, such as the availability of drug exposure levels for patients with longer follow-ups. Furthermore, this study was biased by the initial experience with EVR at our center and the learning curve effect in terms of patient selection, drug discontinuation rates, and post-transplant therapeutic strategies for HCC recurrence.</div><div class='html-p'>Second, we excluded patients with unfavorable tumor characteristics from the current analysis, i.e., neoplastic portal thrombosis, because of its negative impact on RFS and OS and the limited number of cases at our center. Given the clinical expansion of the Milan criteria and the introduction of novel neoadjuvant pre-transplant treatments (i.e., immunotherapy), it would be interesting to analyze the relative benefit of EVR-incorporating immunosuppression for this category of high-risk patients. </div></section><section id='sec5-cancers-16-01243' type='conclusions'><h2 data-nested='1'> 5. Conclusions</h2><div class='html-p'>In conclusion, based on our results, EVR allows us to mitigate the risk of post-transplant HCC recurrence, especially for tumors beyond the Milan criteria and patients with earlier drug introduction, higher drug exposure, and longer treatment duration. These data advocate the use of mTORi for patients with HCC to reduce the attrition rate of chronic immunosuppression after LT.</div></section> </div> <div class="html-back"> <section class='html-notes'><h2 >Author Contributions</h2><div class='html-p'>Methodology, P.D.S.; Formal analysis, P.D.S. and A.P.; Investigation, A.P., J.D. and D.C.; Writing—original draft, P.D.S.; Writing—review & editing, P.D.S., Q.L. and P.M.; Supervision, S.G. All authors have read and agreed to the published version of the manuscript.</div></section><section class='html-notes'><h2>Funding</h2><div class='html-p'>Open access publication was supported by Novartis S.p.A.</div></section><section class='html-notes'><h2 >Institutional Review Board Statement</h2><div class='html-p'>The study was conducted in accordance with the Declaration of Helsinki, and approved by the Institutional Review Board (or Ethics Committee) of University of Pisa (Prot. 0036349/2020).</div></section><section class='html-notes'><h2 >Informed Consent Statement</h2><div class='html-p'>Informed consent was obtained from all subjects involved in the study according to the national and regional regulations.</div></section><section class='html-notes'><h2 >Data Availability Statement</h2><div class='html-p'>The data can be shared up on reasonable request. </div></section><section class='html-notes'><h2 >Conflicts of Interest</h2><div class='html-p'>PDS has served as an advisory board member for Novartis, Astellas, and Chiesi. The other authors have no interests to declare.</div></section><section id='html-glossary'><h2 >Abbreviations</h2><table class='html-array_table'><tbody ><tr ><td align='left' valign='middle' class='html-align-left' >AFP</td><td align='left' valign='middle' class='html-align-left' >alpha-fetoprotein</td></tr><tr ><td align='left' valign='middle' class='html-align-left' >Anti-HBc</td><td align='left' valign='middle' class='html-align-left' >antibody to the hepatitis virus B core antigen</td></tr><tr ><td align='left' valign='middle' class='html-align-left' >Anti-HBs</td><td align='left' valign='middle' class='html-align-left' >antibody to the hepatitis B surface antigen</td></tr><tr ><td align='left' valign='middle' class='html-align-left' >BCLC</td><td align='left' valign='middle' class='html-align-left' >Barcelona Clinic Liver Cancer</td></tr><tr ><td align='left' valign='middle' class='html-align-left' >BMI</td><td align='left' valign='middle' class='html-align-left' >body mass index</td></tr><tr ><td align='left' valign='middle' class='html-align-left' >BPAR</td><td align='left' valign='middle' class='html-align-left' >biopsy-proven acute rejection</td></tr><tr ><td align='left' valign='middle' class='html-align-left' >CHC</td><td align='left' valign='middle' class='html-align-left' >cholangiocarcinoma</td></tr><tr ><td align='left' valign='middle' class='html-align-left' >CNI</td><td align='left' valign='middle' class='html-align-left' >calcineurin inhibitors</td></tr><tr ><td align='left' valign='middle' class='html-align-left' >CT</td><td align='left' valign='middle' class='html-align-left' >computed tomography</td></tr><tr ><td align='left' valign='middle' class='html-align-left' >CyA</td><td align='left' valign='middle' class='html-align-left' >cyclosporine</td></tr><tr ><td align='left' valign='middle' class='html-align-left' >DAA</td><td align='left' valign='middle' class='html-align-left' >direct antiviral agents</td></tr><tr ><td align='left' valign='middle' class='html-align-left' >EASL</td><td align='left' valign='middle' class='html-align-left' >European Association for the Study of Liver Disease</td></tr><tr ><td align='left' valign='middle' class='html-align-left' >eGFR</td><td align='left' valign='middle' class='html-align-left' >estimated glomerular filtration rate</td></tr><tr ><td align='left' valign='middle' class='html-align-left' >EVR</td><td align='left' valign='middle' class='html-align-left' >everolimus</td></tr><tr ><td align='left' valign='middle' class='html-align-left' >HBc</td><td align='left' valign='middle' class='html-align-left' >hepatitis B core antigen</td></tr><tr ><td align='left' valign='middle' class='html-align-left' >HBIg</td><td align='left' valign='middle' class='html-align-left' >anti-HBs immunoglobulin</td></tr><tr ><td align='left' valign='middle' class='html-align-left' >HBs</td><td align='left' valign='middle' class='html-align-left' >hepatitis B surface antigen</td></tr><tr ><td align='left' valign='middle' class='html-align-left' >HBV</td><td align='left' valign='middle' class='html-align-left' >hepatitis B virus</td></tr><tr ><td align='left' valign='middle' class='html-align-left' >HCC</td><td align='left' valign='middle' class='html-align-left' >hepatocellular carcinoma</td></tr><tr ><td align='left' valign='middle' class='html-align-left' >HCV</td><td align='left' valign='middle' class='html-align-left' >hepatitis C virus</td></tr><tr ><td align='left' valign='middle' class='html-align-left' >HDV</td><td align='left' valign='middle' class='html-align-left' >hepatitis delta virus</td></tr><tr ><td align='left' valign='middle' class='html-align-left' >HR</td><td align='left' valign='middle' class='html-align-left' >hazard ratio</td></tr><tr ><td align='left' valign='middle' class='html-align-left' >IQR</td><td align='left' valign='middle' class='html-align-left' >interquartile range</td></tr><tr ><td align='left' valign='middle' class='html-align-left' >LFT</td><td align='left' valign='middle' class='html-align-left' >liver function tests</td></tr><tr ><td align='left' valign='middle' class='html-align-left' >LT</td><td align='left' valign='middle' class='html-align-left' >liver transplantation</td></tr><tr ><td align='left' valign='middle' class='html-align-left' >MACE</td><td align='left' valign='middle' class='html-align-left' >major adverse cardiovascular events</td></tr><tr ><td align='left' valign='middle' class='html-align-left' >MDRD</td><td align='left' valign='middle' class='html-align-left' >modified diet and renal disease</td></tr><tr ><td align='left' valign='middle' class='html-align-left' >MELD</td><td align='left' valign='middle' class='html-align-left' >model for end-stage liver function</td></tr><tr ><td align='left' valign='middle' class='html-align-left' >MPA</td><td align='left' valign='middle' class='html-align-left' >mycophenolic acid derivatives</td></tr><tr ><td align='left' valign='middle' class='html-align-left' >MR</td><td align='left' valign='middle' class='html-align-left' >magnetic resonance</td></tr><tr ><td align='left' valign='middle' class='html-align-left' >mTOR</td><td align='left' valign='middle' class='html-align-left' >mammalian target of rapamycin</td></tr><tr ><td align='left' valign='middle' class='html-align-left' >mTORi</td><td align='left' valign='middle' class='html-align-left' >mammalian target of rapamycin inhibitors</td></tr><tr ><td align='left' valign='middle' class='html-align-left' >NLR</td><td align='left' valign='middle' class='html-align-left' >neutrophil to lymphocyte ratio</td></tr><tr ><td align='left' valign='middle' class='html-align-left' >OS</td><td align='left' valign='middle' class='html-align-left' >overall survival</td></tr><tr ><td align='left' valign='middle' class='html-align-left' >PNF</td><td align='left' valign='middle' class='html-align-left' >primary non-function</td></tr><tr ><td align='left' valign='middle' class='html-align-left' >RFS</td><td align='left' valign='middle' class='html-align-left' >recurrence-free survival</td></tr><tr ><td align='left' valign='middle' class='html-align-left' >RR</td><td align='left' valign='middle' class='html-align-left' >relative risk</td></tr><tr ><td align='left' valign='middle' class='html-align-left' >S</td><td align='left' valign='middle' class='html-align-left' >steroids</td></tr><tr ><td align='left' valign='middle' class='html-align-left' >SD</td><td align='left' valign='middle' class='html-align-left' >standard deviation</td></tr><tr ><td align='left' valign='middle' class='html-align-left' >SRL</td><td align='left' valign='middle' class='html-align-left' >sirolimus</td></tr><tr ><td align='left' valign='middle' class='html-align-left' >TAC</td><td align='left' valign='middle' class='html-align-left' >tacrolimus</td></tr><tr ><td align='left' valign='middle' class='html-align-left' >tBPAR</td><td align='left' valign='middle' class='html-align-left' >treated and biopsy-proven acute rejection</td></tr><tr ><td align='left' valign='middle' class='html-align-left' >X-match</td><td align='left' valign='middle' class='html-align-left' >cross-match</td></tr></tbody></table></section><section id='html-references_list'><h2>References</h2><ol class='html-xx'><li id='B1-cancers-16-01243' class='html-x' data-content='1.'>Di Maira, T.; Little, E.C.; Berenguer, M. Immunosuppression in liver transplant. <span class='html-italic'>Best Pract. Res. Clin. Gastroenterol.</span> <b>2020</b>, <span class='html-italic'>46–47</span>, 101681. [<a href="https://scholar.google.com/scholar_lookup?title=Immunosuppression+in+liver+transplant&author=Di+Maira,+T.&author=Little,+E.C.&author=Berenguer,+M.&publication_year=2020&journal=Best+Pract.+Res.+Clin.+Gastroenterol.&volume=46%E2%80%9347&pages=101681&doi=10.1016/j.bpg.2020.101681&pmid=33158467" class='google-scholar' target='_blank' rel='noopener noreferrer'>Google Scholar</a>] [<a href="https://doi.org/10.1016/j.bpg.2020.101681" class='cross-ref' target='_blank' rel='noopener noreferrer'>CrossRef</a>] [<a href="https://www.ncbi.nlm.nih.gov/pubmed/33158467" class='cross-ref' data-typ='pmid' target='_blank' rel='noopener noreferrer'>PubMed</a>]</li><li id='B2-cancers-16-01243' class='html-x' data-content='2.'>Noble, J.; Terrec, F.; Malvezzi, P.; Rostaing, L. Adverse effects of immunosuppression after liver transplantation. <span class='html-italic'>Best Pract. Res. Clin. Gastroenterol.</span> <b>2021</b>, <span class='html-italic'>54–55</span>, 101762. [<a href="https://scholar.google.com/scholar_lookup?title=Adverse+effects+of+immunosuppression+after+liver+transplantation&author=Noble,+J.&author=Terrec,+F.&author=Malvezzi,+P.&author=Rostaing,+L.&publication_year=2021&journal=Best+Pract.+Res.+Clin.+Gastroenterol.&volume=54%E2%80%9355&pages=101762&doi=10.1016/j.bpg.2021.101762&pmid=34874845" class='google-scholar' target='_blank' rel='noopener noreferrer'>Google Scholar</a>] [<a href="https://doi.org/10.1016/j.bpg.2021.101762" class='cross-ref' target='_blank' rel='noopener noreferrer'>CrossRef</a>] [<a href="https://www.ncbi.nlm.nih.gov/pubmed/34874845" class='cross-ref' data-typ='pmid' target='_blank' rel='noopener noreferrer'>PubMed</a>]</li><li id='B3-cancers-16-01243' class='html-x' data-content='3.'>De Simone, P.; Nevens, F.; De Carlis, L.; Metselaar, H.J.; Beckebaum, S.; Saliba, F.; Jonas, S.; Sudan, D.; Fung, J.; Fischer, L.; et al. Everolimus with Reduced Tacrolimus Improves Renal Function in De Novo Liver Transplant Recipients: A Randomized Controlled Trial. <span class='html-italic'>Am. J. Transplant.</span> <b>2012</b>, <span class='html-italic'>12</span>, 3008–3020. [<a href="https://scholar.google.com/scholar_lookup?title=Everolimus+with+Reduced+Tacrolimus+Improves+Renal+Function+in+De+Novo+Liver+Transplant+Recipients:+A+Randomized+Controlled+Trial&author=De+Simone,+P.&author=Nevens,+F.&author=De+Carlis,+L.&author=Metselaar,+H.J.&author=Beckebaum,+S.&author=Saliba,+F.&author=Jonas,+S.&author=Sudan,+D.&author=Fung,+J.&author=Fischer,+L.&publication_year=2012&journal=Am.+J.+Transplant.&volume=12&pages=3008%E2%80%933020&doi=10.1111/j.1600-6143.2012.04212.x&pmid=22882750" class='google-scholar' target='_blank' rel='noopener noreferrer'>Google Scholar</a>] [<a href="https://doi.org/10.1111/j.1600-6143.2012.04212.x" class='cross-ref' target='_blank' rel='noopener noreferrer'>CrossRef</a>] [<a href="https://www.ncbi.nlm.nih.gov/pubmed/22882750" class='cross-ref' data-typ='pmid' target='_blank' rel='noopener noreferrer'>PubMed</a>]</li><li id='B4-cancers-16-01243' class='html-x' data-content='4.'>Saliba, F.; De Simone, P.; Nevens, F.; De Carlis, L.; Metselaar, H.J.; Beckebaum, S.; Jonas, S.; Sudan, D.; Fischer, L.; Duvoux, C.; et al. Renal function at two years in liver transplant patients receiving everolimus: Results of a randomized, multicenter study. <span class='html-italic'>Am. J. Transplant.</span> <b>2013</b>, <span class='html-italic'>13</span>, 1734–1745. [<a href="https://scholar.google.com/scholar_lookup?title=Renal+function+at+two+years+in+liver+transplant+patients+receiving+everolimus:+Results+of+a+randomized,+multicenter+study&author=Saliba,+F.&author=De+Simone,+P.&author=Nevens,+F.&author=De+Carlis,+L.&author=Metselaar,+H.J.&author=Beckebaum,+S.&author=Jonas,+S.&author=Sudan,+D.&author=Fischer,+L.&author=Duvoux,+C.&publication_year=2013&journal=Am.+J.+Transplant.&volume=13&pages=1734%E2%80%931745&doi=10.1111/ajt.12280&pmid=23714399" class='google-scholar' target='_blank' rel='noopener noreferrer'>Google Scholar</a>] [<a href="https://doi.org/10.1111/ajt.12280" class='cross-ref' target='_blank' rel='noopener noreferrer'>CrossRef</a>] [<a href="https://www.ncbi.nlm.nih.gov/pubmed/23714399" class='cross-ref' data-typ='pmid' target='_blank' rel='noopener noreferrer'>PubMed</a>]</li><li id='B5-cancers-16-01243' class='html-x' data-content='5.'>Fischer, L.; Saliba, F.; Kaiser, G.M.; De Carlis, L.; Metselaar, H.J.; De Simone, P.; Duvoux, C.; Nevens, F.; Fung, J.J.; Dong, G.; et al. Three-year outcomes in de novo liver transplant patients receiving everolimus with reduced tacrolimus: Follow-up results from a randomized, multicenter study. <span class='html-italic'>Transplantation</span> <b>2015</b>, <span class='html-italic'>99</span>, 1455–1462. [<a href="https://scholar.google.com/scholar_lookup?title=Three-year+outcomes+in+de+novo+liver+transplant+patients+receiving+everolimus+with+reduced+tacrolimus:+Follow-up+results+from+a+randomized,+multicenter+study&author=Fischer,+L.&author=Saliba,+F.&author=Kaiser,+G.M.&author=De+Carlis,+L.&author=Metselaar,+H.J.&author=De+Simone,+P.&author=Duvoux,+C.&author=Nevens,+F.&author=Fung,+J.J.&author=Dong,+G.&publication_year=2015&journal=Transplantation&volume=99&pages=1455%E2%80%931462&doi=10.1097/TP.0000000000000555&pmid=26151607" class='google-scholar' target='_blank' rel='noopener noreferrer'>Google Scholar</a>] [<a href="https://doi.org/10.1097/TP.0000000000000555" class='cross-ref' target='_blank' rel='noopener noreferrer'>CrossRef</a>] [<a href="https://www.ncbi.nlm.nih.gov/pubmed/26151607" class='cross-ref' data-typ='pmid' target='_blank' rel='noopener noreferrer'>PubMed</a>]</li><li id='B6-cancers-16-01243' class='html-x' data-content='6.'>Levy, G.; Schmidli, H.; Punch, J.; Tuttle-Newhall, E.; Mayer, D.; Neuhaus, P.; Samuel, D.; Nashan, B.; Klempnauer, J.; Langnas, A.; et al. Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12- and 36-month results. <span class='html-italic'>Liver Transpl.</span> <b>2006</b>, <span class='html-italic'>12</span>, 1640–1648. [<a href="https://scholar.google.com/scholar_lookup?title=Safety,+tolerability,+and+efficacy+of+everolimus+in+de+novo+liver+transplant+recipients:+12-+and+36-month+results&author=Levy,+G.&author=Schmidli,+H.&author=Punch,+J.&author=Tuttle-Newhall,+E.&author=Mayer,+D.&author=Neuhaus,+P.&author=Samuel,+D.&author=Nashan,+B.&author=Klempnauer,+J.&author=Langnas,+A.&publication_year=2006&journal=Liver+Transpl.&volume=12&pages=1640%E2%80%931648&doi=10.1002/lt.20707&pmid=16598777" class='google-scholar' target='_blank' rel='noopener noreferrer'>Google Scholar</a>] [<a href="https://doi.org/10.1002/lt.20707" class='cross-ref' target='_blank' rel='noopener noreferrer'>CrossRef</a>] [<a href="https://www.ncbi.nlm.nih.gov/pubmed/16598777" class='cross-ref' data-typ='pmid' target='_blank' rel='noopener noreferrer'>PubMed</a>]</li><li id='B7-cancers-16-01243' class='html-x' data-content='7.'>Saliba, F.; Dharancy, S.; Salamé, E.; Conti, F.; Eyraud, D.; Radenne, S.; Antonini, T.; Guillaud, O.; Guguenheim, J.; Neau-Cransac, M.; et al. Time to conversion to an everolimus-based regimen: Renal outcomes in liver transplant recipients from the EVEROLIVER registry. <span class='html-italic'>Liver Transpl.</span> <b>2020</b>, <span class='html-italic'>26</span>, 1465–1476. [<a href="https://scholar.google.com/scholar_lookup?title=Time+to+conversion+to+an+everolimus-based+regimen:+Renal+outcomes+in+liver+transplant+recipients+from+the+EVEROLIVER+registry&author=Saliba,+F.&author=Dharancy,+S.&author=Salam%C3%A9,+E.&author=Conti,+F.&author=Eyraud,+D.&author=Radenne,+S.&author=Antonini,+T.&author=Guillaud,+O.&author=Guguenheim,+J.&author=Neau-Cransac,+M.&publication_year=2020&journal=Liver+Transpl.&volume=26&pages=1465%E2%80%931476&doi=10.1002/lt.25879&pmid=32869469" class='google-scholar' target='_blank' rel='noopener noreferrer'>Google Scholar</a>] [<a href="https://doi.org/10.1002/lt.25879" class='cross-ref' target='_blank' rel='noopener noreferrer'>CrossRef</a>] [<a href="https://www.ncbi.nlm.nih.gov/pubmed/32869469" class='cross-ref' data-typ='pmid' target='_blank' rel='noopener noreferrer'>PubMed</a>]</li><li id='B8-cancers-16-01243' class='html-x' data-content='8.'>De Simone, P.; Fagiuoli, S.; Cescon, M.; De Carlis, L.; Tisone, G.; Volpes, R.; Cillo, U. Use of everolimus in liver transplantation: Recommendations from a working group. <span class='html-italic'>Transplantation</span> <b>2017</b>, <span class='html-italic'>101</span>, 239–251. [<a href="https://scholar.google.com/scholar_lookup?title=Use+of+everolimus+in+liver+transplantation:+Recommendations+from+a+working+group&author=De+Simone,+P.&author=Fagiuoli,+S.&author=Cescon,+M.&author=De+Carlis,+L.&author=Tisone,+G.&author=Volpes,+R.&author=Cillo,+U.&publication_year=2017&journal=Transplantation&volume=101&pages=239%E2%80%93251&doi=10.1097/TP.0000000000001438" class='google-scholar' target='_blank' rel='noopener noreferrer'>Google Scholar</a>] [<a href="https://doi.org/10.1097/TP.0000000000001438" class='cross-ref' target='_blank' rel='noopener noreferrer'>CrossRef</a>]</li><li id='B9-cancers-16-01243' class='html-x' data-content='9.'>Lee, S.-G.; Jeng, L.-B.; Saliba, F.; Soin, A.S.; Lee, W.-C.; De Simone, P.; Nevens, F.; Suh, K.-S.; Fischer, L.; Joo, D.J.; et al. Efficacy and safety of everolimus with reduced tacrolimus in liver transplant recipients: 24-month results from the pooled analysis of 2 randomized controlled trials. <span class='html-italic'>Transplantation</span> <b>2021</b>, <span class='html-italic'>105</span>, 1564–1575. [<a href="https://scholar.google.com/scholar_lookup?title=Efficacy+and+safety+of+everolimus+with+reduced+tacrolimus+in+liver+transplant+recipients:+24-month+results+from+the+pooled+analysis+of+2+randomized+controlled+trials&author=Lee,+S.-G.&author=Jeng,+L.-B.&author=Saliba,+F.&author=Soin,+A.S.&author=Lee,+W.-C.&author=De+Simone,+P.&author=Nevens,+F.&author=Suh,+K.-S.&author=Fischer,+L.&author=Joo,+D.J.&publication_year=2021&journal=Transplantation&volume=105&pages=1564%E2%80%931575&doi=10.1097/TP.0000000000003394" class='google-scholar' target='_blank' rel='noopener noreferrer'>Google Scholar</a>] [<a href="https://doi.org/10.1097/TP.0000000000003394" class='cross-ref' target='_blank' rel='noopener noreferrer'>CrossRef</a>]</li><li id='B10-cancers-16-01243' class='html-xx' data-content='10.'>Lin, M.; Mittal, S.; Sahebjam, F.; Rana, A.; Sood, G.K. Everolimus with early withdrawal or reduced dose calcineurin inhibitors improves renal function in liver transplant recipients: A systematic review and meta-analysis. <span class='html-italic'>Clin. Transplant.</span> <b>2017</b>, <span class='html-italic'>31</span>, e12872. [<a href="https://scholar.google.com/scholar_lookup?title=Everolimus+with+early+withdrawal+or+reduced+dose+calcineurin+inhibitors+improves+renal+function+in+liver+transplant+recipients:+A+systematic+review+and+meta-analysis&author=Lin,+M.&author=Mittal,+S.&author=Sahebjam,+F.&author=Rana,+A.&author=Sood,+G.K.&publication_year=2017&journal=Clin.+Transplant.&volume=31&pages=e12872&doi=10.1111/ctr.12872" class='google-scholar' target='_blank' rel='noopener noreferrer'>Google Scholar</a>] [<a href="https://doi.org/10.1111/ctr.12872" class='cross-ref' target='_blank' rel='noopener noreferrer'>CrossRef</a>]</li><li id='B11-cancers-16-01243' class='html-xx' data-content='11.'>Guan, T.W.; Lin, Y.J.; Ou, M.Y.; Chen, K.B. Efficacy and safety of everolimus treatment on liver transplant recipients: A meta-analysis. <span class='html-italic'>Eur. J. Clin. Investig.</span> <b>2019</b>, <span class='html-italic'>49</span>, e13179. [<a href="https://scholar.google.com/scholar_lookup?title=Efficacy+and+safety+of+everolimus+treatment+on+liver+transplant+recipients:+A+meta-analysis&author=Guan,+T.W.&author=Lin,+Y.J.&author=Ou,+M.Y.&author=Chen,+K.B.&publication_year=2019&journal=Eur.+J.+Clin.+Investig.&volume=49&pages=e13179&doi=10.1111/eci.13179" class='google-scholar' target='_blank' rel='noopener noreferrer'>Google Scholar</a>] [<a href="https://doi.org/10.1111/eci.13179" class='cross-ref' target='_blank' rel='noopener noreferrer'>CrossRef</a>]</li><li id='B12-cancers-16-01243' class='html-xx' data-content='12.'>Yan, X.; Huang, S.; Yang, Y.; Lu, Z.; Li, F.; Jiang, L.; Jiang, Y.; Liu, J. Sirolimus or everolimus improves survival after liver transplantation for hepatocellular carcinoma: A systematic review and meta-analysis. <span class='html-italic'>Liver Transpl.</span> <b>2022</b>, <span class='html-italic'>28</span>, 1063–1077. [<a href="https://scholar.google.com/scholar_lookup?title=Sirolimus+or+everolimus+improves+survival+after+liver+transplantation+for+hepatocellular+carcinoma:+A+systematic+review+and+meta-analysis&author=Yan,+X.&author=Huang,+S.&author=Yang,+Y.&author=Lu,+Z.&author=Li,+F.&author=Jiang,+L.&author=Jiang,+Y.&author=Liu,+J.&publication_year=2022&journal=Liver+Transpl.&volume=28&pages=1063%E2%80%931077&doi=10.1002/lt.26387&pmid=34919773" class='google-scholar' target='_blank' rel='noopener noreferrer'>Google Scholar</a>] [<a href="https://doi.org/10.1002/lt.26387" class='cross-ref' target='_blank' rel='noopener noreferrer'>CrossRef</a>] [<a href="https://www.ncbi.nlm.nih.gov/pubmed/34919773" class='cross-ref' data-typ='pmid' target='_blank' rel='noopener noreferrer'>PubMed</a>]</li><li id='B13-cancers-16-01243' class='html-xx' data-content='13.'>Ormonde, D.G.; de Boer, W.B.; Kierath, A.; Bell, R.; Shilkin, K.B.; House, A.K.; Jeffrey, G.P.; Reed, W.D. Banff schema for grading liver allograft rejection: An international consensus document. <span class='html-italic'>Hepatology</span> <b>1997</b>, <span class='html-italic'>25</span>, 658–663. [<a href="https://scholar.google.com/scholar_lookup?title=Banff+schema+for+grading+liver+allograft+rejection:+An+international+consensus+document&author=Ormonde,+D.G.&author=de+Boer,+W.B.&author=Kierath,+A.&author=Bell,+R.&author=Shilkin,+K.B.&author=House,+A.K.&author=Jeffrey,+G.P.&author=Reed,+W.D.&publication_year=1997&journal=Hepatology&volume=25&pages=658%E2%80%93663" class='google-scholar' target='_blank' rel='noopener noreferrer'>Google Scholar</a>]</li><li id='B14-cancers-16-01243' class='html-xx' data-content='14.'>European Association for the Study of the Liver; European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: Management of hepatocellular carcinoma. <span class='html-italic'>J. Hepatol.</span> <b>2012</b>, <span class='html-italic'>56</span>, 908–943. [<a href="https://scholar.google.com/scholar_lookup?title=EASL-EORTC+clinical+practice+guidelines:+Management+of+hepatocellular+carcinoma&author=European+Association+for+the+Study+of+the+Liver&author=European+Organisation+for+Research+and+Treatment+of+Cancer&publication_year=2012&journal=J.+Hepatol.&volume=56&pages=908%E2%80%93943&doi=10.1016/j.jhep.2011.12.001" class='google-scholar' target='_blank' rel='noopener noreferrer'>Google Scholar</a>] [<a href="https://doi.org/10.1016/j.jhep.2011.12.001" class='cross-ref' target='_blank' rel='noopener noreferrer'>CrossRef</a>]</li><li id='B15-cancers-16-01243' class='html-xx' data-content='15.'>Reig, M.; Forner, A.; Rimola, J.; Ferrer-Fàbrega, J.; Burrel, M.; Garcia-Criado, Á.; Kelley, R.K.; Galle, P.R.; Mazzaferro, V.; Salem, R.; et al. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. <span class='html-italic'>J. Hepatol.</span> <b>2022</b>, <span class='html-italic'>76</span>, 681–693. [<a href="https://scholar.google.com/scholar_lookup?title=BCLC+strategy+for+prognosis+prediction+and+treatment+recommendation:+The+2022+update&author=Reig,+M.&author=Forner,+A.&author=Rimola,+J.&author=Ferrer-F%C3%A0brega,+J.&author=Burrel,+M.&author=Garcia-Criado,+%C3%81.&author=Kelley,+R.K.&author=Galle,+P.R.&author=Mazzaferro,+V.&author=Salem,+R.&publication_year=2022&journal=J.+Hepatol.&volume=76&pages=681%E2%80%93693&doi=10.1016/j.jhep.2021.11.018&pmid=34801630" class='google-scholar' target='_blank' rel='noopener noreferrer'>Google Scholar</a>] [<a href="https://doi.org/10.1016/j.jhep.2021.11.018" class='cross-ref' target='_blank' rel='noopener noreferrer'>CrossRef</a>] [<a href="https://www.ncbi.nlm.nih.gov/pubmed/34801630" class='cross-ref' data-typ='pmid' target='_blank' rel='noopener noreferrer'>PubMed</a>]</li><li id='B16-cancers-16-01243' class='html-xx' data-content='16.'>Olthoff, K.M.; Kulik, L.; Samstein, B.; Kaminski, M.; Abecassis, M.; Emond, J.; Shaked, A.; Christie, J.D. Validation of a current definition of early allograft dysfunction in liver transplant recipients and analysis of risk factors. <span class='html-italic'>Liver Transpl.</span> <b>2010</b>, <span class='html-italic'>16</span>, 943–949. [<a href="https://scholar.google.com/scholar_lookup?title=Validation+of+a+current+definition+of+early+allograft+dysfunction+in+liver+transplant+recipients+and+analysis+of+risk+factors&author=Olthoff,+K.M.&author=Kulik,+L.&author=Samstein,+B.&author=Kaminski,+M.&author=Abecassis,+M.&author=Emond,+J.&author=Shaked,+A.&author=Christie,+J.D.&publication_year=2010&journal=Liver+Transpl.&volume=16&pages=943%E2%80%93949&doi=10.1002/lt.22091&pmid=20677285" class='google-scholar' target='_blank' rel='noopener noreferrer'>Google Scholar</a>] [<a href="https://doi.org/10.1002/lt.22091" class='cross-ref' target='_blank' rel='noopener noreferrer'>CrossRef</a>] [<a href="https://www.ncbi.nlm.nih.gov/pubmed/20677285" class='cross-ref' data-typ='pmid' target='_blank' rel='noopener noreferrer'>PubMed</a>]</li><li id='B17-cancers-16-01243' class='html-xx' data-content='17.'>KDIGO Group. KDIGO Clinical Practice Guideline for Acute Kidney Injury. <span class='html-italic'>Kidney Int. Suppl.</span> <b>2012</b>, <span class='html-italic'>2</span>, 1–141. [<a href="https://scholar.google.com/scholar_lookup?title=KDIGO+Clinical+Practice+Guideline+for+Acute+Kidney+Injury&author=KDIGO+Group&publication_year=2012&journal=Kidney+Int.+Suppl.&volume=2&pages=1%E2%80%93141" class='google-scholar' target='_blank' rel='noopener noreferrer'>Google Scholar</a>]</li><li id='B18-cancers-16-01243' class='html-xx' data-content='18.'>Tonon, M.; Rosi, S.; Gambino, C.G.; Piano, S.; Calvino, V.; Romano, A.; Martini, A.; Pontisso, P.; Angeli, P. Natural history of acute kidney disease in patients with cirrhosis. <span class='html-italic'>J. Hepatol.</span> <b>2021</b>, <span class='html-italic'>74</span>, 578–583. [<a href="https://scholar.google.com/scholar_lookup?title=Natural+history+of+acute+kidney+disease+in+patients+with+cirrhosis&author=Tonon,+M.&author=Rosi,+S.&author=Gambino,+C.G.&author=Piano,+S.&author=Calvino,+V.&author=Romano,+A.&author=Martini,+A.&author=Pontisso,+P.&author=Angeli,+P.&publication_year=2021&journal=J.+Hepatol.&volume=74&pages=578%E2%80%93583&doi=10.1016/j.jhep.2020.08.037" class='google-scholar' target='_blank' rel='noopener noreferrer'>Google Scholar</a>] [<a href="https://doi.org/10.1016/j.jhep.2020.08.037" class='cross-ref' target='_blank' rel='noopener noreferrer'>CrossRef</a>]</li><li id='B19-cancers-16-01243' class='html-xx' data-content='19.'>Diabetes Standards of Care: ADA Guidelines. 2018. Available online: <a href='http://diabetesed.net/wp-content/uploads/2017/12/2018-ADA-Standards-of-Care.pdf' target='_blank' rel="noopener noreferrer" >http://diabetesed.net/wp-content/uploads/2017/12/2018-ADA-Standards-of-Care.pdf</a> (accessed on 1 September 2023).</li><li id='B20-cancers-16-01243' class='html-xx' data-content='20.'>Tejada, S.; Martinez-Reviejo, R.; Nogueira, T.A.; Gómez, A.; Pont, T.; Liao, X.; Zhang, Z.; Manuel, O.; Rello, J. The effect of sex inequality on solid organ transplantation: A systematic review and meta-analysis. <span class='html-italic'>Eur. J. Int. Med.</span> <b>2023</b>, <span class='html-italic'>109</span>, 58–67. [<a href="https://scholar.google.com/scholar_lookup?title=The+effect+of+sex+inequality+on+solid+organ+transplantation:+A+systematic+review+and+meta-analysis&author=Tejada,+S.&author=Martinez-Reviejo,+R.&author=Nogueira,+T.A.&author=G%C3%B3mez,+A.&author=Pont,+T.&author=Liao,+X.&author=Zhang,+Z.&author=Manuel,+O.&author=Rello,+J.&publication_year=2023&journal=Eur.+J.+Int.+Med.&volume=109&pages=58%E2%80%9367&doi=10.1016/j.ejim.2022.12.009" class='google-scholar' target='_blank' rel='noopener noreferrer'>Google Scholar</a>] [<a href="https://doi.org/10.1016/j.ejim.2022.12.009" class='cross-ref' target='_blank' rel='noopener noreferrer'>CrossRef</a>]</li><li id='B21-cancers-16-01243' class='html-xx' data-content='21.'>Gil, E.; Kim, J.M.; Jeon, K.; Park, H.; Kang, D.; Cho, J.; Suh, G.Y.; Park, H. Recipient age and mortality after liver transplantation: A population-based cohort study. <span class='html-italic'>Transplantation</span> <b>2018</b>, <span class='html-italic'>102</span>, 2025–2032. [<a href="https://scholar.google.com/scholar_lookup?title=Recipient+age+and+mortality+after+liver+transplantation:+A+population-based+cohort+study&author=Gil,+E.&author=Kim,+J.M.&author=Jeon,+K.&author=Park,+H.&author=Kang,+D.&author=Cho,+J.&author=Suh,+G.Y.&author=Park,+H.&publication_year=2018&journal=Transplantation&volume=102&pages=2025%E2%80%932032&doi=10.1097/TP.0000000000002246" class='google-scholar' target='_blank' rel='noopener noreferrer'>Google Scholar</a>] [<a href="https://doi.org/10.1097/TP.0000000000002246" class='cross-ref' target='_blank' rel='noopener noreferrer'>CrossRef</a>]</li><li id='B22-cancers-16-01243' class='html-xx' data-content='22.'>Bhamidimarri, K.R.; Satapathy, S.K.; Martin, P. Hepatitis C virus and liver transplantation. <span class='html-italic'>Gastroenterol. Hepatol.</span> <b>2017</b>, <span class='html-italic'>13</span>, 214–220. [<a href="https://scholar.google.com/scholar_lookup?title=Hepatitis+C+virus+and+liver+transplantation&author=Bhamidimarri,+K.R.&author=Satapathy,+S.K.&author=Martin,+P.&publication_year=2017&journal=Gastroenterol.+Hepatol.&volume=13&pages=214%E2%80%93220" class='google-scholar' target='_blank' rel='noopener noreferrer'>Google Scholar</a>]</li><li id='B23-cancers-16-01243' class='html-xx' data-content='23.'>Brodosi, L.; Petta, S.; Petroni, M.L.; Marchesini, G.; Morelli, M.C. Management of diabetes in candidates for liver transplantation and in transplant recipients. <span class='html-italic'>Transplantation</span> <b>2022</b>, <span class='html-italic'>106</span>, 462–478. [<a href="https://scholar.google.com/scholar_lookup?title=Management+of+diabetes+in+candidates+for+liver+transplantation+and+in+transplant+recipients&author=Brodosi,+L.&author=Petta,+S.&author=Petroni,+M.L.&author=Marchesini,+G.&author=Morelli,+M.C.&publication_year=2022&journal=Transplantation&volume=106&pages=462%E2%80%93478&doi=10.1097/TP.0000000000003867" class='google-scholar' target='_blank' rel='noopener noreferrer'>Google Scholar</a>] [<a href="https://doi.org/10.1097/TP.0000000000003867" class='cross-ref' target='_blank' rel='noopener noreferrer'>CrossRef</a>]</li><li id='B24-cancers-16-01243' class='html-xx' data-content='24.'>Cullaro, G.; Verna, E.C.; Lee, B.P.; Lai, J.C. Chronic Kidney Disease in Liver Transplant Candidates: A rising burden impacting post-liver transplant outcomes. <span class='html-italic'>Liver Transpl.</span> <b>2020</b>, <span class='html-italic'>26</span>, 498–506. [<a href="https://scholar.google.com/scholar_lookup?title=Chronic+Kidney+Disease+in+Liver+Transplant+Candidates:+A+rising+burden+impacting+post-liver+transplant+outcomes&author=Cullaro,+G.&author=Verna,+E.C.&author=Lee,+B.P.&author=Lai,+J.C.&publication_year=2020&journal=Liver+Transpl.&volume=26&pages=498%E2%80%93506&doi=10.1002/lt.25694&pmid=31785069" class='google-scholar' target='_blank' rel='noopener noreferrer'>Google Scholar</a>] [<a href="https://doi.org/10.1002/lt.25694" class='cross-ref' target='_blank' rel='noopener noreferrer'>CrossRef</a>] [<a href="https://www.ncbi.nlm.nih.gov/pubmed/31785069" class='cross-ref' data-typ='pmid' target='_blank' rel='noopener noreferrer'>PubMed</a>]</li><li id='B25-cancers-16-01243' class='html-xx' data-content='25.'>Avolio, A.W.; Franco, A.; Schlegel, A.; Lai, Q.; Meli, S.; Burra, P.; Patrono, D.; Ravaioli, M.; Bassi, D.; Ferla, F.; et al. Development and validation of a comprehensive model to estimate early allograft failure among patients requiring early liver retransplant. <span class='html-italic'>JAMA Surg.</span> <b>2020</b>, <span class='html-italic'>155</span>, e204095. [<a href="https://scholar.google.com/scholar_lookup?title=Development+and+validation+of+a+comprehensive+model+to+estimate+early+allograft+failure+among+patients+requiring+early+liver+retransplant&author=Avolio,+A.W.&author=Franco,+A.&author=Schlegel,+A.&author=Lai,+Q.&author=Meli,+S.&author=Burra,+P.&author=Patrono,+D.&author=Ravaioli,+M.&author=Bassi,+D.&author=Ferla,+F.&publication_year=2020&journal=JAMA+Surg.&volume=155&pages=e204095&doi=10.1001/jamasurg.2020.4095&pmid=33112390" class='google-scholar' target='_blank' rel='noopener noreferrer'>Google Scholar</a>] [<a href="https://doi.org/10.1001/jamasurg.2020.4095" class='cross-ref' target='_blank' rel='noopener noreferrer'>CrossRef</a>] [<a href="https://www.ncbi.nlm.nih.gov/pubmed/33112390" class='cross-ref' data-typ='pmid' target='_blank' rel='noopener noreferrer'>PubMed</a>]</li><li id='B26-cancers-16-01243' class='html-xx' data-content='26.'>Sarkar, M.; Watt, K.D.; Terrault, N.; Berenguer, M. Outcomes in liver transplantation: Does sex matter? <span class='html-italic'>J. Hepatol.</span> <b>2015</b>, <span class='html-italic'>62</span>, 946–955. [<a href="https://scholar.google.com/scholar_lookup?title=Outcomes+in+liver+transplantation:+Does+sex+matter?&author=Sarkar,+M.&author=Watt,+K.D.&author=Terrault,+N.&author=Berenguer,+M.&publication_year=2015&journal=J.+Hepatol.&volume=62&pages=946%E2%80%93955&doi=10.1016/j.jhep.2014.11.023" class='google-scholar' target='_blank' rel='noopener noreferrer'>Google Scholar</a>] [<a href="https://doi.org/10.1016/j.jhep.2014.11.023" class='cross-ref' target='_blank' rel='noopener noreferrer'>CrossRef</a>]</li><li id='B27-cancers-16-01243' class='html-xx' data-content='27.'>Kanneganti, M.; Olthoff, K.M.; Bittermann, T. Impact of older donor age on recipient and graft survival after LDLT: The US Experience. <span class='html-italic'>Transplantation</span> <b>2023</b>, <span class='html-italic'>107</span>, 162–171. [<a href="https://scholar.google.com/scholar_lookup?title=Impact+of+older+donor+age+on+recipient+and+graft+survival+after+LDLT:+The+US+Experience&author=Kanneganti,+M.&author=Olthoff,+K.M.&author=Bittermann,+T.&publication_year=2023&journal=Transplantation&volume=107&pages=162%E2%80%93171&doi=10.1097/TP.0000000000004289" class='google-scholar' target='_blank' rel='noopener noreferrer'>Google Scholar</a>] [<a href="https://doi.org/10.1097/TP.0000000000004289" class='cross-ref' target='_blank' rel='noopener noreferrer'>CrossRef</a>]</li><li id='B28-cancers-16-01243' class='html-xx' data-content='28.'>Singhal, A.K.; Sheng, X.; Drakos, S.G.; Stehlik, J. Impact of donor cause of death on transplant outcomes: UNOS registry analysis. <span class='html-italic'>Transplant. Proc.</span> <b>2009</b>, <span class='html-italic'>41</span>, 3539–3544. [<a href="https://scholar.google.com/scholar_lookup?title=Impact+of+donor+cause+of+death+on+transplant+outcomes:+UNOS+registry+analysis&author=Singhal,+A.K.&author=Sheng,+X.&author=Drakos,+S.G.&author=Stehlik,+J.&publication_year=2009&journal=Transplant.+Proc.&volume=41&pages=3539%E2%80%933544&doi=10.1016/j.transproceed.2009.06.192" class='google-scholar' target='_blank' rel='noopener noreferrer'>Google Scholar</a>] [<a href="https://doi.org/10.1016/j.transproceed.2009.06.192" class='cross-ref' target='_blank' rel='noopener noreferrer'>CrossRef</a>]</li><li id='B29-cancers-16-01243' class='html-xx' data-content='29.'>Tingle, S.J.; Dobbins, J.J.; Thompson, E.R.; Figueiredo, R.S.; Mahendran, B.; Pandanaboyana, S.; Wilson, C. Machine perfusion in liver transplantation. <span class='html-italic'>Cochrane Database Syst. Rev.</span> <b>2023</b>, <span class='html-italic'>2023</span>, CD014685. [<a href="https://scholar.google.com/scholar_lookup?title=Machine+perfusion+in+liver+transplantation&author=Tingle,+S.J.&author=Dobbins,+J.J.&author=Thompson,+E.R.&author=Figueiredo,+R.S.&author=Mahendran,+B.&author=Pandanaboyana,+S.&author=Wilson,+C.&publication_year=2023&journal=Cochrane+Database+Syst.+Rev.&volume=2023&pages=CD014685&doi=10.1002/14651858.CD014685.pub2" class='google-scholar' target='_blank' rel='noopener noreferrer'>Google Scholar</a>] [<a href="https://doi.org/10.1002/14651858.CD014685.pub2" class='cross-ref' target='_blank' rel='noopener noreferrer'>CrossRef</a>]</li><li id='B30-cancers-16-01243' class='html-xx' data-content='30.'>Figiel, W.; Smoter, P.; Krasnodębski, M.; Rykowski, P.; Morawski, M.; Grąt, M.; Patkowski, W.; Zieniewicz, K. Predictors of long-term outcomes after liver transplantation depending on the length of cold ischemia time. <span class='html-italic'>Transpl. Proc.</span> <b>2022</b>, <span class='html-italic'>54</span>, 1025–1028. [<a href="https://scholar.google.com/scholar_lookup?title=Predictors+of+long-term+outcomes+after+liver+transplantation+depending+on+the+length+of+cold+ischemia+time&author=Figiel,+W.&author=Smoter,+P.&author=Krasnod%C4%99bski,+M.&author=Rykowski,+P.&author=Morawski,+M.&author=Gr%C4%85t,+M.&author=Patkowski,+W.&author=Zieniewicz,+K.&publication_year=2022&journal=Transpl.+Proc.&volume=54&pages=1025%E2%80%931028&doi=10.1016/j.transproceed.2022.03.009" class='google-scholar' target='_blank' rel='noopener noreferrer'>Google Scholar</a>] [<a href="https://doi.org/10.1016/j.transproceed.2022.03.009" class='cross-ref' target='_blank' rel='noopener noreferrer'>CrossRef</a>]</li><li id='B31-cancers-16-01243' class='html-xx' data-content='31.'>Lingiah, V.A.; Niazi, M.; Olivo, R.; Paterno, F.; Guarrera, J.V.; Pyrsopoulos, N.T. Liver transplantation beyond Milan criteria. <span class='html-italic'>J. Clin. Transl. Hepatol.</span> <b>2020</b>, <span class='html-italic'>8</span>, 69–75. [<a href="https://scholar.google.com/scholar_lookup?title=Liver+transplantation+beyond+Milan+criteria&author=Lingiah,+V.A.&author=Niazi,+M.&author=Olivo,+R.&author=Paterno,+F.&author=Guarrera,+J.V.&author=Pyrsopoulos,+N.T.&publication_year=2020&journal=J.+Clin.+Transl.+Hepatol.&volume=8&pages=69%E2%80%9375&doi=10.14218/JCTH.2019.00050" class='google-scholar' target='_blank' rel='noopener noreferrer'>Google Scholar</a>] [<a href="https://doi.org/10.14218/JCTH.2019.00050" class='cross-ref' target='_blank' rel='noopener noreferrer'>CrossRef</a>]</li><li id='B32-cancers-16-01243' class='html-xx' data-content='32.'>Duvoux, C.; Roudot–Thoraval, F.; Decaens, T.; Pessione, F.; Badran, H.; Piardi, T.; Francoz, C.; Compagnon, P.; Vanlemmens, C.; Dumortier, J.; et al. Liver transplantation for hepatocellular carcinoma: A model including α-fetoprotein improves the performance of Milan criteria. <span class='html-italic'>Gastroenterology</span> <b>2012</b>, <span class='html-italic'>143</span>, 986–994. [<a href="https://scholar.google.com/scholar_lookup?title=Liver+transplantation+for+hepatocellular+carcinoma:+A+model+including+%CE%B1-fetoprotein+improves+the+performance+of+Milan+criteria&author=Duvoux,+C.&author=Roudot%E2%80%93Thoraval,+F.&author=Decaens,+T.&author=Pessione,+F.&author=Badran,+H.&author=Piardi,+T.&author=Francoz,+C.&author=Compagnon,+P.&author=Vanlemmens,+C.&author=Dumortier,+J.&publication_year=2012&journal=Gastroenterology&volume=143&pages=986%E2%80%93994&doi=10.1053/j.gastro.2012.05.052" class='google-scholar' target='_blank' rel='noopener noreferrer'>Google Scholar</a>] [<a href="https://doi.org/10.1053/j.gastro.2012.05.052" class='cross-ref' target='_blank' rel='noopener noreferrer'>CrossRef</a>]</li><li id='B33-cancers-16-01243' class='html-xx' data-content='33.'>Mehta, N.; Guy, J.; Frenette, C.T.; Dodge, J.L.; Osorio, R.W.; Minteer, W.B.; Roberts, J.P.; Yao, F.Y. Excellent outcomes of liver transplantation following down-staging of hepatocellular carcinoma to within Milan criteria: A multicenter study. <span class='html-italic'>Clin. Gastroenterol. Hepatol.</span> <b>2018</b>, <span class='html-italic'>16</span>, 955–964. [<a href="https://scholar.google.com/scholar_lookup?title=Excellent+outcomes+of+liver+transplantation+following+down-staging+of+hepatocellular+carcinoma+to+within+Milan+criteria:+A+multicenter+study&author=Mehta,+N.&author=Guy,+J.&author=Frenette,+C.T.&author=Dodge,+J.L.&author=Osorio,+R.W.&author=Minteer,+W.B.&author=Roberts,+J.P.&author=Yao,+F.Y.&publication_year=2018&journal=Clin.+Gastroenterol.+Hepatol.&volume=16&pages=955%E2%80%93964&doi=10.1016/j.cgh.2017.11.037" class='google-scholar' target='_blank' rel='noopener noreferrer'>Google Scholar</a>] [<a href="https://doi.org/10.1016/j.cgh.2017.11.037" class='cross-ref' target='_blank' rel='noopener noreferrer'>CrossRef</a>]</li><li id='B34-cancers-16-01243' class='html-xx' data-content='34.'>Jonas, S.; Bechstein, W.O.; Steinmueller, T.; Hermann, M.; Radke, C.; Berg, T.; Settmacher, U.; Neuhaus, P. Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. <span class='html-italic'>Hepatology</span> <b>2001</b>, <span class='html-italic'>33</span>, 1080–1086. [<a href="https://scholar.google.com/scholar_lookup?title=Vascular+invasion+and+histopathologic+grading+determine+outcome+after+liver+transplantation+for+hepatocellular+carcinoma+in+cirrhosis&author=Jonas,+S.&author=Bechstein,+W.O.&author=Steinmueller,+T.&author=Hermann,+M.&author=Radke,+C.&author=Berg,+T.&author=Settmacher,+U.&author=Neuhaus,+P.&publication_year=2001&journal=Hepatology&volume=33&pages=1080%E2%80%931086&doi=10.1053/jhep.2001.23561" class='google-scholar' target='_blank' rel='noopener noreferrer'>Google Scholar</a>] [<a href="https://doi.org/10.1053/jhep.2001.23561" class='cross-ref' target='_blank' rel='noopener noreferrer'>CrossRef</a>]</li><li id='B35-cancers-16-01243' class='html-xx' data-content='35.'>Rodríguez-Perálvarez, M.; Tsochatzis, E.; Naveas, M.C.; Pieri, G.; García-Caparrós, C.; O’beirne, J.; Poyato-González, A.; Ferrín-Sánchez, G.; Montero-Álvarez, J.L.; Patch, D.; et al. Reduced exposure to calcineurin inhibitors early after liver transplantation prevents recurrence of hepatocellular carcinoma. <span class='html-italic'>J. Hepatol.</span> <b>2013</b>, <span class='html-italic'>59</span>, 1193–1199. [<a href="https://scholar.google.com/scholar_lookup?title=Reduced+exposure+to+calcineurin+inhibitors+early+after+liver+transplantation+prevents+recurrence+of+hepatocellular+carcinoma&author=Rodr%C3%ADguez-Per%C3%A1lvarez,+M.&author=Tsochatzis,+E.&author=Naveas,+M.C.&author=Pieri,+G.&author=Garc%C3%ADa-Caparr%C3%B3s,+C.&author=O%E2%80%99beirne,+J.&author=Poyato-Gonz%C3%A1lez,+A.&author=Ferr%C3%ADn-S%C3%A1nchez,+G.&author=Montero-%C3%81lvarez,+J.L.&author=Patch,+D.&publication_year=2013&journal=J.+Hepatol.&volume=59&pages=1193%E2%80%931199&doi=10.1016/j.jhep.2013.07.012" class='google-scholar' target='_blank' rel='noopener noreferrer'>Google Scholar</a>] [<a href="https://doi.org/10.1016/j.jhep.2013.07.012" class='cross-ref' target='_blank' rel='noopener noreferrer'>CrossRef</a>]</li><li id='B36-cancers-16-01243' class='html-xx' data-content='36.'>Aloun, A.; Abu-Zeid, E.E.D.; Garzali, I.U. Does mTORi based immunosuppression offer survival advantage after liver transplantation for hepatocellular carcinoma? Systematic review and meta-analysis of randomized controlled trials. <span class='html-italic'>Hepatol. Forum</span> <b>2023</b>, <span class='html-italic'>4</span>, 82–88. [<a href="https://scholar.google.com/scholar_lookup?title=Does+mTORi+based+immunosuppression+offer+survival+advantage+after+liver+transplantation+for+hepatocellular+carcinoma?+Systematic+review+and+meta-analysis+of+randomized+controlled+trials&author=Aloun,+A.&author=Abu-Zeid,+E.E.D.&author=Garzali,+I.U.&publication_year=2023&journal=Hepatol.+Forum&volume=4&pages=82%E2%80%9388&pmid=37250931" class='google-scholar' target='_blank' rel='noopener noreferrer'>Google Scholar</a>] [<a href="https://www.ncbi.nlm.nih.gov/pubmed/37250931" class='cross-ref' data-typ='pmid' target='_blank' rel='noopener noreferrer'>PubMed</a>]</li><li id='B37-cancers-16-01243' class='html-xx' data-content='37.'>Zhang, G.; Duan, B.; Li, G. mTORi-based immunosuppression reduces HCC recurrence at the expenses of increased adverse side effects: A systematic review and meta-analysis. <span class='html-italic'>Clin. Transplant.</span> <b>2022</b>, <span class='html-italic'>36</span>, e14823. [<a href="https://scholar.google.com/scholar_lookup?title=mTORi-based+immunosuppression+reduces+HCC+recurrence+at+the+expenses+of+increased+adverse+side+effects:+A+systematic+review+and+meta-analysis&author=Zhang,+G.&author=Duan,+B.&author=Li,+G.&publication_year=2022&journal=Clin.+Transplant.&volume=36&pages=e14823&doi=10.1111/ctr.14823&pmid=36124430" class='google-scholar' target='_blank' rel='noopener noreferrer'>Google Scholar</a>] [<a href="https://doi.org/10.1111/ctr.14823" class='cross-ref' target='_blank' rel='noopener noreferrer'>CrossRef</a>] [<a href="https://www.ncbi.nlm.nih.gov/pubmed/36124430" class='cross-ref' data-typ='pmid' target='_blank' rel='noopener noreferrer'>PubMed</a>]</li><li id='B38-cancers-16-01243' class='html-xx' data-content='38.'>Grigg, S.E.; Sarri, G.L.; Gow, P.J.; Yeomans, N.D. Systematic review with meta-analysis: Sirolimus- or everolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma. <span class='html-italic'>Aliment. Pharmacol. Ther.</span> <b>2019</b>, <span class='html-italic'>49</span>, 1260–1273. [<a href="https://scholar.google.com/scholar_lookup?title=Systematic+review+with+meta-analysis:+Sirolimus-+or+everolimus-based+immunosuppression+following+liver+transplantation+for+hepatocellular+carcinoma&author=Grigg,+S.E.&author=Sarri,+G.L.&author=Gow,+P.J.&author=Yeomans,+N.D.&publication_year=2019&journal=Aliment.+Pharmacol.+Ther.&volume=49&pages=1260%E2%80%931273&doi=10.1111/apt.15253&pmid=30989721" class='google-scholar' target='_blank' rel='noopener noreferrer'>Google Scholar</a>] [<a href="https://doi.org/10.1111/apt.15253" class='cross-ref' target='_blank' rel='noopener noreferrer'>CrossRef</a>] [<a href="https://www.ncbi.nlm.nih.gov/pubmed/30989721" class='cross-ref' data-typ='pmid' target='_blank' rel='noopener noreferrer'>PubMed</a>]</li><li id='B39-cancers-16-01243' class='html-xx' data-content='39.'>Tarantino, G.; Magistri, P.; Ballarin, R.; Di Francia, R.; Berretta, M.; Di Benedetto, F. Oncological impact of mTOR inhibitor immunosuppressive therapy after liver transplantation for hepatocellular carcinoma: Review of the literature. <span class='html-italic'>Front. Pharmacol.</span> <b>2016</b>, <span class='html-italic'>7</span>, 387. [<a href="https://scholar.google.com/scholar_lookup?title=Oncological+impact+of+mTOR+inhibitor+immunosuppressive+therapy+after+liver+transplantation+for+hepatocellular+carcinoma:+Review+of+the+literature&author=Tarantino,+G.&author=Magistri,+P.&author=Ballarin,+R.&author=Di+Francia,+R.&author=Berretta,+M.&author=Di+Benedetto,+F.&publication_year=2016&journal=Front.+Pharmacol.&volume=7&pages=387&doi=10.3389/fphar.2016.00387&pmid=27818634" class='google-scholar' target='_blank' rel='noopener noreferrer'>Google Scholar</a>] [<a href="https://doi.org/10.3389/fphar.2016.00387" class='cross-ref' target='_blank' rel='noopener noreferrer'>CrossRef</a>] [<a href="https://www.ncbi.nlm.nih.gov/pubmed/27818634" class='cross-ref' data-typ='pmid' target='_blank' rel='noopener noreferrer'>PubMed</a>]</li><li id='B40-cancers-16-01243' class='html-xx' data-content='40.'>Holdaas, H.; De Simone, P.; Zuckermann, A. Everolimus and malignancy after solid organ transplantation: A clinical update. <span class='html-italic'>J. Transplant.</span> <b>2016</b>, <span class='html-italic'>2016</span>, 4369574. [<a href="https://scholar.google.com/scholar_lookup?title=Everolimus+and+malignancy+after+solid+organ+transplantation:+A+clinical+update&author=Holdaas,+H.&author=De+Simone,+P.&author=Zuckermann,+A.&publication_year=2016&journal=J.+Transplant.&volume=2016&pages=4369574&doi=10.1155/2016/4369574&pmid=27807479" class='google-scholar' target='_blank' rel='noopener noreferrer'>Google Scholar</a>] [<a href="https://doi.org/10.1155/2016/4369574" class='cross-ref' target='_blank' rel='noopener noreferrer'>CrossRef</a>] [<a href="https://www.ncbi.nlm.nih.gov/pubmed/27807479" class='cross-ref' data-typ='pmid' target='_blank' rel='noopener noreferrer'>PubMed</a>]</li><li id='B41-cancers-16-01243' class='html-xx' data-content='41.'>Geissler, E.K.; Schnitzbauer, A.A.; Zülke, C.; Lamby, P.E.; Proneth, A.; Duvoux, C.; Burra, P.; Jauch, K.W.; Rentsch, M.; Ganten, T.M.; et al. Sirolimus use in liver transplant recipients with hepatocellular carcinoma: A randomized, multicenter, open-label Phase 3 trial. <span class='html-italic'>Transplantation</span> <b>2016</b>, <span class='html-italic'>100</span>, 116–125. [<a href="https://scholar.google.com/scholar_lookup?title=Sirolimus+use+in+liver+transplant+recipients+with+hepatocellular+carcinoma:+A+randomized,+multicenter,+open-label+Phase+3+trial&author=Geissler,+E.K.&author=Schnitzbauer,+A.A.&author=Z%C3%BClke,+C.&author=Lamby,+P.E.&author=Proneth,+A.&author=Duvoux,+C.&author=Burra,+P.&author=Jauch,+K.W.&author=Rentsch,+M.&author=Ganten,+T.M.&publication_year=2016&journal=Transplantation&volume=100&pages=116%E2%80%93125&doi=10.1097/TP.0000000000000965" class='google-scholar' target='_blank' rel='noopener noreferrer'>Google Scholar</a>] [<a href="https://doi.org/10.1097/TP.0000000000000965" class='cross-ref' target='_blank' rel='noopener noreferrer'>CrossRef</a>]</li><li id='B42-cancers-16-01243' class='html-xx' data-content='42.'>Sapisochin, G.; Lee, W.C.; Joo, D.J.; Joh, J.-W.; Hata, K.; Soin, A.S.; Veldandi, U.K.; Kaneko, S.; Meier, M.; Leclair, D.; et al. Long-term effects of everolimus-facilitated tacrolimus reduction in living donor liver transplant recipients with hepatocellular carcinoma. <span class='html-italic'>Ann. Transplant.</span> <b>2022</b>, <span class='html-italic'>27</span>, e937988. [<a href="https://scholar.google.com/scholar_lookup?title=Long-term+effects+of+everolimus-facilitated+tacrolimus+reduction+in+living+donor+liver+transplant+recipients+with+hepatocellular+carcinoma&author=Sapisochin,+G.&author=Lee,+W.C.&author=Joo,+D.J.&author=Joh,+J.-W.&author=Hata,+K.&author=Soin,+A.S.&author=Veldandi,+U.K.&author=Kaneko,+S.&author=Meier,+M.&author=Leclair,+D.&publication_year=2022&journal=Ann.+Transplant.&volume=27&pages=e937988&doi=10.12659/AOT.937988" class='google-scholar' target='_blank' rel='noopener noreferrer'>Google Scholar</a>] [<a href="https://doi.org/10.12659/AOT.937988" class='cross-ref' target='_blank' rel='noopener noreferrer'>CrossRef</a>]</li><li id='B43-cancers-16-01243' class='html-xx' data-content='43.'>Rodríguez-Perálvarez, M.; Guerrero, M.; Barrera, L.; Ferrín, G.; Álamo, J.M.; Ayllón, M.D.; Artacho, G.S.; Montero, J.L.; Briceño, J.; Bernal, C.; et al. Impact of early initiated everolimus on the recurrence of hepatocellular carcinoma after liver transplantation. <span class='html-italic'>Transplantation</span> <b>2018</b>, <span class='html-italic'>102</span>, 2056–2064. [<a href="https://scholar.google.com/scholar_lookup?title=Impact+of+early+initiated+everolimus+on+the+recurrence+of+hepatocellular+carcinoma+after+liver+transplantation&author=Rodr%C3%ADguez-Per%C3%A1lvarez,+M.&author=Guerrero,+M.&author=Barrera,+L.&author=Ferr%C3%ADn,+G.&author=%C3%81lamo,+J.M.&author=Ayll%C3%B3n,+M.D.&author=Artacho,+G.S.&author=Montero,+J.L.&author=Brice%C3%B1o,+J.&author=Bernal,+C.&publication_year=2018&journal=Transplantation&volume=102&pages=2056%E2%80%932064&doi=10.1097/TP.0000000000002270" class='google-scholar' target='_blank' rel='noopener noreferrer'>Google Scholar</a>] [<a href="https://doi.org/10.1097/TP.0000000000002270" class='cross-ref' target='_blank' rel='noopener noreferrer'>CrossRef</a>]</li><li id='B44-cancers-16-01243' class='html-xx' data-content='44.'>Kang, I.; Lee, J.G.; Choi, S.H.; Kim, H.J.; Choi, G.H.; Kim, M.S.; Choi, J.S.; Kim, S.I.; Joo, D.J. Impact of everolimus on survival after liver transplantation for hepatocellular carcinoma. <span class='html-italic'>Clin. Mol. Hepatol.</span> <b>2021</b>, <span class='html-italic'>27</span>, 589–602. [<a href="https://scholar.google.com/scholar_lookup?title=Impact+of+everolimus+on+survival+after+liver+transplantation+for+hepatocellular+carcinoma&author=Kang,+I.&author=Lee,+J.G.&author=Choi,+S.H.&author=Kim,+H.J.&author=Choi,+G.H.&author=Kim,+M.S.&author=Choi,+J.S.&author=Kim,+S.I.&author=Joo,+D.J.&publication_year=2021&journal=Clin.+Mol.+Hepatol.&volume=27&pages=589%E2%80%93602&doi=10.3350/cmh.2021.0038" class='google-scholar' target='_blank' rel='noopener noreferrer'>Google Scholar</a>] [<a href="https://doi.org/10.3350/cmh.2021.0038" class='cross-ref' target='_blank' rel='noopener noreferrer'>CrossRef</a>]</li><li id='B45-cancers-16-01243' class='html-xx' data-content='45.'>Wasilewicz, M.P.; Moczydlowska, D.; Janik, M.; Grat, M.; Zienewicz, K.; Raszeja-Wyszomirska, J. Immunosuppressive treatment with everolimus in patients after liver transplant: 4 years of single-center experience. <span class='html-italic'>Pol. Arch. Intern. Med.</span> <b>2019</b>, <span class='html-italic'>129</span>, 686–691. [<a href="https://scholar.google.com/scholar_lookup?title=Immunosuppressive+treatment+with+everolimus+in+patients+after+liver+transplant:+4+years+of+single-center+experience&author=Wasilewicz,+M.P.&author=Moczydlowska,+D.&author=Janik,+M.&author=Grat,+M.&author=Zienewicz,+K.&author=Raszeja-Wyszomirska,+J.&publication_year=2019&journal=Pol.+Arch.+Intern.+Med.&volume=129&pages=686%E2%80%93691&pmid=31502586" class='google-scholar' target='_blank' rel='noopener noreferrer'>Google Scholar</a>] [<a href="https://www.ncbi.nlm.nih.gov/pubmed/31502586" class='cross-ref' data-typ='pmid' target='_blank' rel='noopener noreferrer'>PubMed</a>]</li><li id='B46-cancers-16-01243' class='html-xx' data-content='46.'>Cholongitas, E.; Antoniadis, N.; Goulis, I.; Theocharidou, E.; Ιmvrios, G.; Giouleme, O.; Filis, D.; Mouloudi, E.; Akriviadis, E.; Fouzas, I. Trough levels of everolimus are associated with recurrence rates of hepatocellular carcinoma after liver transplantation. <span class='html-italic'>Transplant. Proc.</span> <b>2019</b>, <span class='html-italic'>51</span>, 450–453. [<a href="https://scholar.google.com/scholar_lookup?title=Trough+levels+of+everolimus+are+associated+with+recurrence+rates+of+hepatocellular+carcinoma+after+liver+transplantation&author=Cholongitas,+E.&author=Antoniadis,+N.&author=Goulis,+I.&author=Theocharidou,+E.&author=%CE%99mvrios,+G.&author=Giouleme,+O.&author=Filis,+D.&author=Mouloudi,+E.&author=Akriviadis,+E.&author=Fouzas,+I.&publication_year=2019&journal=Transplant.+Proc.&volume=51&pages=450%E2%80%93453&doi=10.1016/j.transproceed.2019.01.069&pmid=30879564" class='google-scholar' target='_blank' rel='noopener noreferrer'>Google Scholar</a>] [<a href="https://doi.org/10.1016/j.transproceed.2019.01.069" class='cross-ref' target='_blank' rel='noopener noreferrer'>CrossRef</a>] [<a href="https://www.ncbi.nlm.nih.gov/pubmed/30879564" class='cross-ref' data-typ='pmid' target='_blank' rel='noopener noreferrer'>PubMed</a>]</li><li id='B47-cancers-16-01243' class='html-xx' data-content='47.'>Engl, T.; Rutz, J.; Maxeiner, S.; Juengel, E.; Roos, F.; Khoder, W.; Bechstein, W.O.; Nelson, K.; Tsaur, I.; Haferkamp, A.; et al. mTOR inhibition reduces growth and adhesion of hepatocellular carcinoma in vitro. <span class='html-italic'>Mol. Med. Rep.</span> <b>2017</b>, <span class='html-italic'>16</span>, 7064–7071. [<a href="https://scholar.google.com/scholar_lookup?title=mTOR+inhibition+reduces+growth+and+adhesion+of+hepatocellular+carcinoma+in+vitro&author=Engl,+T.&author=Rutz,+J.&author=Maxeiner,+S.&author=Juengel,+E.&author=Roos,+F.&author=Khoder,+W.&author=Bechstein,+W.O.&author=Nelson,+K.&author=Tsaur,+I.&author=Haferkamp,+A.&publication_year=2017&journal=Mol.+Med.+Rep.&volume=16&pages=7064%E2%80%937071&doi=10.3892/mmr.2017.7401&pmid=28901501" class='google-scholar' target='_blank' rel='noopener noreferrer'>Google Scholar</a>] [<a href="https://doi.org/10.3892/mmr.2017.7401" class='cross-ref' target='_blank' rel='noopener noreferrer'>CrossRef</a>] [<a href="https://www.ncbi.nlm.nih.gov/pubmed/28901501" class='cross-ref' data-typ='pmid' target='_blank' rel='noopener noreferrer'>PubMed</a>]</li><li id='B48-cancers-16-01243' class='html-xx' data-content='48.'>Ande, A.; Chaar, M.; Ait-Oudhia, S. Multiscale systems pharmacological analysis of everolimus action in hepatocellular carcinoma. <span class='html-italic'>J. Pharmacokinet. Pharmacodyn.</span> <b>2018</b>, <span class='html-italic'>45</span>, 607–620. [<a href="https://scholar.google.com/scholar_lookup?title=Multiscale+systems+pharmacological+analysis+of+everolimus+action+in+hepatocellular+carcinoma&author=Ande,+A.&author=Chaar,+M.&author=Ait-Oudhia,+S.&publication_year=2018&journal=J.+Pharmacokinet.+Pharmacodyn.&volume=45&pages=607%E2%80%93620&doi=10.1007/s10928-018-9590-0&pmid=29725796" class='google-scholar' target='_blank' rel='noopener noreferrer'>Google Scholar</a>] [<a href="https://doi.org/10.1007/s10928-018-9590-0" class='cross-ref' target='_blank' rel='noopener noreferrer'>CrossRef</a>] [<a href="https://www.ncbi.nlm.nih.gov/pubmed/29725796" class='cross-ref' data-typ='pmid' target='_blank' rel='noopener noreferrer'>PubMed</a>]</li><li id='B49-cancers-16-01243' class='html-xx' data-content='49.'>Cillo, U.; De Carlis, L.; Del Gaudio, M.; De Simone, P.; Fagiuoli, S.; Lupo, F.; Tisone, G.; Volpes, R. Immunosuppressive regimens for adult liver transplant recipients in real-life practice: Consensus recommendations from an Italian working group. <span class='html-italic'>Liver Int.</span> <b>2020</b>, <span class='html-italic'>146</span>, 930–943. [<a href="https://scholar.google.com/scholar_lookup?title=Immunosuppressive+regimens+for+adult+liver+transplant+recipients+in+real-life+practice:+Consensus+recommendations+from+an+Italian+working+group&author=Cillo,+U.&author=De+Carlis,+L.&author=Del+Gaudio,+M.&author=De+Simone,+P.&author=Fagiuoli,+S.&author=Lupo,+F.&author=Tisone,+G.&author=Volpes,+R.&publication_year=2020&journal=Liver+Int.&volume=146&pages=930%E2%80%93943&doi=10.1007/s12072-020-10091-5&pmid=33099753" class='google-scholar' target='_blank' rel='noopener noreferrer'>Google Scholar</a>] [<a href="https://doi.org/10.1007/s12072-020-10091-5" class='cross-ref' target='_blank' rel='noopener noreferrer'>CrossRef</a>] [<a href="https://www.ncbi.nlm.nih.gov/pubmed/33099753" class='cross-ref' data-typ='pmid' target='_blank' rel='noopener noreferrer'>PubMed</a>]</li><li id='B50-cancers-16-01243' class='html-xx' data-content='50.'>Vionnet, J.; Sempoux, C.; Pascual, M.; Sánchez-Fueyo, A.; Colmenero, J. Donor-specific antibodies in liver transplantation. <span class='html-italic'>Gastroenterol. Hepatol.</span> <b>2020</b>, <span class='html-italic'>43</span>, 34–45. [<a href="https://scholar.google.com/scholar_lookup?title=Donor-specific+antibodies+in+liver+transplantation&author=Vionnet,+J.&author=Sempoux,+C.&author=Pascual,+M.&author=S%C3%A1nchez-Fueyo,+A.&author=Colmenero,+J.&publication_year=2020&journal=Gastroenterol.+Hepatol.&volume=43&pages=34%E2%80%9345&doi=10.1016/j.gastrohep.2019.09.010&pmid=31810796" class='google-scholar' target='_blank' rel='noopener noreferrer'>Google Scholar</a>] [<a href="https://doi.org/10.1016/j.gastrohep.2019.09.010" class='cross-ref' target='_blank' rel='noopener noreferrer'>CrossRef</a>] [<a href="https://www.ncbi.nlm.nih.gov/pubmed/31810796" class='cross-ref' data-typ='pmid' target='_blank' rel='noopener noreferrer'>PubMed</a>]</li></ol></section><section id='FiguresandTables' type='display-objects'><div class="html-fig-wrap" id="cancers-16-01243-f001"> <div class='html-fig_img'> <div class="html-figpopup html-figpopup-link" data-counterslinkmanual = "https://www.mdpi.com/2072-6694/16/7/1243/display" href="#fig_body_display_cancers-16-01243-f001"> <img data-large="/cancers/cancers-16-01243/article_deploy/html/images/cancers-16-01243-g001.png" data-original="/cancers/cancers-16-01243/article_deploy/html/images/cancers-16-01243-g001.png" alt="Cancers 16 01243 g001" data-lsrc="/cancers/cancers-16-01243/article_deploy/html/images/cancers-16-01243-g001-550.jpg" /> <a class="html-expand html-figpopup" data-counterslinkmanual = "https://www.mdpi.com/2072-6694/16/7/1243/display" href="#fig_body_display_cancers-16-01243-f001"></a> </div> </div> <div class="html-fig_description"> <b>Figure 1.</b> Flowchart of the study cohort.  </div> </div> <div class="html-fig_show mfp-hide" id="fig_body_display_cancers-16-01243-f001"> <div class="html-caption"> <b>Figure 1.</b> Flowchart of the study cohort.</div> <div class="html-img"><img data-large="/cancers/cancers-16-01243/article_deploy/html/images/cancers-16-01243-g001.png" data-original="/cancers/cancers-16-01243/article_deploy/html/images/cancers-16-01243-g001.png" alt="Cancers 16 01243 g001" data-lsrc="/cancers/cancers-16-01243/article_deploy/html/images/cancers-16-01243-g001.png" /></div> </div> <div class="html-fig-wrap" id="cancers-16-01243-f002"> <div class='html-fig_img'> <div class="html-figpopup html-figpopup-link" data-counterslinkmanual = "https://www.mdpi.com/2072-6694/16/7/1243/display" href="#fig_body_display_cancers-16-01243-f002"> <img data-large="/cancers/cancers-16-01243/article_deploy/html/images/cancers-16-01243-g002.png" data-original="/cancers/cancers-16-01243/article_deploy/html/images/cancers-16-01243-g002.png" alt="Cancers 16 01243 g002" data-lsrc="/cancers/cancers-16-01243/article_deploy/html/images/cancers-16-01243-g002-550.jpg" /> <a class="html-expand html-figpopup" data-counterslinkmanual = "https://www.mdpi.com/2072-6694/16/7/1243/display" href="#fig_body_display_cancers-16-01243-f002"></a> </div> </div> <div class="html-fig_description"> <b>Figure 2.</b> Illustrates the OS according to the Milan criteria at transplant and the type of immunosuppressant (EVR versus TAC). The 1-, 3-, and 5-year actuarial OS (95% CI) for EVR patients within the Milan criteria as per pre-transplant radiologic staging were 98% (93–99%), 89% (82–90%), and 84% (79–88%) versus 98% (94–99%), 89% (83–90%), and 85% (80–87%) for EVR and TAC, respectively. For patients exceeding the Milan criteria, the OS (95% CI) was 94% (91–96%), 84% (81–86%), and 76% (72–79%) versus 92% (89–94%), 79% (73–80%), and 69% (66–70%) for EVR and TAC, respectively. Due to the crossing of the Kaplan–Meier curves of patients within the Milan criteria indicating non-proportional hazards, we used Peto-Peto-Prentice’s version of the log-rank test to measure differences across patient groups (log-rank <span class='html-italic'>p</span> = 0.03; χ<sup>2</sup> = 8.34; df = 3).  </div> </div> <div class="html-fig_show mfp-hide" id="fig_body_display_cancers-16-01243-f002"> <div class="html-caption"> <b>Figure 2.</b> Illustrates the OS according to the Milan criteria at transplant and the type of immunosuppressant (EVR versus TAC). The 1-, 3-, and 5-year actuarial OS (95% CI) for EVR patients within the Milan criteria as per pre-transplant radiologic staging were 98% (93–99%), 89% (82–90%), and 84% (79–88%) versus 98% (94–99%), 89% (83–90%), and 85% (80–87%) for EVR and TAC, respectively. For patients exceeding the Milan criteria, the OS (95% CI) was 94% (91–96%), 84% (81–86%), and 76% (72–79%) versus 92% (89–94%), 79% (73–80%), and 69% (66–70%) for EVR and TAC, respectively. Due to the crossing of the Kaplan–Meier curves of patients within the Milan criteria indicating non-proportional hazards, we used Peto-Peto-Prentice’s version of the log-rank test to measure differences across patient groups (log-rank <span class='html-italic'>p</span> = 0.03; χ<sup>2</sup> = 8.34; df = 3).</div> <div class="html-img"><img data-large="/cancers/cancers-16-01243/article_deploy/html/images/cancers-16-01243-g002.png" data-original="/cancers/cancers-16-01243/article_deploy/html/images/cancers-16-01243-g002.png" alt="Cancers 16 01243 g002" data-lsrc="/cancers/cancers-16-01243/article_deploy/html/images/cancers-16-01243-g002.png" /></div> </div> <div class="html-fig-wrap" id="cancers-16-01243-f003"> <div class='html-fig_img'> <div class="html-figpopup html-figpopup-link" data-counterslinkmanual = "https://www.mdpi.com/2072-6694/16/7/1243/display" href="#fig_body_display_cancers-16-01243-f003"> <img data-large="/cancers/cancers-16-01243/article_deploy/html/images/cancers-16-01243-g003.png" data-original="/cancers/cancers-16-01243/article_deploy/html/images/cancers-16-01243-g003.png" alt="Cancers 16 01243 g003" data-lsrc="/cancers/cancers-16-01243/article_deploy/html/images/cancers-16-01243-g003-550.jpg" /> <a class="html-expand html-figpopup" data-counterslinkmanual = "https://www.mdpi.com/2072-6694/16/7/1243/display" href="#fig_body_display_cancers-16-01243-f003"></a> </div> </div> <div class="html-fig_description"> <b>Figure 3.</b> Kaplan–Meier (KM) probability of post-transplant recurrence-free survival (RFS) according to everolimus (EVR) versus tacrolimus (TAC) and Milan stage at transplantation. 1 = Milan-in EVR; 2 = Milan-in TAC; 3 = Milan-out EVR; 4 = Milan-out TAC. Log-rank <span class='html-italic'>p</span> = 0.006 (χ<sup>2</sup> = 12.13; df = 3).  </div> </div> <div class="html-fig_show mfp-hide" id="fig_body_display_cancers-16-01243-f003"> <div class="html-caption"> <b>Figure 3.</b> Kaplan–Meier (KM) probability of post-transplant recurrence-free survival (RFS) according to everolimus (EVR) versus tacrolimus (TAC) and Milan stage at transplantation. 1 = Milan-in EVR; 2 = Milan-in TAC; 3 = Milan-out EVR; 4 = Milan-out TAC. Log-rank <span class='html-italic'>p</span> = 0.006 (χ<sup>2</sup> = 12.13; df = 3).</div> <div class="html-img"><img data-large="/cancers/cancers-16-01243/article_deploy/html/images/cancers-16-01243-g003.png" data-original="/cancers/cancers-16-01243/article_deploy/html/images/cancers-16-01243-g003.png" alt="Cancers 16 01243 g003" data-lsrc="/cancers/cancers-16-01243/article_deploy/html/images/cancers-16-01243-g003.png" /></div> </div> <div class="html-table-wrap" id="cancers-16-01243-t001"> <div class="html-table_wrap_td"> <div class="html-tablepopup html-tablepopup-link" data-counterslinkmanual = "https://www.mdpi.com/2072-6694/16/7/1243/display" href='#table_body_display_cancers-16-01243-t001'> <img data-lsrc="https://pub.mdpi-res.com/img/table.png" /> <a class="html-expand html-tablepopup" data-counterslinkmanual = "https://www.mdpi.com/2072-6694/16/7/1243/display" href="#table_body_display_cancers-16-01243-t001"></a> </div> </div> <div class="html-table_wrap_discription"> <b>Table 1.</b> Demographic and clinical characteristics of interest of the population of patients with HCC transplanted between 1996 and 2021 at our center. </div> </div> <div class="html-table_show mfp-hide " id="table_body_display_cancers-16-01243-t001"> <div class="html-caption"><b>Table 1.</b> Demographic and clinical characteristics of interest of the population of patients with HCC transplanted between 1996 and 2021 at our center.</div> <table > <thead ><tr ><th align='center' valign='middle' style='border-top:solid thin;border-bottom:solid thin' class='html-align-center' >Variable</th><th align='center' valign='middle' style='border-top:solid thin;border-bottom:solid thin' class='html-align-center' >EVR (#463)</th><th align='center' valign='middle' style='border-top:solid thin;border-bottom:solid thin' class='html-align-center' >CNI (#556)</th><th align='center' valign='middle' style='border-top:solid thin;border-bottom:solid thin' class='html-align-center' ><span class='html-italic'>p</span></th></tr></thead><tbody ><tr ><td colspan='4' align='left' valign='middle' style='border-bottom:solid thin' class='html-align-left' ><b>Recipient</b></td></tr><tr ><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >Male sex, n (%)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >386 (83.4)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >487 (87.6)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.55</td></tr><tr ><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >Age at transplant (median, IQR), years</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >56 (10)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >56 (10)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.28</td></tr><tr ><td align='center' valign='middle' class='html-align-center' >Indication to transplant, n (%)</td><td align='center' valign='middle' class='html-align-center' > </td><td align='center' valign='middle' class='html-align-center' > </td><td align='center' valign='middle' class='html-align-center' > </td></tr><tr ><td align='center' valign='middle' class='html-align-center' >HCV</td><td align='center' valign='middle' class='html-align-center' >237 (55.5)</td><td align='center' valign='middle' class='html-align-center' >294 (52.8)</td><td align='center' valign='middle' class='html-align-center' >0.59</td></tr><tr ><td align='center' valign='middle' class='html-align-center' >HBV (±HDV)</td><td align='center' valign='middle' class='html-align-center' >123 (26.5)</td><td align='center' valign='middle' class='html-align-center' >153 (27.5)</td><td align='center' valign='middle' class='html-align-center' >0.73</td></tr><tr ><td align='center' valign='middle' class='html-align-center' >HCV-HBV(±HDV)</td><td align='center' valign='middle' class='html-align-center' >17 (3.7)</td><td align='center' valign='middle' class='html-align-center' >20 (3.5)</td><td align='center' valign='middle' class='html-align-center' >0.94</td></tr><tr ><td align='center' valign='middle' class='html-align-center' >Alcohol</td><td align='center' valign='middle' class='html-align-center' >54 (11.6)</td><td align='center' valign='middle' class='html-align-center' >59 (9.5)</td><td align='center' valign='middle' class='html-align-center' >0.59</td></tr><tr ><td align='center' valign='middle' class='html-align-center' >NAFLD</td><td align='center' valign='middle' class='html-align-center' >20 (4.3)</td><td align='center' valign='middle' class='html-align-center' >24 (4.3)</td><td align='center' valign='middle' class='html-align-center' >0.99</td></tr><tr ><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >Autoimmune/PSC</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >12 (5.2)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >6 (1.1)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.67</td></tr><tr ><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >Lab-MELD at transplant (median, IQR)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >7 (6)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >8 (7)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.45</td></tr><tr ><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >DM at transplant, n (%)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >113 (24.4)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >144 (25.8)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.58</td></tr><tr ><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >CKD at transplant, n (%)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >27 (5.8)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >39 (7.0)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.44</td></tr><tr ><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >Hypertension at transplant, n (%)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >69 (14.9)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >76 (13.6)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.57</td></tr><tr ><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' ><2013, n (%)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >147 (31.7)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >387 (66.0)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' ><0.0001</td></tr><tr ><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >TAC, n (%)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >403 (86.8)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >313 (56.3)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' ><0.0001</td></tr><tr ><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >Mean TAC exposure >10 ng/mL within the first month post-transplantation</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >127 (27.4)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >172 (31.0)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.22</td></tr><tr ><td colspan='4' align='left' valign='middle' style='border-bottom:solid thin' class='html-align-left' ><b>Donor</b></td></tr><tr ><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >Male sex, n (%)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >241 (52.0)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >281 (50.5)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.63</td></tr><tr ><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >Age, median (IQR)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >69 (25)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >67 (26)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.78</td></tr><tr ><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >ICU stay, median (IQR) days</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >3 (4)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >3 (4)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.67</td></tr><tr ><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >CVA as cause of death, n (%)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >333 (71.9)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >411 (73.9)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.47</td></tr><tr ><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >Anti-HCV-positive, n (%)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >4 (0.86)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0 (0)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.58</td></tr><tr ><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >Anti-HBc-positive, n (%)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >60 (12.9)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >77 (13.8)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.67</td></tr><tr ><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >Cardiac arrest episodes, n (%)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >43 (9.3)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >42 (7.5)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.31</td></tr><tr ><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >Use of inotropes, n (%)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >407 (87.9)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >483 (86.8)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.62</td></tr><tr ><td align='left' valign='middle' style='border-bottom:solid thin' class='html-align-left' ><b>HCC</b></td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' > </td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' > </td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' > </td></tr><tr ><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >Tumor nodules *, median (IQR)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >2 (1)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >2 (1)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.78</td></tr><tr ><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >Largest nodule size *, median (IQR) (mm)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >28 (18)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >25 (15)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.04</td></tr><tr ><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >Total tumor size *, median (IQR) (mm)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >39.5 (25)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >36.5 (36)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.003</td></tr><tr ><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >Exceeding Milan criteria at transplant *, n (%)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >152 (32.8)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >101 (18.1)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' ><0.0001</td></tr><tr ><td align='center' valign='middle' class='html-align-center' >Pre-transplant treatment, n (%)</td><td align='center' valign='middle' class='html-align-center' > </td><td align='center' valign='middle' class='html-align-center' > </td><td align='center' valign='middle' class='html-align-center' > </td></tr><tr ><td align='center' valign='middle' class='html-align-center' >None, n (%)</td><td align='center' valign='middle' class='html-align-center' >141 (30.4) </td><td align='center' valign='middle' class='html-align-center' >209 (37.6) </td><td align='center' valign='middle' class='html-align-center' >0.01</td></tr><tr ><td align='center' valign='middle' class='html-align-center' >TACE, n (%)</td><td align='center' valign='middle' class='html-align-center' >229 (49.4)</td><td align='center' valign='middle' class='html-align-center' >307 (55.2)</td><td align='center' valign='middle' class='html-align-center' >0.06</td></tr><tr ><td align='center' valign='middle' class='html-align-center' >RFA/MW, n (%)</td><td align='center' valign='middle' class='html-align-center' >33 (7.1) </td><td align='center' valign='middle' class='html-align-center' >22 (3.9) </td><td align='center' valign='middle' class='html-align-center' >0.02</td></tr><tr ><td align='center' valign='middle' class='html-align-center' >PEI, n (%)</td><td align='center' valign='middle' class='html-align-center' >6 (1.3) </td><td align='center' valign='middle' class='html-align-center' >12 (2.1) </td><td align='center' valign='middle' class='html-align-center' >0.29</td></tr><tr ><td align='center' valign='middle' class='html-align-center' >Resection, n (%)</td><td align='center' valign='middle' class='html-align-center' >6 (1.3) </td><td align='center' valign='middle' class='html-align-center' >4 (0.7) </td><td align='center' valign='middle' class='html-align-center' >0.35</td></tr><tr ><td align='center' valign='middle' class='html-align-center' >TACE + RFA/MW, n (%)</td><td align='center' valign='middle' class='html-align-center' >42 (9.1) </td><td align='center' valign='middle' class='html-align-center' >2 (0.5)</td><td align='center' valign='middle' class='html-align-center' ><0.0001</td></tr><tr ><td align='center' valign='middle' class='html-align-center' >TARE, n (%)</td><td align='center' valign='middle' class='html-align-center' >6 (1.3) </td><td align='center' valign='middle' class='html-align-center' >0 (0)</td><td align='center' valign='middle' class='html-align-center' >0.008</td></tr><tr ><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >Successful downstaging **, n (%)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >75 (16.2)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >45 (8.1)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.0006</td></tr><tr ><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >AFP at transplant, median (IQR) (ng/mL)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >46.3 (28)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >4.7 (19)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.002</td></tr><tr ><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >Milan-out at explant histology, n (%)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >120 (25.9)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >167 (30.0)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.98</td></tr><tr ><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >G3-4, n (%)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >148 (31.9)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >140 (25.1)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.01</td></tr><tr ><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >Microvascular infiltration, n (%)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >88 (39.5)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >182 (32.7)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.02</td></tr><tr ><td align='left' valign='middle' style='border-bottom:solid thin' class='html-align-left' ><b>Transplantation</b></td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' > </td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' > </td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' > </td></tr><tr ><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >CIT, median (IQR) (min)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >424 (89)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >420 (101)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.09</td></tr><tr ><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >MP, n (%)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >9 (1.9)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >7 (1.2)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.89</td></tr><tr ><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >Re-transplantation, n (%)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >18 (3.8)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >23 (4.1)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.45</td></tr><tr ><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >B cell and/or T cell positive X-match, n (%)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >35 (7.5)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >48 (8.6)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.53</td></tr><tr ><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >NLR, median (IQR)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >2.2 (0.2)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >2.1 (0.3)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.68</td></tr></tbody> </table> <div class='html-table_foot html-p'><div class='html-p' style='text-indent:0em;'><span class='html-fn-content'>NOTE: AFP, alpha-fetoprotein; CKD, chronic kidney failure; CNI, calcineurin inhibitor; DM, diabetes mellitus; EVR, everolimus; HBV, hepatitis B virus; HCV, hepatitis C virus; HDV, hepatitis delta virus; IQR, interquartile range; MELD, model for end-stage liver disease; NAFLD, non-alcoholic fatty liver disease; MW, microwave ablation; MP, machine perfusion; NLR, neutrophil-to-lymphocyte ratio; PEI, percutaneous ethanol injection; PSC, primary sclerosing cholangitis; RFA, radiofrequency ablation; TAC, tacrolimus; TACE, trans-arterial chemoembolization; TARE, trans-arterial radioembolization. * Radiological; ** Radiological, as downstaged from outside to within Milan criteria.</span></div><div style='clear:both;'></div></div> </div> <div class="html-table-wrap" id="cancers-16-01243-t002"> <div class="html-table_wrap_td"> <div class="html-tablepopup html-tablepopup-link" data-counterslinkmanual = "https://www.mdpi.com/2072-6694/16/7/1243/display" href='#table_body_display_cancers-16-01243-t002'> <img data-lsrc="https://pub.mdpi-res.com/img/table.png" /> <a class="html-expand html-tablepopup" data-counterslinkmanual = "https://www.mdpi.com/2072-6694/16/7/1243/display" href="#table_body_display_cancers-16-01243-t002"></a> </div> </div> <div class="html-table_wrap_discription"> <b>Table 2.</b> Effect of stabilized IPTW in the population on the variables used for balancing the two groups. </div> </div> <div class="html-table_show mfp-hide " id="table_body_display_cancers-16-01243-t002"> <div class="html-caption"><b>Table 2.</b> Effect of stabilized IPTW in the population on the variables used for balancing the two groups.</div> <table > <thead ><tr ><th rowspan='3' align='center' valign='middle' style='border-top:solid thin;border-bottom:solid thin' class='html-align-center' >Variables</th><th colspan='3' align='center' valign='middle' style='border-top:solid thin;border-bottom:solid thin' class='html-align-center' >Pre-IPTW </th><th colspan='3' align='center' valign='middle' style='border-top:solid thin;border-bottom:solid thin' class='html-align-center' >Post-IPTW</th></tr><tr ><th align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >EVR (n = 463)</th><th align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >CNI (n = 556)</th><th rowspan='2' align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >Cohen’s <br>D-Value</th><th align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >EVR (n = 233)</th><th align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >TAC (n = 278)</th><th rowspan='2' align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >Cohen’s <br>D-Value</th></tr><tr ><th colspan='2' align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >Mean (±SD)</th><th colspan='2' align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >Mean (±SD)</th></tr></thead><tbody ><tr ><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >Patient male sex</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.83 ± 0.15</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.87 ± 0.14</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.05</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.81 ± 0.17</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.82 ± 0.15</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.05</td></tr><tr ><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >Patient age, years</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >55.9 ± 3.92</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >56.4 ± 3.46</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >−0.20</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >55.1 ± 0.55</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >55.3 ± 0.53</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >−0.03</td></tr><tr ><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >HCV</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >55.5 ± 0.70</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >55.8 ± 0.58</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >−0.42</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >24.3 ± 0.56</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >24.1 ± 0.52</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.01</td></tr><tr ><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >Patient diabetes</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.24 ± 0.50</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.26 ± 0.45</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.12</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.23 ± 0.50</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.24 ± 0.50</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.00</td></tr><tr ><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >Patient CKD</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.05 ± 0.02</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.07 ± 0.42</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.42</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.05 ± 0.01</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.05 ± 0.01</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.01</td></tr><tr ><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >MELD</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.07 ± 0.26</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.11 ± 0.33</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >−0.15</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.08 ± 0.38</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.07 ± 0.37</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.01</td></tr><tr ><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >Donor male sex</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.52 ± 0.38</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.50 ± 0.41</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >−0.08</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.51 ± 0.28</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.50 ± 0.28</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.01</td></tr><tr ><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >Donor age, years</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.69 ± 0.65</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.67 ± 0.64</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.01</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.68 ± 0.38</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.67 ± 0.37</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.03</td></tr><tr ><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >Donor cause of death (CVA)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.71 ± 0.50</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.73 ± 0.40</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.13</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.71 ± 0.46</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.72 ± 0.45</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >−0.02</td></tr><tr ><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >MP</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.09 ± 0.02</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.08 ± 0.02</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.01</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.08 ± 0.02</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.08 ± 0.02</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.00</td></tr><tr ><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >CIT, minutes</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >431.77 ± 79.02</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >423.50 ± 85.79</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.10</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.53 ± 0.50</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.53 ± 0.50</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.01</td></tr><tr ><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >Milan-out stage, radiologic</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >32.8 ± 2.33</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >19 ± 1.65</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.42</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >29.2 ± 1.2</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >26.3 ± 0.9</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.02</td></tr><tr ><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >Tumor downstaging</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.17 ± 0.05</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.08 ± 0.04</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.43</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.10 ± 0.02</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.08 ± 0.08</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.04</td></tr><tr ><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >AFP at transplant</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.45 ± 0.27</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.04 ± 0.02</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.38</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.23 ± 0.04</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.19 ± 0.06</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.14</td></tr><tr ><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >Milan-out stage, histology</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >26.1 ± 1.5</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >29.1 ± 2.3</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.16</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >24.0 ± 2.3</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >22.0 ± 2.8</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.12</td></tr><tr ><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >G3–G4</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >32.0 ± 2.4</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >25 ± 1.8</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.23</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >29.0 ± 2.3</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >28.2 ± 2.0</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.21</td></tr><tr ><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >Microinfiltration</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >40.2 ± 1.2</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >33.7 ± 1.7</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.26</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >38.1 ± 2.3</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >32.5 ± 1.9</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.20</td></tr><tr ><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >Mean TAC exposure > 10 ng/mL within the first month</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.28 ± 0.04</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.32 ± 0.45</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.13</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.15 ± 0.02</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.13 ± 0.03</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.00</td></tr></tbody> </table> <div class='html-table_foot html-p'><div class='html-p' style='text-indent:0em;'><span class='html-fn-content'>NOTE: AFP, alpha-fetoprotein; CIT, cold ischemia time; CKD, chronic kidney disease; CVA, cerebrovascular accident; G, grading; HCV, hepatitis C virus; IPTW, inverse probability therapy weighting; MP, machine perfusion; n, number; SD, standard deviation; TAC, tacrolimus.</span></div><div style='clear:both;'></div></div> </div> <div class="html-table-wrap" id="cancers-16-01243-t003"> <div class="html-table_wrap_td"> <div class="html-tablepopup html-tablepopup-link" data-counterslinkmanual = "https://www.mdpi.com/2072-6694/16/7/1243/display" href='#table_body_display_cancers-16-01243-t003'> <img data-lsrc="https://pub.mdpi-res.com/img/table.png" /> <a class="html-expand html-tablepopup" data-counterslinkmanual = "https://www.mdpi.com/2072-6694/16/7/1243/display" href="#table_body_display_cancers-16-01243-t003"></a> </div> </div> <div class="html-table_wrap_discription"> <b>Table 3.</b> The characteristics of the two pseudo-groups after IPTW matching. </div> </div> <div class="html-table_show mfp-hide " id="table_body_display_cancers-16-01243-t003"> <div class="html-caption"><b>Table 3.</b> The characteristics of the two pseudo-groups after IPTW matching.</div> <table > <thead ><tr ><th align='center' valign='middle' style='border-top:solid thin;border-bottom:solid thin' class='html-align-center' >Variable</th><th align='center' valign='middle' style='border-top:solid thin;border-bottom:solid thin' class='html-align-center' >EVR (#233)</th><th align='center' valign='middle' style='border-top:solid thin;border-bottom:solid thin' class='html-align-center' >TAC (#278)</th><th align='center' valign='middle' style='border-top:solid thin;border-bottom:solid thin' class='html-align-center' ><span class='html-italic'>p</span></th></tr></thead><tbody ><tr ><td colspan='4' align='left' valign='middle' style='border-bottom:solid thin' class='html-align-left' >Recipient</td></tr><tr ><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >Male sex, n (%)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >192 (82.4)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >228 (82.0)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.90</td></tr><tr ><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >Age at transplant (median, IQR), years</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >55.5 (9)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >55.3 (10)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.89</td></tr><tr ><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >HCV, n (%)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >58 (24.3)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >69 (24.8)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >1</td></tr><tr ><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >Lab-MELD at transplant (median, IQR) * </td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >8 (6)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >7 (7)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.78</td></tr><tr ><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >DM at transplant, n (%)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >53 (22.7)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >66 (23.7)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.83</td></tr><tr ><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >CKD at transplant, n (%)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >12 (5.1)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >14 (5.0)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >1</td></tr><tr ><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >Mean TAC exposure >10 ng/mL within the first-month post-transplantation</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >35 (15.0)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >36 (12.9)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.52</td></tr><tr ><td colspan='4' align='left' valign='middle' style='border-bottom:solid thin' class='html-align-left' >Donor</td></tr><tr ><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >Male sex, n (%)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >118 (50.6)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >140 (50.3)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >1</td></tr><tr ><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >Age, median (IQR)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >68.0 (23)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >67 (26)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.89</td></tr><tr ><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >CVA as cause of death, n (%)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >181 (77.7)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >200 (71.9)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.15</td></tr><tr ><td align='left' valign='middle' style='border-bottom:solid thin' class='html-align-left' >HCC</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' > </td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' > </td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' > </td></tr><tr ><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >Exceeding Milan criteria at transplant *, n (%)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >67 (28.7)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >72 (25.8)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.48</td></tr><tr ><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >Successful downstaging **, n (%)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >24 (10.3)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >23 (8.2)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.44</td></tr><tr ><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >AFP at transplant, median (IQR) (ng/mL)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >23.3 (18)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >19 (11)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.56</td></tr><tr ><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >Milan-out at explant histology, n (%)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >55 (23.6)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >62 (22.3)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.75</td></tr><tr ><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >G3–4, n (%)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >67 (28.7)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >78 (28.1)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.92</td></tr><tr ><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >Microvascular infiltration, n (%)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >88 (37.8)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >91 (32.7)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.26</td></tr><tr ><td align='left' valign='middle' style='border-bottom:solid thin' class='html-align-left' >Transplantation</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' > </td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' > </td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' > </td></tr><tr ><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >CIT, median (IQR) (min)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >432 (89)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >489 (101)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.06</td></tr><tr ><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >MP, n (%)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >9 (1.9)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >7 (1.2)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.89</td></tr><tr ><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >B cell and/or T cell positive X-match, n (%)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >16 (6.9)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >21 (7.5)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.76</td></tr><tr ><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >NLR, median (IQR)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >2.3 (0.2)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >2.1 (0.2)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.89</td></tr></tbody> </table> <div class='html-table_foot html-p'><div class='html-p' style='text-indent:0em;'><span class='html-fn-content'>NOTE: AFP, alpha-fetoprotein; CIT, cold ischemia time; CKD, chronic kidney failure; CNI, calcineurin inhibitor; DM, diabetes mellitus; EVR, everolimus; HCV, hepatitis C virus; IPTW, inverse probability of treatment weighting; IQR, interquartile range; MELD, model for end-stage liver disease; MP, machine perfusion; TAC, tacrolimus. * Radiological; ** Radiological, as downstaged from outside to within Milan criteria.</span></div><div style='clear:both;'></div></div> </div> <div class="html-table-wrap" id="cancers-16-01243-t004"> <div class="html-table_wrap_td"> <div class="html-tablepopup html-tablepopup-link" data-counterslinkmanual = "https://www.mdpi.com/2072-6694/16/7/1243/display" href='#table_body_display_cancers-16-01243-t004'> <img data-lsrc="https://pub.mdpi-res.com/img/table.png" /> <a class="html-expand html-tablepopup" data-counterslinkmanual = "https://www.mdpi.com/2072-6694/16/7/1243/display" href="#table_body_display_cancers-16-01243-t004"></a> </div> </div> <div class="html-table_wrap_discription"> <b>Table 4.</b> Results in the study groups after stabilized IPTW matching. </div> </div> <div class="html-table_show mfp-hide " id="table_body_display_cancers-16-01243-t004"> <div class="html-caption"><b>Table 4.</b> Results in the study groups after stabilized IPTW matching.</div> <table > <thead ><tr ><th align='center' valign='middle' style='border-top:solid thin;border-bottom:solid thin' class='html-align-center' >Variable</th><th align='center' valign='middle' style='border-top:solid thin;border-bottom:solid thin' class='html-align-center' >EVR (#233)</th><th align='center' valign='middle' style='border-top:solid thin;border-bottom:solid thin' class='html-align-center' >TAC (#278)</th><th align='center' valign='middle' style='border-top:solid thin;border-bottom:solid thin' class='html-align-center' ><span class='html-italic'>p</span></th></tr></thead><tbody ><tr ><td align='center' valign='middle' class='html-align-center' >Death, n (%)</td><td align='center' valign='middle' class='html-align-center' >62 (26.6)</td><td align='center' valign='middle' class='html-align-center' >105 (37.8)</td><td align='center' valign='middle' class='html-align-center' >0.007</td></tr><tr ><td align='center' valign='middle' class='html-align-center' >HCC recurrence, n (%)</td><td align='center' valign='middle' class='html-align-center' >16 (6.8)</td><td align='center' valign='middle' class='html-align-center' >42 (15.1)</td><td align='center' valign='middle' class='html-align-center' >0.003</td></tr><tr ><td align='center' valign='middle' class='html-align-center' >HCV recurrence, n (%)</td><td align='center' valign='middle' class='html-align-center' >16 (6.9)</td><td align='center' valign='middle' class='html-align-center' >15 (5.4)</td><td align='center' valign='middle' class='html-align-center' >0.48</td></tr><tr ><td align='center' valign='middle' class='html-align-center' >Incomplete/delayed graft function, n (%)</td><td align='center' valign='middle' class='html-align-center' >1 (0.4)</td><td align='center' valign='middle' class='html-align-center' >2 (0.7)</td><td align='center' valign='middle' class='html-align-center' >0.22</td></tr><tr ><td align='center' valign='middle' class='html-align-center' >MACE, n (%)</td><td align='center' valign='middle' class='html-align-center' >2 (0.8)</td><td align='center' valign='middle' class='html-align-center' >6 (2.1)</td><td align='center' valign='middle' class='html-align-center' >0.30</td></tr><tr ><td align='center' valign='middle' class='html-align-center' >Intra/peri-operative, n (%)</td><td align='center' valign='middle' class='html-align-center' >2 (0.8)</td><td align='center' valign='middle' class='html-align-center' >3 (1.1)</td><td align='center' valign='middle' class='html-align-center' >1</td></tr><tr ><td align='center' valign='middle' class='html-align-center' >Ischemic cholangiopathy, n (%)</td><td align='center' valign='middle' class='html-align-center' >4 (1.7)</td><td align='center' valign='middle' class='html-align-center' >7 (2.5)</td><td align='center' valign='middle' class='html-align-center' >0.76</td></tr><tr ><td align='center' valign='middle' class='html-align-center' >Infection/sepsis, n (%)</td><td align='center' valign='middle' class='html-align-center' >12 (5.1)</td><td align='center' valign='middle' class='html-align-center' >16 (5.7)</td><td align='center' valign='middle' class='html-align-center' >0.84</td></tr><tr ><td align='center' valign='middle' class='html-align-center' >De novo malignancy, n (%)</td><td align='center' valign='middle' class='html-align-center' >5 (2.1)</td><td align='center' valign='middle' class='html-align-center' >11 (3.9)</td><td align='center' valign='middle' class='html-align-center' >0.31</td></tr><tr ><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >Stroke, n (%)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >4 (1.7)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >3 (1.1)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.70</td></tr><tr ><td align='center' valign='middle' class='html-align-center' >Re-transplantation, n (%)</td><td align='center' valign='middle' class='html-align-center' >9 (3.9)</td><td align='center' valign='middle' class='html-align-center' >11 (3.9)</td><td align='center' valign='middle' class='html-align-center' >1</td></tr><tr ><td align='center' valign='middle' class='html-align-center' >Ischemic cholangiopathy, n (%)</td><td align='center' valign='middle' class='html-align-center' >3 (1.3)</td><td align='center' valign='middle' class='html-align-center' >3 (1.1)</td><td align='center' valign='middle' class='html-align-center' >1</td></tr><tr ><td align='center' valign='middle' class='html-align-center' >PNF, n (%)</td><td align='center' valign='middle' class='html-align-center' >3 (1.3)</td><td align='center' valign='middle' class='html-align-center' >5 (1.8)</td><td align='center' valign='middle' class='html-align-center' >0.73</td></tr><tr ><td align='center' valign='middle' class='html-align-center' >HAT, n %</td><td align='center' valign='middle' class='html-align-center' >2 (0.8)</td><td align='center' valign='middle' class='html-align-center' >1 (0.3)</td><td align='center' valign='middle' class='html-align-center' >0.59</td></tr><tr ><td align='center' valign='middle' class='html-align-center' >Chronic rejection, n (%)</td><td align='center' valign='middle' class='html-align-center' >1 (0.4)</td><td align='center' valign='middle' class='html-align-center' >1 (0.3)</td><td align='center' valign='middle' class='html-align-center' >1</td></tr><tr ><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >HCV recurrence, n (%)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0 (0)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >1 (0.3)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.99</td></tr><tr ><td align='center' valign='middle' class='html-align-center' >HCC recurrence, n (%)</td><td align='center' valign='middle' class='html-align-center' >18 (7.7)</td><td align='center' valign='middle' class='html-align-center' >47 (16.9)</td><td align='center' valign='middle' class='html-align-center' >0.002</td></tr><tr ><td align='center' valign='middle' class='html-align-center' >Liver only, n (%)</td><td align='center' valign='middle' class='html-align-center' >7 (3.0)</td><td align='center' valign='middle' class='html-align-center' >15 (5.4)</td><td align='center' valign='middle' class='html-align-center' >0.19</td></tr><tr ><td align='center' valign='middle' class='html-align-center' >Liver and lung, n (%)</td><td align='center' valign='middle' class='html-align-center' >1 (0.4)</td><td align='center' valign='middle' class='html-align-center' >8 (2.8)</td><td align='center' valign='middle' class='html-align-center' >0.04</td></tr><tr ><td align='center' valign='middle' class='html-align-center' >Liver and bone, n (%)</td><td align='center' valign='middle' class='html-align-center' >0 (0)</td><td align='center' valign='middle' class='html-align-center' >4 (1.4)</td><td align='center' valign='middle' class='html-align-center' >0.12</td></tr><tr ><td align='center' valign='middle' class='html-align-center' >Lung only, n (%)</td><td align='center' valign='middle' class='html-align-center' >4 (1.7)</td><td align='center' valign='middle' class='html-align-center' >9 (1.8)</td><td align='center' valign='middle' class='html-align-center' >0.39</td></tr><tr ><td align='center' valign='middle' class='html-align-center' >Bone only, n (%)</td><td align='center' valign='middle' class='html-align-center' >4 (1.7)</td><td align='center' valign='middle' class='html-align-center' >1 (0.2)</td><td align='center' valign='middle' class='html-align-center' >0.18</td></tr><tr ><td align='center' valign='middle' class='html-align-center' >Lung and bone, n (%)</td><td align='center' valign='middle' class='html-align-center' >1 (0.4)</td><td align='center' valign='middle' class='html-align-center' >4 (1.4)</td><td align='center' valign='middle' class='html-align-center' >0.38</td></tr><tr ><td align='center' valign='middle' class='html-align-center' >Nodes, n (%)</td><td align='center' valign='middle' class='html-align-center' >1 (0.4)</td><td align='center' valign='middle' class='html-align-center' >6 (2.1)</td><td align='center' valign='middle' class='html-align-center' >0.13</td></tr><tr ><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >>2 organs, n (%)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >2 (0.8)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >16 (5.7)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.002</td></tr></tbody> </table> <div class='html-table_foot html-p'><div class='html-p' style='text-indent:0em;'><span class='html-fn-content'>NOTE: EVR, everolimus; HAT, hepatic artery thrombosis; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; IPTW, inverse probability of treatment weighting; IQR, interquartile range; MACE, major cardiovascular events; PNF, primary non-function; TAC, tacrolimus.</span></div><div style='clear:both;'></div></div> </div> <div class="html-table-wrap" id="cancers-16-01243-t005"> <div class="html-table_wrap_td"> <div class="html-tablepopup html-tablepopup-link" data-counterslinkmanual = "https://www.mdpi.com/2072-6694/16/7/1243/display" href='#table_body_display_cancers-16-01243-t005'> <img data-lsrc="https://pub.mdpi-res.com/img/table.png" /> <a class="html-expand html-tablepopup" data-counterslinkmanual = "https://www.mdpi.com/2072-6694/16/7/1243/display" href="#table_body_display_cancers-16-01243-t005"></a> </div> </div> <div class="html-table_wrap_discription"> <b>Table 5.</b> Immunosuppression in the EVR study groups after stabilized IPTW matching. </div> </div> <div class="html-table_show mfp-hide " id="table_body_display_cancers-16-01243-t005"> <div class="html-caption"><b>Table 5.</b> Immunosuppression in the EVR study groups after stabilized IPTW matching.</div> <table > <thead ><tr ><th align='center' valign='middle' style='border-top:solid thin;border-bottom:solid thin' class='html-align-center' >Variable</th><th align='center' valign='middle' style='border-top:solid thin;border-bottom:solid thin' class='html-align-center' >EVR (#233)</th></tr></thead><tbody ><tr ><td align='center' valign='middle' class='html-align-center' >Reason for EVR use, n (%)</td><td align='center' valign='middle' class='html-align-center' > </td></tr><tr ><td align='center' valign='middle' class='html-align-center' >HCC recurrence prophylaxis, n (%)</td><td align='center' valign='middle' class='html-align-center' >212 (91.0)</td></tr><tr ><td align='center' valign='middle' class='html-align-center' >Deteriorating renal function, n (%)</td><td align='center' valign='middle' class='html-align-center' >14 (6.0)</td></tr><tr ><td align='center' valign='middle' class='html-align-center' >Neurologic complication, n (%)</td><td align='center' valign='middle' class='html-align-center' >4 (1.7)</td></tr><tr ><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >MACE, n (%)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >3 (1.2)</td></tr><tr ><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >Timing of EVR introduction, median (IQR) (days)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >30 (16) </td></tr><tr ><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >Duration of EVR treatment, median (IQR) (months)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >46.6 (36.1)</td></tr><tr ><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >EVR whole-blood exposure, median (IQR) (ng/mL)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >5.8 (1.7)</td></tr><tr ><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >EVR monotherapy, n (%)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >177 (75.9)</td></tr><tr ><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >EVR ± TAC, n (%)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >56 (24.1)</td></tr><tr ><td align='center' valign='middle' class='html-align-center' >EVR discontinuation, n (%)</td><td align='center' valign='middle' class='html-align-center' >12 (5.1)</td></tr><tr ><td align='center' valign='middle' class='html-align-center' >t/BPAR, n (%)</td><td align='center' valign='middle' class='html-align-center' >4 (1.7)</td></tr><tr ><td align='center' valign='middle' class='html-align-center' >Progressing proteinuria, n (%)</td><td align='center' valign='middle' class='html-align-center' >5 (2.1)</td></tr><tr ><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >Infection, n (%)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >3 (1.3)</td></tr></tbody> </table> <div class='html-table_foot html-p'><div class='html-p' style='text-indent:0em;'><span class='html-fn-content'>NOTE: EVR, everolimus; HCC, hepatocellular carcinoma; IPTW, inverse probability of treatment weighting; IQR, interquartile range; MACE, major cardiovascular events.</span></div><div style='clear:both;'></div></div> </div> <div class="html-table-wrap" id="cancers-16-01243-t006"> <div class="html-table_wrap_td"> <div class="html-tablepopup html-tablepopup-link" data-counterslinkmanual = "https://www.mdpi.com/2072-6694/16/7/1243/display" href='#table_body_display_cancers-16-01243-t006'> <img data-lsrc="https://pub.mdpi-res.com/img/table.png" /> <a class="html-expand html-tablepopup" data-counterslinkmanual = "https://www.mdpi.com/2072-6694/16/7/1243/display" href="#table_body_display_cancers-16-01243-t006"></a> </div> </div> <div class="html-table_wrap_discription"> <b>Table 6.</b> EVR mode of administration and exposure in recurring versus non-recurring patients of the EVR group. </div> </div> <div class="html-table_show mfp-hide " id="table_body_display_cancers-16-01243-t006"> <div class="html-caption"><b>Table 6.</b> EVR mode of administration and exposure in recurring versus non-recurring patients of the EVR group.</div> <table > <thead ><tr ><th align='center' valign='middle' style='border-top:solid thin;border-bottom:solid thin' class='html-align-center' >Variable</th><th align='center' valign='middle' style='border-top:solid thin;border-bottom:solid thin' class='html-align-center' >Recurring HCC (#18)</th><th align='center' valign='middle' style='border-top:solid thin;border-bottom:solid thin' class='html-align-center' >Non-Recurring HCC (#215)</th><th align='center' valign='middle' style='border-top:solid thin;border-bottom:solid thin' class='html-align-center' ><span class='html-italic'>p</span></th></tr></thead><tbody ><tr ><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >Timing of EVR introduction, median (IQR) (days) </td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >52 (26.4)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >30 (12) </td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' ><0.001</td></tr><tr ><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >Duration of EVR treatment, median (IQR) (months)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >46.5 (57.0)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >69.9 (24.8)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' ><0.001</td></tr><tr ><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >EVR whole-blood exposure, median (IQR) (ng/mL)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >3.65 (0.55)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >5.9 (1.4)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' ><0.001</td></tr></tbody> </table> <div class='html-table_foot html-p'><div class='html-p' style='text-indent:0em;'><span class='html-fn-content'>NOTE: EVR, everolimus; HCC, hepatocellular carcinoma; IQR, interquartile range.</span></div><div style='clear:both;'></div></div> </div> <div class="html-table-wrap" id="cancers-16-01243-t007"> <div class="html-table_wrap_td"> <div class="html-tablepopup html-tablepopup-link" data-counterslinkmanual = "https://www.mdpi.com/2072-6694/16/7/1243/display" href='#table_body_display_cancers-16-01243-t007'> <img data-lsrc="https://pub.mdpi-res.com/img/table.png" /> <a class="html-expand html-tablepopup" data-counterslinkmanual = "https://www.mdpi.com/2072-6694/16/7/1243/display" href="#table_body_display_cancers-16-01243-t007"></a> </div> </div> <div class="html-table_wrap_discription"> <b>Table 7.</b> Results of the multivariable analysis of risk factors for both recurrence-free and overall survival. </div> </div> <div class="html-table_show mfp-hide " id="table_body_display_cancers-16-01243-t007"> <div class="html-caption"><b>Table 7.</b> Results of the multivariable analysis of risk factors for both recurrence-free and overall survival.</div> <table > <thead ><tr ><th align='center' valign='middle' style='border-top:solid thin;border-bottom:solid thin' class='html-align-center' >Variable </th><th align='center' valign='middle' style='border-top:solid thin;border-bottom:solid thin' class='html-align-center' >Coefficients (95%CI)</th><th align='center' valign='middle' style='border-top:solid thin;border-bottom:solid thin' class='html-align-center' >SE</th><th align='center' valign='middle' style='border-top:solid thin;border-bottom:solid thin' class='html-align-center' >z</th><th align='center' valign='middle' style='border-top:solid thin;border-bottom:solid thin' class='html-align-center' >HR</th><th align='center' valign='middle' style='border-top:solid thin;border-bottom:solid thin' class='html-align-center' ><span class='html-italic'>p</span></th></tr></thead><tbody ><tr ><td colspan='6' align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >OS</td></tr><tr ><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >Successful pre-transplant downstaging</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.6 (0.15; 1.06)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.23</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >2.6</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.79</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.006</td></tr><tr ><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >Within Milan criteria at transplant</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >−1.15 (−1.61; −0.7)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.23</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >5.02</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.67</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' ><0.01</td></tr><tr ><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >Within Milan criteria at histology</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.01 (0; 0.01)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >2.41</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.78</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.02</td></tr><tr ><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >Micro-infiltration</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.39 (−0.01; 0.78)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.2</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >1.91</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >1.13</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.056</td></tr><tr ><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >G3-G4</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.25 (0.01; 0.5)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.12</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >2.02</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >1.18</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.077</td></tr><tr ><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >EVR</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >−0.59 (−1.02; −0.16)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.22</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >2.7</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.69</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.009</td></tr><tr ><td colspan='6' align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >RFS</td></tr><tr ><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >Successful pre-transplant downstaging </td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.57 (0.12; 1.02)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.23</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >2.47</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.65</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.01</td></tr><tr ><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >Within Milan criteria at transplant</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >−1.18 (−1.63; −0.72)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.23</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >5.11</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.56</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.01</td></tr><tr ><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >Within Milan criteria at histology</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.01 (0; 0.01)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >2.52</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.68</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.012</td></tr><tr ><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >Micro-infiltration</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.42 (0.02; 0.81)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.2</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >2.06</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >1.22</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.04</td></tr><tr ><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >G3-G4</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.22 (−0.02; 0.47)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.13</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >1.77</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >1.27</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.04</td></tr><tr ><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >EVR</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >−0.78 (1.2; −0.36)</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.21</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >3.66</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' >0.46</td><td align='center' valign='middle' style='border-bottom:solid thin' class='html-align-center' ><0.001</td></tr></tbody> </table> <div class='html-table_foot html-p'><div class='html-p' style='text-indent:0em;'><span class='html-fn-content'>NOTE: AFP, alpha-fetoprotein; EVR, everolimus; HCV, hepatitis C virus; OS, overall survival; RFS, recurrence-free survival.</span></div><div style='clear:both;'></div></div> </div> </section><section class='html-fn_group'><table><tr id=''><td></td><td><div class='html-p'><b>Disclaimer/Publisher’s Note:</b> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</div></td></tr></table></section> <section id="html-copyright"><br>© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<a href='https://creativecommons.org/licenses/by/4.0/' target='_blank' rel="noopener noreferrer" >https://creativecommons.org/licenses/by/4.0/</a>).</section> </div> </div> <div class="additional-content"> <h2><a name="cite"></a>Share and Cite</h2> <div class="social-media-links" style="text-align: left;"> <a href="/cdn-cgi/l/email-protection#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" title="Email"> <i class="fa fa-envelope-square" style="font-size: 30px;"></i> </a> <a href="https://twitter.com/intent/tweet?text=Everolimus+Mitigates+the+Risk+of+Hepatocellular+Carcinoma+Recurrence+after+Liver+Transplantation&hashtags=mdpicancers&url=https%3A%2F%2Fwww.mdpi.com%2F2723432&via=Cancers_MDPI" onclick="windowOpen(this.href,600,800); return false" target="_blank" rel="noopener noreferrer"> <i class="fa fa-twitter-x-square" style="font-size: 30px;"></i> </a> <a href=" http://www.linkedin.com/shareArticle?mini=true&url=https%3A%2F%2Fwww.mdpi.com%2F2723432&title=Everolimus%20Mitigates%20the%20Risk%20of%20Hepatocellular%20Carcinoma%20Recurrence%20after%20Liver%20Transplantation%26source%3Dhttps%3A%2F%2Fwww.mdpi.com%26summary%3DTo%20obtain%20long-term%20data%20on%20the%20use%20of%20everolimus%20in%20patients%20who%20underwent%20liver%20transplantation%20for%20hepatocellular%20carcinoma%2C%20we%20conducted%20a%20retrospective%2C%20single-center%20analysis%20of%20adult%20recipients%20transplanted%20between%202013%20and%202021.%20Patients%20on%20%5B...%5D" onclick="windowOpen(this.href,600,800); return false" title="LinkedIn" target="_blank" rel="noopener noreferrer"> <i class="fa fa-linkedin-square" style="font-size: 30px;"></i> </a> <a href="https://www.facebook.com/sharer.php?u=https://www.mdpi.com/2723432" title="facebook" target="_blank" rel="noopener noreferrer"> <i class="fa fa-facebook-square" style="font-size: 30px;"></i> </a> <a href="javascript:void(0);" title="Wechat" data-reveal-id="weixin-share-modal"> <i class="fa fa-weixin-square" style="font-size: 26px;"></i> </a> <a href="http://www.reddit.com/submit?url=https://www.mdpi.com/2723432" title="Reddit" target="_blank" rel="noopener noreferrer"> <i class="fa fa-reddit-square" style="font-size: 30px;"></i> </a> <a href="http://www.mendeley.com/import/?url=https://www.mdpi.com/2723432" title="Mendeley" target="_blank" rel="noopener noreferrer"> <i class="fa fa-mendeley-square" style="font-size: 30px;"></i> </a> </div> <div class="in-tab" style="padding-top: 0px!important; margin-top: 15px;"> <div><b>MDPI and ACS Style</b></div> <p> De Simone, P.; Precisi, A.; Lai, Q.; Ducci, J.; Campani, D.; Marchetti, P.; Gitto, S. Everolimus Mitigates the Risk of Hepatocellular Carcinoma Recurrence after Liver Transplantation. <em>Cancers</em> <b>2024</b>, <em>16</em>, 1243. https://doi.org/10.3390/cancers16071243 </p> <div style="display: block"> <b>AMA Style</b><br> <p> De Simone P, Precisi A, Lai Q, Ducci J, Campani D, Marchetti P, Gitto S. Everolimus Mitigates the Risk of Hepatocellular Carcinoma Recurrence after Liver Transplantation. <em>Cancers</em>. 2024; 16(7):1243. https://doi.org/10.3390/cancers16071243 </p> <b>Chicago/Turabian Style</b><br> <p> De Simone, Paolo, Arianna Precisi, Quirino Lai, Juri Ducci, Daniela Campani, Piero Marchetti, and Stefano Gitto. 2024. "Everolimus Mitigates the Risk of Hepatocellular Carcinoma Recurrence after Liver Transplantation" <em>Cancers</em> 16, no. 7: 1243. https://doi.org/10.3390/cancers16071243 </p> <b>APA Style</b><br> <p> De Simone, P., Precisi, A., Lai, Q., Ducci, J., Campani, D., Marchetti, P., & Gitto, S. (2024). Everolimus Mitigates the Risk of Hepatocellular Carcinoma Recurrence after Liver Transplantation. <em>Cancers</em>, <em>16</em>(7), 1243. https://doi.org/10.3390/cancers16071243 </p> </div> </div> <div class="info-box no-margin"> Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details <a target="_blank" href="https://www.mdpi.com/about/announcements/784">here</a>. </div> <h2><a name="metrics"></a>Article Metrics</h2> <div class="row"> <div class="small-12 columns"> <div id="loaded_cite_count" style="display:none">No</div> <div id="framed_div_cited_count" class="in-tab" style="display: none; overflow: auto;"></div> <div id="loaded" style="display:none">No</div> <div id="framed_div" class="in-tab" style="display: none; margin-top: 10px;"></div> </div> <div class="small-12 columns"> <div id="article_stats_div" style="display: none; margin-bottom: 1em;"> <h3>Article Access Statistics</h3> <div id="article_stats_swf" ></div> For more information on the journal statistics, click <a href="/journal/cancers/stats">here</a>. <div class="info-box"> Multiple requests from the same IP address are counted as one view. </div> </div> </div> </div> </div> </div> </article> </div> </div></div> <div class="webpymol-controls webpymol-controls-template" style="margin-top: 10px; display: none;"> <a class="bzoom">Zoom</a> <span style="display: inline-block; margin-left: 5px; margin-right: 5px;">|</span> <a class="borient"> Orient </a> <span style="display: inline-block; margin-left: 5px; margin-right: 5px;">|</span> <a class="blines"> As Lines </a> <span style="display: inline-block; margin-left: 5px; margin-right: 5px;">|</span> <a class="bsticks"> As Sticks </a> <span style="display: inline-block; margin-left: 5px; margin-right: 5px;">|</span> <a class="bcartoon"> As Cartoon </a> <span style="display: inline-block; margin-left: 5px; margin-right: 5px;">|</span> <a class="bsurface"> As Surface </a> <span style="display: inline-block; margin-left: 5px; margin-right: 5px;">|</span> <a class="bprevscene">Previous Scene</a> <span style="display: inline-block; margin-left: 5px; margin-right: 5px;">|</span> <a class="bnextscene">Next Scene</a> </div> <div id="scifeed-modal" class="reveal-modal reveal-modal-new" data-reveal aria-labelledby="modalTitle" aria-hidden="true" role="dialog"> </div> <div id="recommended-articles-modal" class="reveal-modal reveal-modal-new" data-reveal aria-labelledby="modalTitle" aria-hidden="true" role="dialog"> </div> <div id="author-biographies-modal" class="reveal-modal reveal-modal-new" data-reveal aria-labelledby="modalTitle" aria-hidden="true" role="dialog"> </div> <div id="cite-modal" class="reveal-modal reveal-modal-new" data-reveal aria-labelledby="Captcha" aria-hidden="true" role="dialog"> <div class="row"> <div class="small-12 columns"> <h2 style="margin: 0;">Cite</h2> </div> <div class="small-12 columns">  <form style="margin:0; padding:0; display:inline;" name="export-bibtex" method="POST" action="/export"> <input type="hidden" name="articles_ids[]" value="1361716"> <input type="hidden" name="export_format_top" value="bibtex"> <input type="hidden" name="export_submit_top" value=""> </form>  <form style="margin:0; padding:0; display:inline;" name="export-endnote" method="POST" action="/export"> <input type="hidden" name="articles_ids[]" value="1361716"> <input type="hidden" name="export_format_top" value="endnote_no_abstract"> <input type="hidden" name="export_submit_top" value=""> </form>  <form style="margin:0; padding:0; display:inline;" name="export-ris" method="POST" action="/export"> <input type="hidden" name="articles_ids[]" value="1361716"> <input type="hidden" name="export_format_top" value="ris"> <input type="hidden" name="export_submit_top" value=""> </form> <div> Export citation file: <a href="javascript:window.document.forms['export-bibtex'].submit()">BibTeX</a> | <a href="javascript:window.document.forms['export-endnote'].submit()">EndNote</a> | <a href="javascript:window.document.forms['export-ris'].submit()">RIS</a> </div> </div> <div class="small-12 columns"> <div class="in-tab"> <div><b>MDPI and ACS Style</b></div> <p> De Simone, P.; Precisi, A.; Lai, Q.; Ducci, J.; Campani, D.; Marchetti, P.; Gitto, S. Everolimus Mitigates the Risk of Hepatocellular Carcinoma Recurrence after Liver Transplantation. <em>Cancers</em> <b>2024</b>, <em>16</em>, 1243. https://doi.org/10.3390/cancers16071243 </p> <div style="display: block"> <b>AMA Style</b><br> <p> De Simone P, Precisi A, Lai Q, Ducci J, Campani D, Marchetti P, Gitto S. Everolimus Mitigates the Risk of Hepatocellular Carcinoma Recurrence after Liver Transplantation. <em>Cancers</em>. 2024; 16(7):1243. https://doi.org/10.3390/cancers16071243 </p> <b>Chicago/Turabian Style</b><br> <p> De Simone, Paolo, Arianna Precisi, Quirino Lai, Juri Ducci, Daniela Campani, Piero Marchetti, and Stefano Gitto. 2024. "Everolimus Mitigates the Risk of Hepatocellular Carcinoma Recurrence after Liver Transplantation" <em>Cancers</em> 16, no. 7: 1243. https://doi.org/10.3390/cancers16071243 </p> <b>APA Style</b><br> <p> De Simone, P., Precisi, A., Lai, Q., Ducci, J., Campani, D., Marchetti, P., & Gitto, S. (2024). Everolimus Mitigates the Risk of Hepatocellular Carcinoma Recurrence after Liver Transplantation. <em>Cancers</em>, <em>16</em>(7), 1243. https://doi.org/10.3390/cancers16071243 </p> </div> </div> <div class="info-box no-margin"> Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details <a target="_blank" href="https://www.mdpi.com/about/announcements/784">here</a>. </div> </div> </div> <a class="close-reveal-modal" aria-label="Close"> <i class="material-icons">clear</i> </a> </div> </div> </div> </div> </div> </section> <div id="footer"> <div class="journal-info"> <span> <em><a class="Var_JournalInfo" href="/journal/cancers">Cancers</a></em>, EISSN 2072-6694, Published by MDPI </span> <div class="large-right"> <span> <a href="/rss/journal/cancers" class="rss-link">RSS</a> </span> <span> <a href="/journal/cancers/toc-alert">Content Alert</a> </span> </div> </div> <div class="row full-width footer-links" data-equalizer="footer" data-equalizer-mq="small"> <div class="large-2 large-push-4 medium-3 small-6 columns" data-equalizer-watch="footer"> <h3> Further Information </h3> <a href="/apc"> Article Processing Charges </a> <a href="/about/payment"> Pay an Invoice </a> <a href="/openaccess"> Open Access Policy </a> <a href="/about/contact"> Contact MDPI </a> <a href="https://careers.mdpi.com" target="_blank" rel="noopener noreferrer"> Jobs at MDPI </a> </div> <div class="large-2 large-push-4 medium-3 small-6 columns" data-equalizer-watch="footer"> <h3> Guidelines </h3> <a href="/authors"> For Authors </a> <a href="/reviewers"> For Reviewers </a> <a href="/editors"> For Editors </a> <a href="/librarians"> For Librarians </a> <a href="/publishing_services"> For Publishers </a> <a href="/societies"> For Societies </a> <a href="/conference_organizers"> For Conference Organizers </a> </div> <div class="large-2 large-push-4 medium-3 small-6 columns"> <h3> MDPI Initiatives </h3> <a href="https://sciforum.net" target="_blank" rel="noopener noreferrer"> Sciforum </a> <a href="https://www.mdpi.com/books" target="_blank" rel="noopener noreferrer"> MDPI Books </a> <a href="https://www.preprints.org" target="_blank" rel="noopener noreferrer"> Preprints.org </a> <a href="https://www.scilit.net" target="_blank" rel="noopener noreferrer"> Scilit </a> <a href="https://sciprofiles.com?utm_source=mpdi.com&utm_medium=bottom_menu&utm_campaign=initiative" target="_blank" rel="noopener noreferrer"> SciProfiles </a> <a href="https://encyclopedia.pub" target="_blank" rel="noopener noreferrer"> Encyclopedia </a> <a href="https://jams.pub" target="_blank" rel="noopener noreferrer"> JAMS </a> <a href="/about/proceedings"> Proceedings Series </a> </div> <div class="large-2 large-push-4 medium-3 small-6 right-border-large-without columns UA_FooterFollowMDPI"> <h3> Follow MDPI </h3> <a href="https://www.linkedin.com/company/mdpi" target="_blank" rel="noopener noreferrer"> LinkedIn </a> <a href="https://www.facebook.com/MDPIOpenAccessPublishing" target="_blank" rel="noopener noreferrer"> Facebook </a> <a href="https://twitter.com/MDPIOpenAccess" target="_blank" rel="noopener noreferrer"> Twitter </a> </div> <div id="footer-subscribe" class="large-4 large-pull-8 medium-12 small-12 left-border-large columns"> <div class="footer-subscribe__container"> <img class="show-for-large-up" src="https://pub.mdpi-res.com/img/design/mdpi-pub-logo-white-small.png?71d18e5f805839ab?1732286508" alt="MDPI" title="MDPI Open Access Journals" style="height: 50px; margin-bottom: 10px;"> <form id="newsletter" method="POST" action="/subscribe"> <p> Subscribe to receive issue release notifications and newsletters from MDPI journals </p> <select multiple id="newsletter-journal" class="foundation-select" name="journals[]"> <option value="acoustics">Acoustics</option> <option value="amh">Acta Microbiologica Hellenica</option> <option value="actuators">Actuators</option> <option value="admsci">Administrative Sciences</option> <option value="adolescents">Adolescents</option> <option value="arm">Advances in Respiratory Medicine</option> <option value="aerobiology">Aerobiology</option> <option value="aerospace">Aerospace</option> <option value="agriculture">Agriculture</option> <option value="agriengineering">AgriEngineering</option> <option value="agrochemicals">Agrochemicals</option> <option value="agronomy">Agronomy</option> <option value="ai">AI</option> <option value="air">Air</option> <option value="algorithms">Algorithms</option> <option value="allergies">Allergies</option> <option value="alloys">Alloys</option> <option value="analytica">Analytica</option> <option value="analytics">Analytics</option> <option value="anatomia">Anatomia</option> <option value="anesthres">Anesthesia Research</option> <option value="animals">Animals</option> <option value="antibiotics">Antibiotics</option> <option value="antibodies">Antibodies</option> <option value="antioxidants">Antioxidants</option> <option value="applbiosci">Applied Biosciences</option> <option value="applmech">Applied Mechanics</option> <option value="applmicrobiol">Applied Microbiology</option> <option value="applnano">Applied Nano</option> <option value="applsci">Applied Sciences</option> <option value="asi">Applied System Innovation</option> <option value="appliedchem">AppliedChem</option> <option value="appliedmath">AppliedMath</option> <option value="aquacj">Aquaculture Journal</option> <option value="architecture">Architecture</option> <option value="arthropoda">Arthropoda</option> <option value="arts">Arts</option> <option value="astronomy">Astronomy</option> <option value="atmosphere">Atmosphere</option> <option value="atoms">Atoms</option> <option value="audiolres">Audiology Research</option> <option value="automation">Automation</option> <option value="axioms">Axioms</option> <option value="bacteria">Bacteria</option> <option value="batteries">Batteries</option> <option value="behavsci">Behavioral Sciences</option> <option value="beverages">Beverages</option> <option value="BDCC">Big Data and Cognitive Computing</option> <option value="biochem">BioChem</option> <option value="bioengineering">Bioengineering</option> <option value="biologics">Biologics</option> <option value="biology">Biology</option> <option value="blsf">Biology and Life Sciences Forum</option> <option value="biomass">Biomass</option> <option value="biomechanics">Biomechanics</option> <option value="biomed">BioMed</option> <option value="biomedicines">Biomedicines</option> <option value="biomedinformatics">BioMedInformatics</option> <option value="biomimetics">Biomimetics</option> <option value="biomolecules">Biomolecules</option> <option value="biophysica">Biophysica</option> <option value="biosensors">Biosensors</option> <option value="biotech">BioTech</option> <option value="birds">Birds</option> <option value="blockchains">Blockchains</option> <option value="brainsci">Brain Sciences</option> <option value="buildings">Buildings</option> <option value="businesses">Businesses</option> <option value="carbon">C</option> <option value="cancers">Cancers</option> <option value="cardiogenetics">Cardiogenetics</option> <option value="catalysts">Catalysts</option> <option value="cells">Cells</option> <option value="ceramics">Ceramics</option> <option value="challenges">Challenges</option> <option value="ChemEngineering">ChemEngineering</option> <option value="chemistry">Chemistry</option> <option value="chemproc">Chemistry Proceedings</option> <option value="chemosensors">Chemosensors</option> <option value="children">Children</option> <option value="chips">Chips</option> <option value="civileng">CivilEng</option> <option value="cleantechnol">Clean Technologies</option> <option value="climate">Climate</option> <option value="ctn">Clinical and Translational Neuroscience</option> <option value="clinbioenerg">Clinical Bioenergetics</option> <option value="clinpract">Clinics and Practice</option> <option value="clockssleep">Clocks & Sleep</option> <option value="coasts">Coasts</option> <option value="coatings">Coatings</option> <option value="colloids">Colloids and Interfaces</option> <option value="colorants">Colorants</option> <option value="commodities">Commodities</option> <option value="complications">Complications</option> <option value="compounds">Compounds</option> <option value="computation">Computation</option> <option value="csmf">Computer Sciences & Mathematics Forum</option> <option value="computers">Computers</option> <option value="condensedmatter">Condensed Matter</option> <option value="conservation">Conservation</option> <option value="constrmater">Construction Materials</option> <option value="cmd">Corrosion and Materials Degradation</option> <option value="cosmetics">Cosmetics</option> <option value="covid">COVID</option> <option value="crops">Crops</option> <option value="cryo">Cryo</option> <option value="cryptography">Cryptography</option> <option value="crystals">Crystals</option> <option value="cimb">Current Issues in Molecular Biology</option> <option value="curroncol">Current Oncology</option> <option value="dairy">Dairy</option> <option value="data">Data</option> <option value="dentistry">Dentistry Journal</option> <option value="dermato">Dermato</option> <option value="dermatopathology">Dermatopathology</option> <option value="designs">Designs</option> <option value="diabetology">Diabetology</option> <option value="diagnostics">Diagnostics</option> <option value="dietetics">Dietetics</option> <option value="digital">Digital</option> <option value="disabilities">Disabilities</option> <option value="diseases">Diseases</option> <option value="diversity">Diversity</option> <option value="dna">DNA</option> <option value="drones">Drones</option> <option value="ddc">Drugs and Drug Candidates</option> <option value="dynamics">Dynamics</option> <option value="earth">Earth</option> <option value="ecologies">Ecologies</option> <option value="econometrics">Econometrics</option> <option value="economies">Economies</option> <option value="education">Education Sciences</option> <option value="electricity">Electricity</option> <option value="electrochem">Electrochem</option> <option value="electronicmat">Electronic Materials</option> <option value="electronics">Electronics</option> <option value="ecm">Emergency Care and Medicine</option> <option value="encyclopedia">Encyclopedia</option> <option value="endocrines">Endocrines</option> <option value="energies">Energies</option> <option value="esa">Energy Storage and Applications</option> <option value="eng">Eng</option> <option value="engproc">Engineering Proceedings</option> <option value="entropy">Entropy</option> <option value="environsciproc">Environmental Sciences Proceedings</option> <option value="environments">Environments</option> <option value="epidemiologia">Epidemiologia</option> <option value="epigenomes">Epigenomes</option> <option value="ebj">European Burn Journal</option> <option value="ejihpe">European Journal of Investigation in Health, Psychology and Education</option> <option value="fermentation">Fermentation</option> <option value="fibers">Fibers</option> <option value="fintech">FinTech</option> <option value="fire">Fire</option> <option value="fishes">Fishes</option> <option value="fluids">Fluids</option> <option value="foods">Foods</option> <option value="forecasting">Forecasting</option> <option value="forensicsci">Forensic Sciences</option> <option value="forests">Forests</option> <option value="fossstud">Fossil Studies</option> <option value="foundations">Foundations</option> <option value="fractalfract">Fractal and Fractional</option> <option value="fuels">Fuels</option> <option value="future">Future</option> <option value="futureinternet">Future Internet</option> <option value="futurepharmacol">Future Pharmacology</option> <option value="futuretransp">Future Transportation</option> <option value="galaxies">Galaxies</option> <option value="games">Games</option> <option value="gases">Gases</option> <option value="gastroent">Gastroenterology Insights</option> <option value="gastrointestdisord">Gastrointestinal Disorders</option> <option value="gastronomy">Gastronomy</option> <option value="gels">Gels</option> <option value="genealogy">Genealogy</option> <option value="genes">Genes</option> <option value="geographies">Geographies</option> <option value="geohazards">GeoHazards</option> <option value="geomatics">Geomatics</option> <option value="geometry">Geometry</option> <option value="geosciences">Geosciences</option> <option value="geotechnics">Geotechnics</option> <option value="geriatrics">Geriatrics</option> <option value="glacies">Glacies</option> <option value="gucdd">Gout, Urate, and Crystal Deposition Disease</option> <option value="grasses">Grasses</option> <option value="hardware">Hardware</option> <option value="healthcare">Healthcare</option> <option value="hearts">Hearts</option> <option value="hemato">Hemato</option> <option value="hematolrep">Hematology Reports</option> <option value="heritage">Heritage</option> <option value="histories">Histories</option> <option value="horticulturae">Horticulturae</option> <option value="hospitals">Hospitals</option> <option value="humanities">Humanities</option> <option value="humans">Humans</option> <option value="hydrobiology">Hydrobiology</option> <option value="hydrogen">Hydrogen</option> <option value="hydrology">Hydrology</option> <option value="hygiene">Hygiene</option> <option value="immuno">Immuno</option> <option value="idr">Infectious Disease Reports</option> <option value="informatics">Informatics</option> <option value="information">Information</option> <option value="infrastructures">Infrastructures</option> <option value="inorganics">Inorganics</option> <option value="insects">Insects</option> <option value="instruments">Instruments</option> <option value="iic">Intelligent Infrastructure and Construction</option> <option value="ijerph">International Journal of Environmental Research and Public Health</option> <option value="ijfs">International Journal of Financial Studies</option> <option value="ijms">International Journal of Molecular Sciences</option> <option value="IJNS">International Journal of Neonatal Screening</option> <option value="ijpb">International Journal of Plant Biology</option> <option value="ijt">International Journal of Topology</option> <option value="ijtm">International Journal of Translational Medicine</option> <option value="ijtpp">International Journal of Turbomachinery, Propulsion and Power</option> <option value="ime">International Medical Education</option> <option value="inventions">Inventions</option> <option value="IoT">IoT</option> <option value="ijgi">ISPRS International Journal of Geo-Information</option> <option value="J">J</option> <option value="jal">Journal of Ageing and Longevity</option> <option value="jcdd">Journal of Cardiovascular Development and Disease</option> <option value="jcto">Journal of Clinical & Translational Ophthalmology</option> <option value="jcm">Journal of Clinical Medicine</option> <option value="jcs">Journal of Composites Science</option> <option value="jcp">Journal of Cybersecurity and Privacy</option> <option value="jdad">Journal of Dementia and Alzheimer's Disease</option> <option value="jdb">Journal of Developmental Biology</option> <option value="jeta">Journal of Experimental and Theoretical Analyses</option> <option value="jfb">Journal of Functional Biomaterials</option> <option value="jfmk">Journal of Functional Morphology and Kinesiology</option> <option value="jof">Journal of Fungi</option> <option value="jimaging">Journal of Imaging</option> <option value="jintelligence">Journal of Intelligence</option> <option value="jlpea">Journal of Low Power Electronics and Applications</option> <option value="jmmp">Journal of Manufacturing and Materials Processing</option> <option value="jmse">Journal of Marine Science and Engineering</option> <option value="jmahp">Journal of Market Access & Health Policy</option> <option value="jmp">Journal of Molecular Pathology</option> <option value="jnt">Journal of Nanotheranostics</option> <option value="jne">Journal of Nuclear Engineering</option> <option value="ohbm">Journal of Otorhinolaryngology, Hearing and Balance Medicine</option> <option value="jop">Journal of Parks</option> <option value="jpm">Journal of Personalized Medicine</option> <option value="jpbi">Journal of Pharmaceutical and BioTech Industry</option> <option value="jor">Journal of Respiration</option> <option value="jrfm">Journal of Risk and Financial Management</option> <option value="jsan">Journal of Sensor and Actuator Networks</option> <option value="joma">Journal of the Oman Medical Association</option> <option value="jtaer">Journal of Theoretical and Applied Electronic Commerce Research</option> <option value="jvd">Journal of Vascular Diseases</option> <option value="jox">Journal of Xenobiotics</option> <option value="jzbg">Journal of Zoological and Botanical Gardens</option> <option value="journalmedia">Journalism and Media</option> <option value="kidneydial">Kidney and Dialysis</option> <option value="kinasesphosphatases">Kinases and Phosphatases</option> <option value="knowledge">Knowledge</option> <option value="labmed">LabMed</option> <option value="laboratories">Laboratories</option> <option value="land">Land</option> <option value="languages">Languages</option> <option value="laws">Laws</option> <option value="life">Life</option> <option value="limnolrev">Limnological Review</option> <option value="lipidology">Lipidology</option> <option value="liquids">Liquids</option> <option value="literature">Literature</option> <option value="livers">Livers</option> <option value="logics">Logics</option> <option value="logistics">Logistics</option> <option value="lubricants">Lubricants</option> <option value="lymphatics">Lymphatics</option> <option value="make">Machine Learning and Knowledge Extraction</option> <option value="machines">Machines</option> <option value="macromol">Macromol</option> <option value="magnetism">Magnetism</option> <option value="magnetochemistry">Magnetochemistry</option> <option value="marinedrugs">Marine Drugs</option> <option value="materials">Materials</option> <option value="materproc">Materials Proceedings</option> <option value="mca">Mathematical and Computational Applications</option> <option value="mathematics">Mathematics</option> <option value="medsci">Medical Sciences</option> <option value="msf">Medical Sciences Forum</option> <option value="medicina">Medicina</option> <option value="medicines">Medicines</option> <option value="membranes">Membranes</option> <option value="merits">Merits</option> <option value="metabolites">Metabolites</option> <option value="metals">Metals</option> <option value="meteorology">Meteorology</option> <option value="methane">Methane</option> <option value="mps">Methods and Protocols</option> <option value="metrics">Metrics</option> <option value="metrology">Metrology</option> <option value="micro">Micro</option> <option value="microbiolres">Microbiology Research</option> <option value="micromachines">Micromachines</option> <option value="microorganisms">Microorganisms</option> <option value="microplastics">Microplastics</option> <option value="minerals">Minerals</option> <option value="mining">Mining</option> <option value="modelling">Modelling</option> <option value="mmphys">Modern Mathematical Physics</option> <option value="molbank">Molbank</option> <option value="molecules">Molecules</option> <option value="mti">Multimodal Technologies and Interaction</option> <option value="muscles">Muscles</option> <option value="nanoenergyadv">Nanoenergy Advances</option> <option value="nanomanufacturing">Nanomanufacturing</option> <option value="nanomaterials">Nanomaterials</option> <option value="ndt">NDT</option> <option value="network">Network</option> <option value="neuroglia">Neuroglia</option> <option value="neurolint">Neurology International</option> <option value="neurosci">NeuroSci</option> <option value="nitrogen">Nitrogen</option> <option value="ncrna">Non-Coding RNA</option> <option value="nursrep">Nursing Reports</option> <option value="nutraceuticals">Nutraceuticals</option> <option value="nutrients">Nutrients</option> <option value="obesities">Obesities</option> <option value="oceans">Oceans</option> <option value="onco">Onco</option> <option value="optics">Optics</option> <option value="oral">Oral</option> <option value="organics">Organics</option> <option value="organoids">Organoids</option> <option value="osteology">Osteology</option> <option value="oxygen">Oxygen</option> <option value="parasitologia">Parasitologia</option> <option value="particles">Particles</option> <option value="pathogens">Pathogens</option> <option value="pathophysiology">Pathophysiology</option> <option value="pediatrrep">Pediatric Reports</option> <option value="pets">Pets</option> <option value="pharmaceuticals">Pharmaceuticals</option> <option value="pharmaceutics">Pharmaceutics</option> <option value="pharmacoepidemiology">Pharmacoepidemiology</option> <option value="pharmacy">Pharmacy</option> <option value="philosophies">Philosophies</option> <option value="photochem">Photochem</option> <option value="photonics">Photonics</option> <option value="phycology">Phycology</option> <option value="physchem">Physchem</option> <option value="psf">Physical Sciences Forum</option> <option value="physics">Physics</option> <option value="physiologia">Physiologia</option> <option value="plants">Plants</option> <option value="plasma">Plasma</option> <option value="platforms">Platforms</option> <option value="pollutants">Pollutants</option> <option value="polymers">Polymers</option> <option value="polysaccharides">Polysaccharides</option> <option value="populations">Populations</option> <option value="poultry">Poultry</option> <option value="powders">Powders</option> <option value="proceedings">Proceedings</option> <option value="processes">Processes</option> <option value="prosthesis">Prosthesis</option> <option value="proteomes">Proteomes</option> <option value="psychiatryint">Psychiatry International</option> <option value="psychoactives">Psychoactives</option> <option value="psycholint">Psychology International</option> <option value="publications">Publications</option> <option value="qubs">Quantum Beam Science</option> <option value="quantumrep">Quantum Reports</option> <option value="quaternary">Quaternary</option> <option value="radiation">Radiation</option> <option value="reactions">Reactions</option> <option value="realestate">Real Estate</option> <option value="receptors">Receptors</option> <option value="recycling">Recycling</option> <option value="rsee">Regional Science and Environmental Economics</option> <option value="religions">Religions</option> <option value="remotesensing">Remote Sensing</option> <option value="reports">Reports</option> <option value="reprodmed">Reproductive Medicine</option> <option value="resources">Resources</option> <option value="rheumato">Rheumato</option> <option value="risks">Risks</option> <option value="robotics">Robotics</option> <option value="ruminants">Ruminants</option> <option value="safety">Safety</option> <option value="sci">Sci</option> <option value="scipharm">Scientia Pharmaceutica</option> <option value="sclerosis">Sclerosis</option> <option value="seeds">Seeds</option> <option value="sensors">Sensors</option> <option value="separations">Separations</option> <option value="sexes">Sexes</option> <option value="signals">Signals</option> <option value="sinusitis">Sinusitis</option> <option value="smartcities">Smart Cities</option> <option value="socsci">Social Sciences</option> <option value="siuj">Société Internationale d’Urologie Journal</option> <option value="societies">Societies</option> <option value="software">Software</option> <option value="soilsystems">Soil Systems</option> <option value="solar">Solar</option> <option value="solids">Solids</option> <option value="spectroscj">Spectroscopy Journal</option> <option value="sports">Sports</option> <option value="standards">Standards</option> <option value="stats">Stats</option> <option value="stresses">Stresses</option> <option value="surfaces">Surfaces</option> <option value="surgeries">Surgeries</option> <option value="std">Surgical Techniques Development</option> <option value="sustainability">Sustainability</option> <option value="suschem">Sustainable Chemistry</option> <option value="symmetry">Symmetry</option> <option value="synbio">SynBio</option> <option value="systems">Systems</option> <option value="targets">Targets</option> <option value="taxonomy">Taxonomy</option> <option value="technologies">Technologies</option> <option value="telecom">Telecom</option> <option value="textiles">Textiles</option> <option value="thalassrep">Thalassemia Reports</option> <option value="therapeutics">Therapeutics</option> <option value="thermo">Thermo</option> <option value="timespace">Time and Space</option> <option value="tomography">Tomography</option> <option value="tourismhosp">Tourism and Hospitality</option> <option value="toxics">Toxics</option> <option value="toxins">Toxins</option> <option value="transplantology">Transplantology</option> <option value="traumacare">Trauma Care</option> <option value="higheredu">Trends in Higher Education</option> <option value="tropicalmed">Tropical Medicine and Infectious Disease</option> <option value="universe">Universe</option> <option value="urbansci">Urban Science</option> <option value="uro">Uro</option> <option value="vaccines">Vaccines</option> <option value="vehicles">Vehicles</option> <option value="venereology">Venereology</option> <option value="vetsci">Veterinary Sciences</option> <option value="vibration">Vibration</option> <option value="virtualworlds">Virtual Worlds</option> <option value="viruses">Viruses</option> <option value="vision">Vision</option> <option value="waste">Waste</option> <option value="water">Water</option> <option value="wild">Wild</option> <option value="wind">Wind</option> <option value="women">Women</option> <option value="world">World</option> <option value="wevj">World Electric Vehicle Journal</option> <option value="youth">Youth</option> <option value="zoonoticdis">Zoonotic Diseases</option> </select> <input name="email" type="email" placeholder="Enter your email address..." required="required" /> <button class="genericCaptcha button button--dark UA_FooterNewsletterSubscribeButton" type="submit">Subscribe</button> </form> </div> </div> </div> <div id="footer-copyright"> <div class="row"> <div class="columns large-6 medium-6 small-12 text-left"> © 1996-2024 MDPI (Basel, Switzerland) unless otherwise stated </div> <div class="columns large-6 medium-6 small-12 small-text-left medium-text-right large-text-right"> <a data-dropdown="drop-view-disclaimer" aria-controls="drop-view-disclaimer" aria-expanded="false" data-options="align:top; is_hover:true; hover_timeout:2000;"> Disclaimer </a> <div id="drop-view-disclaimer" class="f-dropdown label__btn__dropdown label__btn__dropdown--wide text-left" data-dropdown-content aria-hidden="true" tabindex="-1"> Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. </div> <a href="/about/terms-and-conditions"> Terms and Conditions </a> <a href="/about/privacy"> Privacy Policy </a> </div> </div> </div> </div> <div id="cookie-notification" class="js-allow-cookies" style="display: none;"> <div class="columns large-10 medium-10 small-12"> We use cookies on our website to ensure you get the best experience.<br class="show-for-medium-up"/> Read more about our cookies <a href="/about/privacy">here</a>. </div> <div class="columns large-2 medium-2 small-12 small-only-text-left text-right"> <a class="button button--default" href="/accept_cookies">Accept</a> </div> </div> </div> <div id="main-share-modal" class="reveal-modal reveal-modal-new reveal-modal-new--small" data-reveal aria-labelledby="modalTitle" aria-hidden="true" role="dialog"> <div class="row"> <div class="small-12 columns"> <h2 style="margin: 0;">Share Link</h2> </div> <div class="small-12 columns"> <div class="social-media-links UA_ShareModalLinks" style="text-align: left;"> <a href="/cdn-cgi/l/email-protection#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" title="Email"> <i class="fa fa-envelope-square" style="font-size: 30px;"></i> </a> <a href="https://twitter.com/intent/tweet?text=Everolimus+Mitigates+the+Risk+of+Hepatocellular+Carcinoma+Recurrence+after+Liver+Transplantation&hashtags=mdpicancers&url=https%3A%2F%2Fwww.mdpi.com%2F2723432&via=Cancers_MDPI" onclick="windowOpen(this.href,600,800); return false" title="Twitter" target="_blank" rel="noopener noreferrer"> <i class="fa fa-twitter-x-square" style="font-size: 30px;"></i> </a> <a href=" http://www.linkedin.com/shareArticle?mini=true&url=https%3A%2F%2Fwww.mdpi.com%2F2723432&title=Everolimus%20Mitigates%20the%20Risk%20of%20Hepatocellular%20Carcinoma%20Recurrence%20after%20Liver%20Transplantation%26source%3Dhttps%3A%2F%2Fwww.mdpi.com%26summary%3DTo%20obtain%20long-term%20data%20on%20the%20use%20of%20everolimus%20in%20patients%20who%20underwent%20liver%20transplantation%20for%20hepatocellular%20carcinoma%2C%20we%20conducted%20a%20retrospective%2C%20single-center%20analysis%20of%20adult%20recipients%20transplanted%20between%202013%20and%202021.%20Patients%20on%20%5B...%5D" onclick="windowOpen(this.href,600,800); return false" title="LinkedIn" target="_blank" rel="noopener noreferrer"> <i class="fa fa-linkedin-square" style="font-size: 30px;"></i> </a> <a href="https://www.facebook.com/sharer.php?u=https://www.mdpi.com/2723432" title="facebook" target="_blank" rel="noopener noreferrer"> <i class="fa fa-facebook-square" style="font-size: 30px;"></i> </a> <a href="javascript:void(0);" title="Wechat" data-reveal-id="weixin-share-modal"> <i class="fa fa-weixin-square" style="font-size: 26px;"></i> </a> <a href="http://www.reddit.com/submit?url=https://www.mdpi.com/2723432" title="Reddit" target="_blank" rel="noopener noreferrer"> <i class="fa fa-reddit-square" style="font-size: 30px;"></i> </a> <a href="http://www.mendeley.com/import/?url=https://www.mdpi.com/2723432" title="Mendeley" target="_blank" rel="noopener noreferrer"> <i class="fa fa-mendeley-square" style="font-size: 30px;"></i> </a> <a href="http://www.citeulike.org/posturl?url=https://www.mdpi.com/2723432" title="CiteULike" target="_blank" rel="noopener noreferrer"> <i class="fa fa-citeulike-square" style="font-size: 30px;"></i> </a> </div> </div> <div class="small-9 columns"> <input id="js-clipboard-text" type="text" readonly value="https://www.mdpi.com/2723432" /> </div> <div class="small-3 columns text-left"> <a class="button button--color js-clipboard-copy" data-clipboard-target="#js-clipboard-text">Copy</a> </div> </div> <a class="close-reveal-modal" aria-label="Close"> <i class="material-icons">clear</i> </a> </div> <div id="weixin-share-modal" class="reveal-modal reveal-modal-new" data-reveal aria-labelledby="weixin-share-modal-title" aria-hidden="true" role="dialog"> <div class="row"> <div class="small-12 columns"> <h2 id="weixin-share-modal-title" style="margin: 0;">Share</h2> </div> <div class="small-12 columns"> <div class="weixin-qr-code-section"> <?xml version="1.0" standalone="no"?> <!DOCTYPE svg PUBLIC "-//W3C//DTD SVG 1.1//EN" "http://www.w3.org/Graphics/SVG/1.1/DTD/svg11.dtd"> <svg width="300" height="300" version="1.1" xmlns="http://www.w3.org/2000/svg"> <desc>https://www.mdpi.com/2723432</desc> <g id="elements" fill="black" stroke="none"> <rect x="0" y="0" width="12" height="12" /> <rect x="12" y="0" width="12" height="12" /> <rect x="24" y="0" width="12" height="12" /> <rect x="36" y="0" width="12" height="12" /> <rect x="48" y="0" width="12" height="12" /> <rect x="60" y="0" width="12" height="12" /> <rect x="72" y="0" width="12" height="12" /> <rect x="96" y="0" width="12" height="12" /> <rect x="108" y="0" width="12" height="12" /> <rect x="120" y="0" width="12" height="12" /> <rect x="132" y="0" width="12" height="12" /> <rect x="156" y="0" width="12" height="12" /> <rect x="168" y="0" width="12" height="12" /> <rect x="216" y="0" width="12" height="12" /> <rect x="228" y="0" width="12" height="12" /> <rect x="240" y="0" width="12" height="12" /> <rect x="252" y="0" width="12" height="12" /> <rect x="264" y="0" width="12" height="12" /> <rect x="276" y="0" width="12" height="12" /> <rect x="288" y="0" width="12" height="12" /> <rect x="0" y="12" width="12" height="12" /> <rect x="72" y="12" width="12" height="12" /> <rect x="132" y="12" width="12" height="12" /> <rect x="144" y="12" width="12" height="12" /> <rect x="168" y="12" width="12" height="12" /> <rect x="216" y="12" width="12" height="12" /> <rect x="288" y="12" width="12" height="12" /> <rect x="0" y="24" width="12" height="12" /> <rect x="24" y="24" width="12" height="12" /> <rect x="36" y="24" width="12" height="12" /> <rect x="48" y="24" width="12" height="12" /> <rect x="72" y="24" width="12" height="12" /> <rect x="108" y="24" width="12" height="12" /> <rect x="132" y="24" width="12" height="12" /> <rect x="156" y="24" width="12" height="12" /> <rect x="168" y="24" width="12" height="12" /> <rect x="216" y="24" width="12" height="12" /> <rect x="240" y="24" width="12" height="12" /> <rect x="252" y="24" width="12" height="12" /> <rect x="264" y="24" width="12" height="12" /> <rect x="288" y="24" width="12" height="12" /> <rect x="0" y="36" width="12" height="12" /> <rect x="24" y="36" width="12" height="12" /> <rect x="36" y="36" width="12" height="12" /> <rect x="48" y="36" width="12" height="12" /> <rect x="72" y="36" width="12" height="12" /> <rect x="120" y="36" width="12" height="12" /> <rect x="132" y="36" width="12" height="12" /> <rect x="144" y="36" width="12" height="12" /> <rect x="156" y="36" width="12" height="12" /> <rect x="180" y="36" width="12" height="12" /> <rect x="192" y="36" width="12" height="12" /> <rect x="216" y="36" width="12" height="12" /> <rect x="240" y="36" width="12" height="12" /> <rect x="252" y="36" width="12" height="12" /> <rect x="264" y="36" width="12" height="12" /> <rect x="288" y="36" width="12" height="12" /> <rect x="0" y="48" width="12" height="12" /> <rect x="24" y="48" width="12" height="12" /> <rect x="36" y="48" width="12" height="12" /> <rect x="48" y="48" width="12" height="12" /> <rect x="72" y="48" width="12" height="12" /> <rect x="120" y="48" width="12" height="12" /> <rect x="132" y="48" width="12" height="12" /> <rect x="144" y="48" width="12" height="12" /> <rect x="156" y="48" width="12" height="12" /> <rect x="168" y="48" width="12" height="12" /> <rect x="216" y="48" width="12" height="12" /> <rect x="240" y="48" width="12" height="12" /> <rect x="252" y="48" width="12" height="12" /> <rect x="264" y="48" width="12" height="12" /> <rect x="288" y="48" width="12" height="12" /> <rect x="0" y="60" width="12" height="12" /> <rect x="72" y="60" width="12" height="12" /> <rect x="108" y="60" width="12" height="12" /> <rect x="132" y="60" width="12" height="12" /> <rect x="144" y="60" width="12" height="12" /> <rect x="156" y="60" width="12" height="12" /> <rect x="168" y="60" width="12" height="12" /> <rect x="216" y="60" width="12" height="12" /> <rect x="288" y="60" width="12" height="12" /> <rect x="0" y="72" width="12" height="12" /> <rect x="12" y="72" width="12" height="12" /> <rect x="24" y="72" width="12" height="12" /> <rect x="36" y="72" width="12" height="12" /> <rect x="48" y="72" width="12" height="12" /> <rect x="60" y="72" width="12" height="12" /> <rect x="72" y="72" width="12" height="12" /> <rect x="96" y="72" width="12" height="12" /> <rect x="120" y="72" width="12" height="12" /> <rect x="144" y="72" width="12" height="12" /> <rect x="168" y="72" width="12" height="12" /> <rect x="192" y="72" width="12" height="12" /> <rect x="216" y="72" width="12" height="12" /> <rect x="228" y="72" width="12" height="12" /> <rect x="240" y="72" width="12" height="12" /> <rect x="252" y="72" width="12" height="12" /> <rect x="264" y="72" width="12" height="12" /> <rect x="276" y="72" width="12" height="12" /> <rect x="288" y="72" width="12" height="12" /> <rect x="96" y="84" width="12" height="12" /> <rect x="108" y="84" width="12" height="12" /> <rect x="144" y="84" width="12" height="12" /> <rect x="156" y="84" width="12" height="12" /> <rect x="0" y="96" width="12" height="12" /> <rect x="12" y="96" width="12" height="12" /> <rect x="36" y="96" width="12" height="12" /> <rect x="48" y="96" width="12" height="12" /> <rect x="72" y="96" width="12" height="12" /> <rect x="108" y="96" width="12" height="12" /> <rect x="144" y="96" width="12" height="12" /> <rect x="168" y="96" width="12" height="12" /> <rect x="192" y="96" width="12" height="12" /> <rect x="216" y="96" width="12" height="12" /> <rect x="288" y="96" width="12" height="12" /> <rect x="12" y="108" width="12" height="12" /> <rect x="24" y="108" width="12" height="12" /> <rect x="36" y="108" width="12" height="12" /> <rect x="48" y="108" width="12" height="12" /> <rect x="60" y="108" width="12" height="12" /> <rect x="84" y="108" width="12" height="12" /> <rect x="120" y="108" width="12" height="12" /> <rect x="144" y="108" width="12" height="12" /> <rect x="156" y="108" width="12" height="12" /> <rect x="168" y="108" width="12" height="12" /> <rect x="180" y="108" width="12" height="12" /> <rect x="204" y="108" width="12" height="12" /> <rect x="228" y="108" width="12" height="12" /> <rect x="240" y="108" width="12" height="12" /> <rect x="252" y="108" width="12" height="12" /> <rect x="264" y="108" width="12" height="12" /> <rect x="276" y="108" width="12" height="12" /> <rect x="12" y="120" width="12" height="12" /> <rect x="24" y="120" width="12" height="12" /> <rect x="36" y="120" width="12" height="12" /> <rect x="72" y="120" width="12" height="12" /> <rect x="108" y="120" width="12" height="12" /> <rect x="144" y="120" width="12" height="12" /> <rect x="180" y="120" width="12" height="12" /> <rect x="216" y="120" width="12" height="12" /> <rect x="228" y="120" width="12" height="12" /> <rect x="252" y="120" width="12" height="12" /> <rect x="288" y="120" width="12" height="12" /> <rect x="12" y="132" width="12" height="12" /> <rect x="24" y="132" width="12" height="12" /> <rect x="48" y="132" width="12" height="12" /> <rect x="60" y="132" width="12" height="12" /> <rect x="84" y="132" width="12" height="12" /> <rect x="132" y="132" width="12" height="12" /> <rect x="168" y="132" width="12" height="12" /> <rect x="192" y="132" width="12" height="12" /> <rect x="228" y="132" width="12" height="12" /> <rect x="252" y="132" width="12" height="12" /> <rect x="264" y="132" width="12" height="12" /> <rect x="276" y="132" width="12" height="12" /> <rect x="288" y="132" width="12" height="12" /> <rect x="0" y="144" width="12" height="12" /> <rect x="24" y="144" width="12" height="12" /> <rect x="36" y="144" width="12" height="12" /> <rect x="48" y="144" width="12" height="12" /> <rect x="60" y="144" width="12" height="12" /> <rect x="72" y="144" width="12" height="12" /> <rect x="108" y="144" width="12" height="12" /> <rect x="120" y="144" width="12" height="12" /> <rect x="132" y="144" width="12" height="12" /> <rect x="144" y="144" width="12" height="12" /> <rect x="168" y="144" width="12" height="12" /> <rect x="180" y="144" width="12" height="12" /> <rect x="216" y="144" width="12" height="12" /> <rect x="288" y="144" width="12" height="12" /> <rect x="0" y="156" width="12" height="12" /> <rect x="12" y="156" width="12" height="12" /> <rect x="24" y="156" width="12" height="12" /> <rect x="36" y="156" width="12" height="12" /> <rect x="48" y="156" width="12" height="12" /> <rect x="84" y="156" width="12" height="12" /> <rect x="96" y="156" width="12" height="12" /> <rect x="108" y="156" width="12" height="12" /> <rect x="120" y="156" width="12" height="12" /> <rect x="156" y="156" width="12" height="12" /> <rect x="168" y="156" width="12" height="12" /> <rect x="180" y="156" width="12" height="12" /> <rect x="192" y="156" width="12" height="12" /> <rect x="204" y="156" width="12" height="12" /> <rect x="240" y="156" width="12" height="12" /> <rect x="276" y="156" width="12" height="12" /> <rect x="0" y="168" width="12" height="12" /> <rect x="12" y="168" width="12" height="12" /> <rect x="36" y="168" width="12" height="12" /> <rect x="60" y="168" width="12" height="12" /> <rect x="72" y="168" width="12" height="12" /> <rect x="108" y="168" width="12" height="12" /> <rect x="120" y="168" width="12" height="12" /> <rect x="144" y="168" width="12" height="12" /> <rect x="156" y="168" width="12" height="12" /> <rect x="180" y="168" width="12" height="12" /> <rect x="192" y="168" width="12" height="12" /> <rect x="204" y="168" width="12" height="12" /> <rect x="216" y="168" width="12" height="12" /> <rect x="240" y="168" width="12" height="12" /> <rect x="252" y="168" width="12" height="12" /> <rect x="264" y="168" width="12" height="12" /> <rect x="276" y="168" width="12" height="12" /> <rect x="288" y="168" width="12" height="12" /> <rect x="0" y="180" width="12" height="12" /> <rect x="84" y="180" width="12" height="12" /> <rect x="108" y="180" width="12" height="12" /> <rect x="168" y="180" width="12" height="12" /> <rect x="204" y="180" width="12" height="12" /> <rect x="228" y="180" width="12" height="12" /> <rect x="252" y="180" width="12" height="12" /> <rect x="264" y="180" width="12" height="12" /> <rect x="288" y="180" width="12" height="12" /> <rect x="0" y="192" width="12" height="12" /> <rect x="24" y="192" width="12" height="12" /> <rect x="60" y="192" width="12" height="12" /> <rect x="72" y="192" width="12" height="12" /> <rect x="84" y="192" width="12" height="12" /> <rect x="120" y="192" width="12" height="12" /> <rect x="144" y="192" width="12" height="12" /> <rect x="180" y="192" width="12" height="12" /> <rect x="192" y="192" width="12" height="12" /> <rect x="204" y="192" width="12" height="12" /> <rect x="216" y="192" width="12" height="12" /> <rect x="228" y="192" width="12" height="12" /> <rect x="240" y="192" width="12" height="12" /> <rect x="264" y="192" width="12" height="12" /> <rect x="276" y="192" width="12" height="12" /> <rect x="96" y="204" width="12" height="12" /> <rect x="144" y="204" width="12" height="12" /> <rect x="192" y="204" width="12" height="12" /> <rect x="240" y="204" width="12" height="12" /> <rect x="264" y="204" width="12" height="12" /> <rect x="276" y="204" width="12" height="12" /> <rect x="0" y="216" width="12" height="12" /> <rect x="12" y="216" width="12" height="12" /> <rect x="24" y="216" width="12" height="12" /> <rect x="36" y="216" width="12" height="12" /> <rect x="48" y="216" width="12" height="12" /> <rect x="60" y="216" width="12" height="12" /> <rect x="72" y="216" width="12" height="12" /> <rect x="132" y="216" width="12" height="12" /> <rect x="144" y="216" width="12" height="12" /> <rect x="192" y="216" width="12" height="12" /> <rect x="216" y="216" width="12" height="12" /> <rect x="240" y="216" width="12" height="12" /> <rect x="288" y="216" width="12" height="12" /> <rect x="0" y="228" width="12" height="12" /> <rect x="72" y="228" width="12" height="12" /> <rect x="120" y="228" width="12" height="12" /> <rect x="132" y="228" width="12" height="12" /> <rect x="144" y="228" width="12" height="12" /> <rect x="180" y="228" width="12" height="12" /> <rect x="192" y="228" width="12" height="12" /> <rect x="240" y="228" width="12" height="12" /> <rect x="288" y="228" width="12" height="12" /> <rect x="0" y="240" width="12" height="12" /> <rect x="24" y="240" width="12" height="12" /> <rect x="36" y="240" width="12" height="12" /> <rect x="48" y="240" width="12" height="12" /> <rect x="72" y="240" width="12" height="12" /> <rect x="96" y="240" width="12" height="12" /> <rect x="120" y="240" width="12" height="12" /> <rect x="144" y="240" width="12" height="12" /> <rect x="156" y="240" width="12" height="12" /> <rect x="180" y="240" width="12" height="12" /> <rect x="192" y="240" width="12" height="12" /> <rect x="204" y="240" width="12" height="12" /> <rect x="216" y="240" width="12" height="12" /> <rect x="228" y="240" width="12" height="12" /> <rect x="240" y="240" width="12" height="12" /> <rect x="276" y="240" width="12" height="12" /> <rect x="288" y="240" width="12" height="12" /> <rect x="0" y="252" width="12" height="12" /> <rect x="24" y="252" width="12" height="12" /> <rect x="36" y="252" width="12" height="12" /> <rect x="48" y="252" width="12" height="12" /> <rect x="72" y="252" width="12" height="12" /> <rect x="96" y="252" width="12" height="12" /> <rect x="132" y="252" width="12" height="12" /> <rect x="144" y="252" width="12" height="12" /> <rect x="180" y="252" width="12" height="12" /> <rect x="192" y="252" width="12" height="12" /> <rect x="216" y="252" width="12" height="12" /> <rect x="276" y="252" width="12" height="12" /> <rect x="288" y="252" width="12" height="12" /> <rect x="0" y="264" width="12" height="12" /> <rect x="24" y="264" width="12" height="12" /> <rect x="36" y="264" width="12" height="12" /> <rect x="48" y="264" width="12" height="12" /> <rect x="72" y="264" width="12" height="12" /> <rect x="168" y="264" width="12" height="12" /> <rect x="192" y="264" width="12" height="12" /> <rect x="204" y="264" width="12" height="12" /> <rect x="240" y="264" width="12" height="12" /> <rect x="252" y="264" width="12" height="12" /> <rect x="264" y="264" width="12" height="12" /> <rect x="276" y="264" width="12" height="12" /> <rect x="288" y="264" width="12" height="12" /> <rect x="0" y="276" width="12" height="12" /> <rect x="72" y="276" width="12" height="12" /> <rect x="96" y="276" width="12" height="12" /> <rect x="108" y="276" width="12" height="12" /> <rect x="120" y="276" width="12" height="12" /> <rect x="168" y="276" width="12" height="12" /> <rect x="228" y="276" width="12" height="12" /> <rect x="240" y="276" width="12" height="12" /> <rect x="264" y="276" width="12" height="12" /> <rect x="276" y="276" width="12" height="12" /> <rect x="288" y="276" width="12" height="12" /> <rect x="0" y="288" width="12" height="12" /> <rect x="12" y="288" width="12" height="12" /> <rect x="24" y="288" width="12" height="12" /> <rect x="36" y="288" width="12" height="12" /> <rect x="48" y="288" width="12" height="12" /> <rect x="60" y="288" width="12" height="12" /> <rect x="72" y="288" width="12" height="12" /> <rect x="96" y="288" width="12" height="12" /> <rect x="120" y="288" width="12" height="12" /> <rect x="132" y="288" width="12" height="12" /> <rect x="144" y="288" width="12" height="12" /> <rect x="168" y="288" width="12" height="12" /> <rect x="192" y="288" width="12" height="12" /> <rect x="204" y="288" width="12" height="12" /> <rect x="252" y="288" width="12" height="12" /> <rect x="288" y="288" width="12" height="12" /> </g> </svg> </div> </div> </div> <a class="close-reveal-modal" aria-label="Close"> <i class="material-icons">clear</i> </a> </div> <a href="#" class="back-to-top"><span class="show-for-medium-up">Back to Top</span><span class="show-for-small">Top</span></a> <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script src="https://pub.mdpi-res.com/assets/js/modernizr-2.8.3.min.js?5227e0738f7f421d?1732286508"></script> <script src="https://pub.mdpi-res.com/assets/js/jquery-1.12.4.min.js?4f252523d4af0b47?1732286508"></script> <script src="https://pub.mdpi-res.com/assets/js/foundation-5.5.3.min.js?6b2ec41c18b29054?1732286508"></script> <script src="https://pub.mdpi-res.com/assets/js/foundation-5.5.3.equalizer.min.js?0f6c549b75ec554c?1732286508"></script> <script src="https://pub.mdpi-res.com/assets/js/jquery.multiselect.js?0edd3998731d1091?1732286508"></script> <script src="https://pub.mdpi-res.com/assets/js/jquery.cycle2.min.js?63413052928f97ee?1732286508"></script> <script> // old browser fix - this way the console log rows won't throw (silent) errors in browsers not supporting console log if (!window.console) window.console = {}; if (!window.console.log) window.console.log = function () { }; var currentJournalNameSystem = "cancers"; $(document).ready(function() { $('select.foundation-select').multiselect({ search: true, minHeight: 130, maxHeight: 130, }); $(document).foundation({ orbit: { timer_speed: 4000, }, reveal: { animation: 'fadeAndPop', animation_speed: 100, } }); $(".chosen-select").each(function(element) { var maxSelected = (undefined !== $(this).data('maxselectedoptions') ? $(this).data('maxselectedoptions') : 100); $(this).on('chosen:ready', function(event, data) { var select = $(data.chosen.form_field); if (select.attr('id') === 'journal-browser-volume') { $(data.chosen.dropdown).addClass('UI_JournalBrowser_Volume_Options'); } if (select.attr('id') === 'journal-browser-issue') { $(data.chosen.dropdown).addClass('UI_JournalBrowser_Issue_Options'); } }).chosen({ display_disabled_options: false, disable_search_threshold: 7, max_selected_options: maxSelected, width: "100%" }); }); $(".toEncode").each(function(e) { var oldHref = $(this).attr("href"); var newHref = oldHref.replace('.botdefense.please.enable.javascript.','@'); $(this).attr("href", newHref); if (!$(this).hasClass("emailCaptcha")) { $(this).html(newHref.replace('mailto:', '')); } $(this).removeClass("visibility-hidden"); }); $(document).on('opened.fndtn.reveal', '[data-reveal]', function() { $(document).foundation('equalizer', 'reflow'); }); // fix the images that have tag height / width defined // otherwise the default foundation styles overwrite the tag definitions $("img").each(function() { if ($(this).attr('width') != undefined || $(this).attr('height') != undefined) { $(this).addClass("img-fixed"); } }); $("#basic_search, #advanced_search").submit(function(e) { var searchArguments = false; $(this).find("input,select").not("#search,.search-button").each(function() { if (undefined === $(this).val() || "" === $(this).val()) { $(this).attr('name', null); } else { $(this).attr('name'); searchArguments = true; } }); if (!searchArguments) { window.location = $(this).attr('action'); return false; } }); $(".hide-show-desktop-option").click(function(e) { e.preventDefault(); var parentDiv = $(this).closest("div"); $.ajax({ url: $(this).attr('href'), success: function(msg) { parentDiv.removeClass().hide(); } }); }); $(".generic-toggleable-header").click(function(e) { $(this).toggleClass("active"); $(this).next(".generic-toggleable-content").toggleClass("active"); }); /* * handle whole row as a link if the row contains only one visible link */ $("table.new tr").hover(function() { if ($(this).find("td:visible a").length == 1) { $(this).addClass("single-link"); } }, function() { $(this).removeClass("single-link"); }); $("table.new:not(.table-of-tables)").on("click", "tr.single-link", function(e) { var target = $(e.target); if (!e.ctrlKey && !target.is("a")) { $(this).find("td:visible a")[0].click(); } }); $(document).on("click", ".custom-accordion-for-small-screen-link", function(e) { if ($(this).closest("#basic_search").length > 0) { if ($(".search-container__advanced").first().is(":visible")) { openAdvanced() } } if (Foundation.utils.is_small_only()) { if ($(this).hasClass("active")) { $(this).removeClass("active"); $(this).next(".custom-accordion-for-small-screen-content").addClass("show-for-medium-up"); } else { $(this).addClass("active"); $(this).next(".custom-accordion-for-small-screen-content").removeClass("show-for-medium-up"); $(document).foundation('orbit', 'reflow'); } } if (undefined !== $(this).data("callback")) { var customCallback = $(this).data("callback"); func = window[customCallback]; func(); } }); $(document).on("click", ".js-open-small-search", function(e) { e.preventDefault(); $(this).toggleClass("active").closest(".tab-bar").toggleClass("active"); $(".search-container").toggleClass("hide-for-small-down"); }); $(document).on("click", ".js-open-menu", function(e) { $(".search-container").addClass("hide-for-small-down"); }); $(window).on('resize', function() { recalculate_main_browser_position(); recalculate_responsive_moving_containers(); }); updateSearchLabelVisibilities(); recalculate_main_browser_position(); recalculate_responsive_moving_containers(); if (window.document.documentMode == 11) { $("<link/>", { rel: "stylesheet", type: "text/css", href: "https://fonts.googleapis.com/icon?family=Material+Icons"}).appendTo("head"); } }); function recalculate_main_browser_position() { if (Foundation.utils.is_small_only()) { if ($("#js-main-top-container").parent("#js-large-main-top-container").length > 0) { $("#js-main-top-container").appendTo($("#js-small-main-top-container")); } } else { if ($("#js-main-top-container").parent("#js-small-main-top-container").length > 0) { $("#js-main-top-container").appendTo($("#js-large-main-top-container")); } } } function recalculate_responsive_moving_containers() { $(".responsive-moving-container.large").each(function() { var previousParent = $(".responsive-moving-container.active[data-id='"+$(this).data("id")+"']"); var movingContent = previousParent.html(); if (Foundation.utils.is_small_only()) { var currentParent = $(".responsive-moving-container.small[data-id='"+$(this).data("id")+"']"); } else if (Foundation.utils.is_medium_only()) { var currentParent = $(".responsive-moving-container.medium[data-id='"+$(this).data("id")+"']"); } else { var currentParent = $(".responsive-moving-container.large[data-id='"+$(this).data("id")+"']"); } if (previousParent.attr("class") !== currentParent.attr("class")) { currentParent.html(movingContent); previousParent.html(); currentParent.addClass("active"); previousParent.removeClass("active"); } }); } // cookies allowed is checked from a) local storage and b) from server separately so that the footer bar doesn't // get included in the custom page caches function checkCookiesAllowed() { var cookiesEnabled = localStorage.getItem("mdpi_cookies_enabled"); if (null === cookiesEnabled) { $.ajax({ url: "/ajax_cookie_value/mdpi_cookies_accepted", success: function(data) { if (data.value) { localStorage.setItem("mdpi_cookies_enabled", true); checkDisplaySurvey(); } else { $(".js-allow-cookies").show(); } } }); } else { checkDisplaySurvey(); } } function checkDisplaySurvey() { } window.addEventListener('CookiebotOnAccept', function (e) { var CookieDate = new Date; if (Cookiebot.consent.preferences) { CookieDate.setFullYear(CookieDate.getFullYear() + 1); document.cookie = "mdpi_layout_type_v2=mobile; path=/; expires=" + CookieDate.toUTCString() + ";"; $(".js-toggle-desktop-layout-link").css("display", "inline-block"); } }, false); window.addEventListener('CookiebotOnDecline', function (e) { if (!Cookiebot.consent.preferences) { $(".js-toggle-desktop-layout-link").hide(); if ("" === "desktop") { window.location = "/toggle_desktop_layout_cookie"; } } }, false); var hash = $(location).attr('hash'); if ("#share" === hash) { if (1 === $("#main-share-modal").length) { $('#main-share-modal').foundation('reveal', 'open'); } } </script> <script src="https://pub.mdpi-res.com/assets/js/lib.js?f8d3d71b3a772f9d?1732286508"></script> <script src="https://pub.mdpi-res.com/assets/js/mdpi.js?c267ce58392b15da?1732286508"></script> <script>var banners_url = 'https://serve.mdpi.com';</script> <script type='text/javascript' src='https://pub.mdpi-res.com/assets/js/ifvisible.min.js?c621d19ecb761212?1732286508'></script> <script src="https://pub.mdpi-res.com/assets/js/xmltohtml/affix.js?ac4ea55275297c15?1732286508"></script> <script src="https://pub.mdpi-res.com/assets/js/clipboard.min.js?3f3688138a1b9fc4?1732286508"></script> <script type="text/javascript"> $(document).ready(function() { var helpFunctions = $(".middle-column__help__fixed"); var leftColumnAffix = $(".left-column__fixed"); var middleColumn = $("#middle-column"); var clone = null; helpFunctions.affix({ offset: { top: function() { return middleColumn.offset().top - 8 - (Foundation.utils.is_medium_only() ? 30 : 0); }, bottom: function() { return $("#footer").innerHeight() + 74 + (Foundation.utils.is_medium_only() ? 0 : 0); } } }); if (leftColumnAffix.length > 0) { clone = leftColumnAffix.clone(); clone.addClass("left-column__fixed__affix"); clone.insertBefore(leftColumnAffix); clone.css('width', leftColumnAffix.outerWidth() + 50); clone.affix({ offset: { top: function() { return leftColumnAffix.offset().top - 30 - (Foundation.utils.is_medium_only() ? 50 : 0); }, bottom: function() { return $("#footer").innerHeight() + 92 + (Foundation.utils.is_medium_only() ? 0 : 0); } } }); } $(window).on("resize", function() { if (clone !== null) { clone.css('width', leftColumnAffix.outerWidth() + 50); } }); new ClipboardJS('.js-clipboard-copy'); }); </script> <script src="https://pub.mdpi-res.com/assets/js/jquery-ui-1.13.2.min.js?1e2047978946a1d2?1732286508"></script> <script src="https://pub.mdpi-res.com/assets/js/slick.min.js?d5a61c749e44e471?1732286508"></script> <script> $(document).ready(function() { $(".link-article-menu").click(function(e) { e.preventDefault(); $(this).find('span').toggle(); $(this).next("div").toggleClass("active"); }); $(".js-similarity-related-articles").click(function(e) { e.preventDefault(); if ('' !== $('#recommended-articles-modal').attr('data-url')) { $('#recommended-articles-modal').foundation('reveal', 'open', $('#recommended-articles-modal').attr('data-url')); } }); $.ajax({ url: "/article/1361716/similarity-related/show-link", success: function(result) { if (result.show) { $('#recommended-articles-modal').attr('data-url', result.link); $('.js-article-similarity-container').show(); } } }); $(document).on('opened.fndtn.reveal', '[data-reveal]', function() { var modal = $(this); if (modal.attr('id') === "author-biographies-modal") { modal.find('.multiple-items').slick({ slidesToShow: 1, nextArrow: '<a class="slick-next" href="#"><i class="material-icons">chevron_right</i></a>', prevArrow: '<a class="slick-prev" href="#"><i class="material-icons">chevron_left</i></a>', slidesToScroll: 1, draggable: false, }); modal.find('.multiple-items').slick('refresh'); } }); }); </script> <script> $(document).ready(function() { $(document).on('keyup', function (e) { if (e.keyCode == 27) { var hElem = $(this).find(".annotator-adder"); if (hElem.length){ hElem.css({'visibility':'hidden'}); } else { document.querySelector("hypothesis-adder").shadowRoot.querySelector(".annotator-adder").style.visibility = "hidden"; } } }); }); </script> <script> window.hypothesisConfig = function () { return { sidebarAppUrl: 'https://commenting.mdpi.com/app.html', showHighlights: 'whenSidebarOpen' , openSidebar: false , assetRoot: 'https://commentingres.mdpi.com/hypothesis', services: [{ apiUrl: 'https://commenting.mdpi.com/api/', authority: 'mdpi', grantToken: '', doi: '10.3390/cancers16071243' }], }; }; </script> <script async id="hypothesis_frame"></script> <script type="text/javascript"> if (-1 !== window.location.href.indexOf("?src=")) { window.history.replaceState({}, '', `${location.pathname}`); } $(document).ready(function() { var scifeedCounter = 0; var search = window.location.search; var mathjaxReady = false; // late image file loading $("img[data-lsrc]").each(function() { $(this).attr("src", $(this).data("lsrc")); }); // late mathjax initialization var head = document.getElementsByTagName("head")[0]; var script = document.createElement("script"); script.type = "text/x-mathjax-config"; script[(window.opera ? "innerHTML" : "text")] = "MathJax.Hub.processSectionDelay = 0;\n" + "MathJax.Hub.Config({\n" + " \"menuSettings\": {\n" + " CHTMLpreview: false\n" + " },\n" + " \"CHTML-preview\":{\n" + " disabled: true\n" + " },\n" + " \"HTML-CSS\": {\n" + " scale: 90,\n" + " availableFonts: [],\n" + " preferredFont: null,\n" + " preferredFonts: null,\n" + " webFont:\"Gyre-Pagella\",\n" + " imageFont:'TeX',\n" + " undefinedFamily:\"'Arial Unicode MS',serif\",\n" + " linebreaks: { automatic: false }\n" + " },\n" + " \"TeX\": {\n" + " extensions: ['noErrors.js'],\n" + " noErrors: {\n" + " inlineDelimiters: [\"\",\"\"],\n" + " multiLine: true,\n" + " style: {\n" + " 'font-size': '90%',\n" + " 'text-align': 'left',\n" + " 'color': 'black',\n" + " 'padding': '1px 3px',\n" + " 'border': '1px solid'\n" + " }\n" + " }\n" + " }\n" + "});\n" + "MathJax.Hub.Register.StartupHook('End', function() {\n" + " refreshMathjaxWidths();\n" + " mathjaxReady = true;\n" + "});\n" + "MathJax.Hub.Startup.signal.Interest(function (message) {\n" + " if (message == 'End') {\n" + " var hypoLink = document.getElementById('hypothesis_frame');\n" + " if (null !== hypoLink) {\n" + " hypoLink.setAttribute('src', 'https://commenting.mdpi.com/embed.js');\n" + " }\n" + " }\n" + "});"; head.appendChild(script); script = document.createElement("script"); script.type = "text/javascript"; script.src = "https://pub.mdpi-res.com/bundles/mathjax/MathJax.js?config=TeX-AMS-MML_HTMLorMML"; head.appendChild(script); // article version checker if (0 === search.indexOf('?type=check_update&version=')) { $.ajax({ url: "/2072-6694/16/7/1243" + "/versioncheck" + search, success: function(result) { $(".js-check-update-container").html(result); } }); } $('#feed_option').click(function() { // tracker if ($('#scifeed_clicked').length<1) { $(this).append('<span style="display:none" id="scifeed_clicked">done</span>'); } $('#feed_data').toggle('slide', { direction: 'up'}, '1000'); // slideToggle(700); OR toggle(700) $("#scifeed_error_msg").html('').hide(); $("#scifeed_notice_msg").html('').hide(); }); $('#feed_option').click(function(event) { setTimeout(function(){ var captchaSection = $("#captchaSection"); captchaSection.removeClass('ui-helper-hidden').find('input').prop('disabled', false); // var img = captchaSection.find('img'); // img.attr('src', img.data('url') + "?" + (new Date()).getTime()); // $(".captcha_reload").trigger("click"); var img = document.getElementById('gregwar_captcha_scifeed'); img.src = '/generate-captcha/gcb_captcha?n=' + (new Date()).getTime(); },800); }); $(document).on('click', '.split_feeds', function() { var name = $( this ).attr('name'); var flag = 1 - ($(this).is(":checked")*1); $('.split_feeds').each(function (index) { if ($( this ).attr('name') !== name) { $(this)[0].checked = flag; } }); }); $(document).on('click', '#scifeed_submit, #scifeed_submit1', function(event) { event.preventDefault(); $(".captcha_reload").trigger("click"); $("#scifeed_error_msg").html(""); $("#scifeed_error_msg").hide(); }); $(document).on('click', '.subscription_toggle', function(event) { if ($(this).val() === 'Create SciFeed' && $('#scifeed_hidden_flag').length>0) { event.preventDefault(); // alert('Here there would be a captcha because user is not logged in'); var captchaSection = $("#captchaSection"); if (captchaSection.hasClass('ui-helper-hidden')) { captchaSection.removeClass('ui-helper-hidden').find('input').prop('disabled', false); var img = captchaSection.find('img'); img.attr('src', img.data('url') + "?" + (new Date()).getTime()); $("#reloadCaptcha").trigger("click"); } } }); $(document).on('click', '.scifeed_msg', function(){ $(this).hide(); }); $(document).on('click', '.article-scilit-search', function(e) { e.preventDefault(); var data = $(".article-scilit-search-data").val(); var dataArray = data.split(';').map(function(keyword) { return "(\"" + keyword.trim() + "\")"; }); var searchQuery = dataArray.join(" OR "); var searchUrl = encodeURI("https://www.scilit.net/articles/search?q="+ searchQuery + "&advanced=1&highlight=1"); var win = window.open(searchUrl, '_blank'); if (win) { win.focus(); } else { window.location(searchUrl); } }); display_stats(); citedCount(); follow_goto(); // Select the node that will be observed for mutations const targetNodes = document.getElementsByClassName('hypothesis-count-container'); // Options for the observer (which mutations to observe) const config = { attributes: false, childList: true, subtree: false }; // Callback function to execute when mutations are observed const callback = function(mutationList, observer) { for(const mutation of mutationList) { if (mutation.type === 'childList') { let node = $(mutation.target); if (parseInt(node.html()) > 0) { node.show(); } } } }; // Create an observer instance linked to the callback function const observer = new MutationObserver(callback); // Start observing the target node for configured mutations for(const targetNode of targetNodes) { observer.observe(targetNode, config); } // Select the node that will be observed for mutations const mathjaxTargetNode = document.getElementById('middle-column'); // Callback function to execute when mutations are observed const mathjaxCallback = function(mutationList, observer) { if (mathjaxReady && typeof(MathJax) !== 'undefined') { refreshMathjaxWidths(); } }; // Create an observer instance linked to the callback function const mathjaxObserver = new ResizeObserver(mathjaxCallback); // Start observing the target node for configured mutations mathjaxObserver.observe(mathjaxTargetNode); }); /* END $(document).ready */ function refreshMathjaxWidths() { let width = ($('.html-body').width()*0.9) + "px"; $('.MathJax_Display').css('max-width', width); $('.MJXc-display').css('max-width', width); } function sendScifeedFrom(form) { if (!$('#scifeed_email').val().trim()) { // empty email alert('Please, provide an email for subscribe to this scifeed'); return false; } else if (!$('#captchaSection').hasClass('ui-helper-hidden') && !$('#captchaSection').find('input').val().trim()) { // empty captcha alert('Please, fill the captcha field.'); return false; } else if( ((($('#scifeed_form').find('input:checkbox:checked').length)-($('#split_feeds:checked').length))<1) || ($('#scifeed_kwd_txt').length < 0 && !$('#scifeed_kwd_txt').val().trim()) || ($('#scifeed_author_txt').length<0 &&!$('#scifeed_author_txt').val().trim()) ) { alert('You did not select anything to subscribe'); return false; } else if(($('#scifeed_form').find('input:checkbox:checked').length)-($('#split_feeds2:checked').length)<1){ alert("You did not select anything to subscribe"); return false; } else { var url = $('#scifeed_subscribe_url').html(); var formData = $(form).serializeArray(); $.post(url, formData).done(function (data) { if (JSON.parse(data)) { $('.scifeed_msg').hide(); var res = JSON.parse(data); var successFeeds = 0; var errorFeeds = 0; if (res) { $('.scifeed_msg').html(''); $.each(res, function (index, val) { if (val) { if (val.error) { errorFeeds++; $("#scifeed_error_msg").append(index+' - '+val.error+'<br>'); } if (val.notice) // for successful feed creation { successFeeds++; // $("#scifeed_notice_msg").append(index+' - '+val.notice+'<br>'); $("#scifeed_notice_msg").append('<li>'+index+'</li>'); } } }); if (successFeeds>0) { text = $('#scifeed_notice_msg').html(); text = 'The following feed'+(successFeeds>1?'s have':' has')+ ' been sucessfully created:<br><ul>'+ text + '</ul>' +($('#scifeed_hidden_flag').length>0 ? 'You are not logged in, so you probably need to validate '+ (successFeeds>1?'them':' it')+'.<br>' :'' ) +'Please check your email'+(successFeeds>1?'s':'')+' for more details.'; //(successFeeds>1?' for each of them':'')+'.<br>'; $("#scifeed_notice_msg").html(text); $("#scifeed_notice_msg").show(); } if (errorFeeds>0) { $("#scifeed_error_msg").show();; } } $("#feed_data").hide(); } }); } } function follow_goto() { var hashStr = location.hash.replace("#",""); if(typeof hashStr !== 'undefined') { if( hashStr == 'supplementary') { document.getElementById('suppl_id').scrollIntoView(); } if( hashStr == 'citedby') { document.getElementById('cited_id').scrollIntoView(); } } } function cited() { $("#framed_div").toggle('fast', function(){ if ($(this).css('display') != 'none') { var loaded = document.getElementById("loaded"); if(loaded.innerHTML == "No") { // Load Xref result var container = document.getElementById("framed_div"); // This replace the content container.innerHTML = "<img src=\"https://pub.mdpi-res.com/img/loading_circle.gif?9a82694213036313?1732286508\" height=\"20\" width=\"20\" alt=\"Processing...\" style=\"vertical-align:middle; margin-right:0.6em;\">"; var url = "/citedby/10.3390%252Fcancers16071243/23"; $.post(url, function(result) { if (result.success) { container.innerHTML = result.view; } loaded.innerHTML = "Yes"; }); } } return true; // for not going at the beginning of the page... }) return true; // for not going at the beginning of the page... } function detect_device() { // Added by Bastien (18/08/2014): based on the http://detectmobilebrowsers.com/ detector var check = false; (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows (ce|phone)|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4)))check = true})(navigator.userAgent||navigator.vendor||window.opera); return check; } function display_stats(){ $("#article_stats_div").toggle(); return false; } /* * Cited By Scopus */ function citedCount(){ $("#framed_div_cited_count").toggle('fast', function(){ if ($(this).css('display') != 'none') { var loaded = document.getElementById("loaded_cite_count"); // to load only once the result! if(loaded.innerHTML == "No") { // Load Xref result var d = document.getElementById("framed_div_cited_count"); // This replace the content d.innerHTML = "<img src=\"https://pub.mdpi-res.com/img/loading_circle.gif?9a82694213036313?1732286508\" height=\"20\" width=\"20\" alt=\"Processing...\" style=\"vertical-align:middle; margin-right:0.6em;\">"; $.ajax({ method : "POST", url : "/cite-count/10.3390%252Fcancers16071243", success : function(data) { if (data.succ) { d.innerHTML = data.view; loaded.innerHTML = "Yes"; follow_goto(); } } }); } } // end else return true; // for not going at the beginning of the page... }) return true; // for not going at the beginning of the page... } </script><script type="text/javascript" src="https://pub.mdpi-res.com/assets/js/third-party/highcharts/highcharts.js?bdd06f45e34c33df?1732286508"></script><script type="text/javascript" src="https://pub.mdpi-res.com/assets/js/third-party/highcharts/modules/exporting.js?944dc938d06de3a8?1732286508"></script><script type="text/javascript" defer="defer"> var advancedStatsData; var selectedStatsType = "abstract"; $(function(){ var countWrapper = $('#counts-wrapper'); $('#author_stats_id #type_links a').on('click', function(e) { e.preventDefault(); selectedStatsType = $(this).data('type'); $('#article_advanced_stats').vectorMap('set', 'values', advancedStatsData[selectedStatsType]); $('#advanced_stats_max').html(advancedStatsData[selectedStatsType].max); $('#type_links a').removeClass('active'); $(this).addClass('active'); }); $.get('/2072-6694/16/7/1243/stats', function (result) { if (!result.success) { return; } // process article metrics part in left column var viewNumber = countWrapper.find(".view-number"); viewNumber.html(result.metrics.views); viewNumber.parent().toggleClass("count-div--grey", result.metrics.views == 0); var downloadNumber = countWrapper.find(".download-number"); downloadNumber.html(result.metrics.downloads); downloadNumber.parent().toggleClass("count-div--grey", result.metrics.downloads == 0); var citationsNumber = countWrapper.find(".citations-number"); citationsNumber.html(result.metrics.citations); citationsNumber.parent().toggleClass("count-div--grey", result.metrics.citations == 0); if (result.metrics.views > 0 || result.metrics.downloads > 0 || result.metrics.citations > 0) { countWrapper.find("#js-counts-wrapper__views, #js-counts-wrapper__downloads").addClass("visible").show(); if (result.metrics.citations > 0) { countWrapper.find('.citations-number').html(result.metrics.citations).show(); countWrapper.find("#js-counts-wrapper__citations").addClass("visible").show(); } else { countWrapper.find("#js-counts-wrapper__citations").remove(); } $("[data-id='article-counters']").removeClass("hidden"); } if (result.metrics.altmetrics_score > 0) { $("#js-altmetrics-donut").show(); } // process view chart in main column var jsondata = result.chart; var series = new Array(); $.each(jsondata.elements, function(i, element) { var dataValues = new Array(); $.each(element.values, function(i, value) { dataValues.push(new Array(value.tip, value.value)); }); series[i] = {name: element.text, data:dataValues}; }); Highcharts.setOptions({ chart: { style: { fontFamily: 'Arial,sans-serif' } } }); $('#article_stats_swf').highcharts({ chart: { type: 'line', width: $("#tabs").width() //* 0.91 }, credits: { enabled: false }, exporting: { enabled: true }, title: { text: jsondata.title.text, x: -20 //center }, xAxis: { categories: jsondata.x_axis.labels.labels, offset: jsondata.x_axis.offset, labels:{ step: jsondata.x_axis.labels.steps, rotation: 30 } }, yAxis: { max: jsondata.y_axis.max, min: jsondata.y_axis.min, offset: jsondata.y_axis.offset, labels: { steps: jsondata.y_axis.steps }, title: { enabled: false } }, tooltip: { formatter: function (){ return this.key.replace("#val#", this.y); } }, legend: { align: 'top', itemDistance: 50 }, series: series }); }); $('#supplement_link').click(function() { document.getElementById('suppl_id').scrollIntoView(); }); $('#stats_link').click(function() { document.getElementById('stats_id').scrollIntoView(); }); // open mol viewer for molbank special supplementary files $('.showJmol').click(function(e) { e.preventDefault(); var jmolModal = $("#jmolModal"); var url = "/article/1361716/jsmol_viewer/__supplementary_id__"; url = url.replace(/__supplementary_id__/g, $(this).data('index')); $('#jsmol-content').attr('src', url); jmolModal.find(".content").html($(this).data('description')); jmolModal.foundation("reveal", "open"); }); }); !function() { "use strict"; function e(e) { try { if ("undefined" == typeof console) return; "error"in console ? console.error(e) : console.log(e) } catch (e) {} } function t(e) { return d.innerHTML = '<a href="' + e.replace(/"/g, """) + '"></a>', d.childNodes[0].getAttribute("href") || "" } function n(n, c) { var o = ""; var k = parseInt(n.substr(c + 4, 2), 16); for (var i = c; i < n.length; i += 2) { if (i != c + 4) { var s = parseInt(n.substr(i, 2), 16) ^ k; o += String.fromCharCode(s); } } try { o = decodeURIComponent(escape(o)); } catch (error) { console.error(error); } return t(o); } function c(t) { for (var r = t.querySelectorAll("a"), c = 0; c < r.length; c++) try { var o = r[c] , a = o.href.indexOf(l); a > -1 && (o.href = "mailto:" + n(o.href, a + l.length)) } catch (i) { e(i) } } function o(t) { for (var r = t.querySelectorAll(u), c = 0; c < r.length; c++) try { var o = r[c] , a = o.parentNode , i = o.getAttribute(f); if (i) { var l = n(i, 0) , d = document.createTextNode(l); a.replaceChild(d, o) } } catch (h) { e(h) } } function a(t) { for (var r = t.querySelectorAll("template"), n = 0; n < r.length; n++) try { i(r[n].content) } catch (c) { e(c) } } function i(t) { try { c(t), o(t), a(t) } catch (r) { e(r) } } var l = "/cnd-cgi/l/email-protection#" , u = ".__cf_email__" , f = "data-cfemail" , d = document.createElement("div"); i(document), function() { var e = document.currentScript || document.scripts[document.scripts.length - 1]; e.parentNode.removeChild(e) }() }(); </script><script type="text/javascript"> function setCookie(cname, cvalue, ctime) { ctime = (typeof ctime === 'undefined') ? 10*365*24*60*60*1000 : ctime; // default => 10 years var d = new Date(); d.setTime(d.getTime() + ctime); // ==> 1 hour = 60*60*1000 var expires = "expires="+d.toUTCString(); document.cookie = cname + "=" + cvalue + "; " + expires +"; path=/"; } function getCookie(cname) { var name = cname + "="; var ca = document.cookie.split(';'); for(var i=0; i<ca.length; i++) { var c = ca[i]; while (c.charAt(0)==' ') c = c.substring(1); if (c.indexOf(name) == 0) return c.substring(name.length, c.length); } return ""; } </script><script type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js"></script><script> $(document).ready(function() { if ($("#js-similarity-related-data").length > 0) { $.ajax({ url: '/article/1361716/similarity-related', success: function(response) { $("#js-similarity-related-data").html(response); $("#js-related-articles-menu").show(); $(document).foundation('tab', 'reflow'); MathJax.Hub.Queue(["Typeset", MathJax.Hub]); } }); } }); </script><link rel="stylesheet" href="https://pub.mdpi-res.com/assets/css/jquery-ui-1.10.4.custom.min.css?80647d88647bf347?1732286508"><link rel="stylesheet" href="https://pub.mdpi-res.com/assets/css/magnific-popup.min.css?04d343e036f8eecd?1732286508"><script type="text/javascript" src="https://pub.mdpi-res.com/assets/js/magnific-popup.min.js?2be3d9e7dc569146?1732286508"></script><script> $(function() { $(".js-show-more-academic-editors").on("click", function(e) { e.preventDefault(); $(this).hide(); $(".academic-editor-container").removeClass("hidden"); }); }); </script> <link rel="stylesheet" href="https://pub.mdpi-res.com/assets/css/vmap/jqvmap.min.css?126a06688aa11c13?1732286508"> <script src="https://pub.mdpi-res.com/assets/js/vmap/jquery.vmap.min.js?935f68d33bdd88a1?1732286508"></script> <script src="https://pub.mdpi-res.com/assets/js/vmap/jquery.vmap.world.js?16677403c0e1bef1?1732286508"></script> <script> function updateSlick() { $('.multiple-items').slick('setPosition'); } $(document).ready(function() { $('.multiple-items').slick({ slidesToShow: 1, nextArrow: '<a class="slick-next" href="#"><i class="material-icons">chevron_right</i></a>', prevArrow: '<a class="slick-prev" href="#"><i class="material-icons">chevron_left</i></a>', slidesToScroll: 1, responsive: [ { breakpoint: 1024, settings: { slidesToShow: 1, slidesToScroll: 1, } }, { breakpoint: 600, settings: { slidesToShow: 1, slidesToScroll: 1, } }, { breakpoint: 480, settings: { slidesToShow: 1, slidesToScroll: 1, } } ] }); $('.multiple-items').show(); $(document).on('click', '.reviewReportSelector', function(e) { let path = $(this).attr('data-path'); handleReviews(path, $(this)); }); $(document).on('click', '.viewReviewReports', function(e) { let versionOne = $('#versionTab_1'); if (!versionOne.hasClass('activeTab')) { let path = $(this).attr('data-path'); handleReviews(path, versionOne); } location.href = "#reviewReports"; }); $(document).on('click', '.reviewersResponse, .authorResponse', function(e) { let version = $(this).attr('data-version'); let targetVersion = $('#versionTab_' + version); if (!targetVersion.hasClass('activeTab')) { let path = targetVersion.attr('data-path'); handleReviews(path, targetVersion); } location.href = $(this).attr('data-link'); }); $(document).on('click', '.tab', function (e) { e.preventDefault(); $('.tab').removeClass('activeTab'); $(this).addClass('activeTab') $('.tab').each(function() { $(this).closest('.tab-title').removeClass('active'); }); $(this).closest('.tab-title').addClass('active') }); }); function handleReviews(path, target) { $.ajax({ url: path, context: this, success: function (data) { $('.activeTab').removeClass('activeTab'); target.addClass('activeTab'); $('#reviewSection').html(data.view); }, error: function (xhr, ajaxOptions, thrownError) { console.log(xhr.status); console.log(thrownError); } }); } </script> <script src="https://pub.mdpi-res.com/assets/js/xmltohtml/affix.js?v1?1732286508"></script> <script src="https://pub.mdpi-res.com/assets/js/xmltohtml/storage.js?e9b262d3a3476d25?1732286508"></script> <script src="https://pub.mdpi-res.com/assets/js/xmltohtml/jquery-scrollspy.js?09cbaec0dbb35a67?1732286508"></script> <script src="https://pub.mdpi-res.com/assets/js/xmltohtml/magnific-popup.js?4a09c18460afb26c?1732286508"></script> <script src="https://pub.mdpi-res.com/assets/js/xmltohtml/underscore.js?f893e294cde60c24?1732286508"></script> <script type="text/javascript"> $('document').ready(function(){ $("#left-column").addClass("show-for-large-up"); $("#middle-column").removeClass("medium-9").removeClass("left-bordered").addClass("medium-12"); $(window).on('resize scroll', function() { /* if ($('.button--drop-down').isInViewport($(".top-bar").outerHeight())) { */ if ($('.button--drop-down').isInViewport()) { $("#js-button-download").hide(); } else { $("#js-button-download").show(); } }); }); $(document).on('DOMNodeInserted', function(e) { var element = $(e.target); if (element.hasClass('menu') && element.hasClass('html-nav') ) { element.addClass("side-menu-ul"); } }); </script> <script src="https://pub.mdpi-res.com/assets/js/xmltohtml/articles.js?5118449d9ad8913a?1732286508"></script> <script> repositionOpenSideBar = function() { $('#left-column').addClass("show-for-large-up show-for-medium-up").show(); $('#middle-column').removeClass('large-12').removeClass('medium-12'); $('#middle-column').addClass('large-9'); } repositionCloseSideBar = function() { $('#left-column').removeClass("show-for-large-up show-for-medium-up").hide(); $('#middle-column').removeClass('large-9'); $('#middle-column').addClass('large-12').addClass('medium-12'); } </script>   <script type="text/plain" data-cookieconsent="marketing"> !function(e,t,n,s,u,a){e.twq||(s=e.twq=function(){s.exe?s.exe.apply(s,arguments):s.queue.push(arguments); },s.version='1.1',s.queue=[],u=t.createElement(n),u.async=!0,u.src='//static.ads-twitter.com/uwt.js', a=t.getElementsByTagName(n)[0],a.parentNode.insertBefore(u,a))}(window,document,'script'); // Insert Twitter Pixel ID and Standard Event data below twq('init','o2pip'); twq('track','PageView'); </script>  <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'8e72c7aa5be79c89',t:'MTczMjM4MTkwMi4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html>

CINXE.COM

Everolimus Mitigates the Risk of Hepatocellular Carcinoma Recurrence after Liver Transplantation